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ABSTRACT OF THE DISSERTATION 
 
 
Expression Analysis and Stem Cell Engineering 
by 
Cara Rachel Rieger 
Doctor of Philosphy in Biomedical Engineering 
Washington University in St. Louis, 2009 
Research co-advisors:  Professor David Gottlieb and Professor Robi Mitra 
 
The overall goal of the thesis was to develop tools to advance investigations of stem 
cells in tissue engineering therapeutics for neurodegenerative disease and spinal cord injury.  
Two tools to characterize cell fate and a tool to separate a subset of neural cells were 
developed and evaluated. In the first study, a digital PCR technology, called polonies, was 
applied to measure mRNA from several key stem cell genes in small numbers of ES cells. 
Due to its properties, we hypothesized that polonies would be uniquely poised to profile 
stem cells. Polonies were counted for Oct3 in a sample of 10 ES cells and from three 
pluripotency genes: Oct3, Nanog, and Rex1 from a single blastocyst, containing 30 ICM 
cells. The polony method is sensitive, can be applied to most genes, and allows for a degree 
of multiplexing. Second, DNA methylation was explored as a tool to measure cell fate as ES 
cells are differentiated into neural cells. We tested the hypothesis that promoter DNA 
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methylation correlates to gene silencing. Promoter methylation of a pluripotency and neural 
fate determining genes in ES cells, ES derived neural cells, and non-neural tissues was 
measured by direct bisulfite sequencing. As expected Oct3, was methylated in differentiated 
cells and tissues.  Unexpectedly, neural genes: Sox1, Olig1, and Olig2 were unmethylated in 
non-neural cells and tissues. The correlation between methylation and silencing was not 
universal; it was gene specific. In the third study, ES cells were genetically engineered to 
permit drug selection of subset of ES derived neural cells. We hypothesized that engineering 
ES cells with puromycin acetyltransferase gene (PAC) under the control of the Olig2 
promoter would allow for selection of Olig2 expressing neural cells with puromycin. Two 
targeted ES cell lines were generated with PAC inserted into the Olig2 gene. Both lines have 
the expected functional properties and enable purification of Olig2 expressing cells from ES 
derived neural cells by puromycin selection. Overall, the tools developed in this thesis are a 
small step toward generating well-defined cell populations from stem cells needed to 
advance tissue engineering therapeutics for neurodegenerative disease and injury.  
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Chapter 1 
 
Introduction 
 
Harnessing the promise of stem cells holds the potential to revolutionize modern 
medicine. Many devastating diseases are a result of cellular deficiencies. Stem cells, as the 
originators of all the tissues of the body, are a viable source of therapeutic replacement 
cells and a potential treatment for these diseases. Neurodegenerative disease and spinal 
cord injury are of particular interest because cell loss results in devastating loss of 
function for which no effective treatments currently exist. 
Development of cellular replacement therapeutics for neurodegeneration and 
spinal cord injury is a focus of tissue engineering research. Tissue engineering combines 
therapeutic cells with instructive growth factors and biomaterial scaffolds to provide an 
organized method to deliver therapeutic cells. The ability of stem cells to self-renew and 
differentiate into all cell types gives great hope for their use as the cellular component in 
tissue engineering based therapeutics. One of the challenges with this process is to define 
and limit the heterogeneity of stem cells and differentiated cells to the desired cell type. 
To achieve this, tools to investigate and limit stem cell heterogeneity must be developed.  
This thesis focuses on the development of tools to further the use of stem cells as 
part of tissue engineering approaches for neurodegenerative disease and spinal cord 
injury. The first study explores a new method to characterize stem cell heterogeneity. The 
second study investigates an assay for monitoring differentiation from ES cell to neural 
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cell fate. The final study builds a tool that will aid in limiting cellular heterogeneity 
enabling isolation and delivery of a defined set of ES derived neural cells.  These tools 
were developed with emphasis on the use of stem cells in tissue engineering approaches 
for treatment of neurodegenerative disease and injury, but will have general implications 
for the use of stem cells in other applications.  
The introduction will cover several topics encompassing the broad scope of the 
thesis. First, a primer on the biology of embryonic stem cells and benefits of their use for 
tissue engineering will be provided. Next, research in tissue engineering approaches for 
SCI using ES derived neural cells, instructive growth factors, and biomaterial scaffolds 
will be reviewed.  Challenges encountered due to cellular heterogeneity will be described 
which provide the rationale for experimental work. Finally, tools for discovering and 
limiting cellular heterogeneity will be described. 
1.1 Embryonic Stem Cells   
Embryonic stem cells are ideal cells for tissue engineering applications because 
they can be grown on a large scale, differentiated into the needed lineage, and be 
genetically engineered to select for therapeutic cell type(s). The promise of embryonic 
stem (ES) cells as a renewable source of therapeutic cells is based on their fundamental 
ability to self-renew and differentiate into all cell types of the body. This is important for 
tissue engineering research and applications which require “therapeutic cells” at a 
clinically relevant scale [50x106-5x109] (Palsson and Bhatia 2004). 
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1.1.1 Mouse Embryonic Stem Cells  
Mouse embryonic stem cells were discovered nearly thirty years ago (Evans and 
Kaufman 1981; Martin 1981). ES cells are isolated from the inner cell mass of the 
embryonic day 3.5 blastocyst.  Signaling molecules, including leukemia inhibitory factor 
(LIF,(Williams, Hilton et al. 1988)), are added in vitro to instruct daughter cells to remain 
undifferentiated and divide. ES cells are pluripotent. The differentiation potential of ES 
cells in vitro directly reflects their role in the embryo as the founder of all three germ 
layers: ectoderm, mesoderm, and endoderm which later form all somatic tissues in the 
adult animal (Rossant 2007).  Years of research on mammalian embryonic development 
using mice and mouse ES cells as a model system, has given strong evidence that ES cells 
are a promising candidate for therapeutic use. For clincal applications, it is clear human 
ES cells will be needed.  
1.1.2 Human Embryonic Stem Cells 
In 1998, human embryonic stem (hES) cells were derived from the inner cell mass 
of human embryos produced by in vitro fertilization (Thomson, Itskovitz-Eldor et al. 
1998). Like mouse ES cells, hES cells can be expanded in an undifferentiated state in vitro, 
and are capable of differentiation into cells of all three germ layers, making them capable 
of producing all somatic cell types. In contrast to mouse ES cells, LIF does not promote 
hES cell self renewal (Thomson, Itskovitz-Eldor et al. 1998). Instead, the combination of 
activin and FGF2 is required to maintain hES cells in an undifferentiated state in the 
absence of feeder-cell layers, conditioned medium or serum replacement (Vallier, 
Alexander et al. 2005). Differentiation of hES cells to neural lineages uses many of the 
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same instructive factors as mouse ES cells (Wichterle, Lieberam et al. 2002; Hu, Du et al. 
2009). The discovery of hES cells enabled the use of human cells to study human 
development and model disease.  Because of their properties, hES cells will be a critical 
component in the development and application of cellular based therapeutics.   
1.1.3 Induced Pluripotent Stem Cells  
Recent discovery of the ability to reprogram differentiated cells into a pluripotent 
state has the potential to advance the use of stem cells for therapeutic applications. 
Induced pluripotent stem (iPS) cells are pluripotent cells artificially derived from 
differentiated cells by transfection of stem-cell associated transcription factors. The 
capability to generate iPS cells was first discovered by Yamanaka et al (Takahashi and 
Yamanaka 2006) using adult mouse fibroblasts and has been repeated using human 
fibroblasts (Takahashi, Tanabe et al. 2007; Wernig, Meissner et al. 2007) and other 
differentiated cell types (Reviewed in (Hochedlinger and Plath 2009). Growth profiles, 
gene expression profiles, and DNA methylation patterns closely resemble ES cells 
(Takahashi, Tanabe et al. 2007; Wernig, Meissner et al. 2007). Initial work with iPS cells 
used retroviruses to deliver reprogramming factors, raising concerns for clinical 
application of these cells. Other approaches including soluble signaling molecules are 
promising alternatives for clinical use (Shi, Desponts et al. 2008; Woltjen, Michael et al. 
2009; Yu, Hu et al. 2009). The discovery of iPS may supplant needs for hES cells as the 
source of pluripotent cells, alleviating ethical concerns regarding the production of hES 
cells. The ability to reprogram adult cells has potential benefits for tissue engineering 
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applications because for the first time pluripotent cells can be obtained from a patient 
that will not be immunologically rejected.  
 
1.1.4 Engineering ES by Gene Targeting 
Gene targeting allows for precise manipulation of both mouse and human ES cell 
genomes (Smithies, Gregg et al. 1985; Thomas and Capecchi 1987; Capecchi 1989; Zwaka 
and Thomson 2003). This technology is widely used by biologists to disrupt gene 
function (a “knock-out”) to study its function. Most often “knock-out” ES cells are 
injected into early-stage mouse embryos which are implanted in the uterus of a female 
mouse and allowed to develop into a mouse in order to study the effects of gene 
disruption on physiology. Gene targeting technology is also of great interest to the tissue 
engineer. ES cells can be engineered to facilitate monitoring and selection of specific cell 
fates. Introducing reporter and selector genes under the control of fate specific 
promoters, (a “knock-in” line), has shown great utility (Fehling, Lacaud et al. 2003; Xian, 
McNichols et al. 2003; Ying, Stavridis et al. 2003; Bibel, Richter et al. 2004; Xue, Wu et al. 
2009). Knock-in lines will be instrumental for success in monitoring differentiation 
strategies and selecting for desired cell types. 
 
In summary, the properties of ES cells make them promising candidates for 
therapeutic use. ES can be grown on a large scale, can differentiate into cells of many 
lineages, and furthermore can be genetically engineered to select for therapeutic cell 
type(s).  Discoveries of hES and iPS have brought the dream of therapeutic cells even 
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closer. Nevertheless, harnessing stem cells for therapeutic applications is going to be a 
challenge. A tissue engineering approach combining engineered stem cells, instructive 
growth factors, and biomaterial scaffolds is desirable. 
 
1.2 Tissue Engineering with ES Derived 
Neural Cells 
ES cells offer a new opportunity for cell based therapy for both 
neurodegenerative disease and injuries. Neurodegenerative diseases are characterized by 
loss of function due to death of specific neural cell types. Traumatic injuries sever critical 
neural connections and result in cell death. In both cases there is hope that delivering 
healthy cells will be able to replace missing cells, repair connections, and restore function. 
ES cells can be differentiated to generate neural cells. Growth factors and culture 
conditions have been defined to differentiate both mouse and human ES cells into 
various neural lineages useful for therapeutics including: dopaminergic neurons 
(Kawasaki, Mizuseki et al. 2000; Wernig, Zhao et al. 2008) for  Parkinson’s disease, 
oligodendrocytes for myleinating deficiencies (Brustle, Jones et al. 1999; Nistor, Totoiu et 
al. 2005; Kang, Cho et al. 2007; Hu, Du et al. 2009), spinal motor neurons (Wichterle, 
Lieberam et al. 2002; Silani, Cova et al. 2004; Hu and Zhang 2009) for Lou Gerhig’s 
Disease and spinal cord injury, and retinal cells for age related macular degeneration 
(Lamba, Karl et al. 2006; Zhao, Liu et al. 2006).  
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For the purposes of this dissertation, we will focus on the use of ES cells alone 
and as part of tissue engineering approaches, combined with growth factors and 
scaffolds, to aid in regeneration of cells following spinal cord injury (SCI) (Reviewed by 
(Coutts and Keirstead 2008; Willerth and Sakiyama-Elbert 2008). This is particularly 
relevant given the clinical trial using hES cells in human SCI by Geron.   
1.2.1 Spinal Cord Injury   
Traumatic injury to the spinal cord initiates a complex biological cascade 
characterized by inflammation, swelling, cell death, and demyelination. In the early stages 
of spinal cord injury, severed connections result in degradation and retraction of axons. 
Both neurons and oligodendrocytes are lost due to SCI.  Resident astrocytes respond to 
the injury immediately and over time create a glial scar. This scar will inhibit axonal 
growth and myelination making the body unable to repair the severed connections 
(Coutts and Keirstead 2008). Depending on the location of the injury and its extent, the 
patient could have minor to catastrophic sensory and motor impairment. One strategy 
with the potential to regenerate the severed connections is to deliver healthy motor 
neurons and oligodendrocytes to the injury site to return some motor control.  
1.2.2 ES Cells as Therapeutic Cells for Spinal Cord Injury 
For safety reasons, undifferentiated ES cells cannot be used directly as a 
therapeutic because they will form teratomas or other cancers (Martin 1981). In addition, 
normal or injured adult tissues do not send proper inducing signals to direct stem cells to 
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desired fates (Nussbaum, Minami et al. 2007). Therefore, ES cells must be differentiated 
towards the therapeutic cell type in vitro before delivery.  
1.2.3 From ES Cells to ES Derived Neural Cells Using Growth Factors 
While many combinations of growth factors have been investigated to direct ES 
cells to a neural lineage, retinoic acid and sonic hedgehog have been the primary focus of 
research to direct ES cells to therapeutic cells for SCI.  Initially, ES cells were directed to 
a general neural lineage by induction with retinoic acid (RA) (Bain, Kitchens et al. 1995). 
The ES cells are first cultured without LIF and RA for four days as embryoid bodies, 
spherical clusters of 100-1000 ES cells. After four days without RA, cells are then 
cultured in the presence of RA for four days to direct ES cells to a general neural lineage. 
These cultures are heterogeneous, containing astrocytes, oligodendrocytes and neurons. 
When these neural cells were implanted in a rat spinal cord injury model, cells survived 
and differentiated into oligodendrocytes, astrocytes, and neurons. Rats that received cells 
exhibited a small, but measurable functional improvement in locomotor function 
compared to animals that did not receive cells (McDonald, Liu et al. 1999). This early 
transplantation study showed delivery of ES derived neural cells contribute to improved 
outcomes and these cells warrant further investigation as a therapeutic for SCI.  
The combination of retinoic acid and sonic hedgehog (Shh) further specifies 
differentiation of ES cells to cell types from the ventral portion of the central nervous 
system (Wichterle, Lieberam et al. 2002). ES cells are cultured as embryoid bodies for two 
days and then in the presence of RA and Shh for up to six days. A Shh agonist or 
purmophamine, which also acts on the hedgehog signaling pathway can be used to 
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substitute for Shh (Wichterle, Lieberam et al. 2002; Sinha and Chen 2006; Xue, Wu et al. 
2009).  These cultures are enriched in motor neurons and oligodendrocyte precursor cells, 
but still contain many cell types. ES derived ventral neural cells have been transplanted 
into rat spinal cord injury models and show surviving transplanted cells are enriched in 
motor neurons (Deshpande, Kim et al. 2006) where as ES cells treated with RA alone did 
not form motor neurons. Transplantation of ES derived ventral neural cells also resulted 
in improved motor function over controls with no therapeutic cells and general neural 
cells. Optimized protocols for further differentiation of hES derived ventral neural cells 
to motor neurons  (Hu and Zhang 2009) and fully functional oligodendrocytes (Hu, Du 
et al. 2009) were recently described and may become useful for the next phase of research 
in spinal cord injury models. 
1.2.4 Biomaterial Scaffolds for SCI 
For SCI, scaffolds are important to provide a structural conduit to aid cells in 
bridging severed connections and enable delivery of additional differentiation signals or 
therapeutic agents. Tissue engineers have incorporated ES derived neural cells into a 
variety of biomaterial scaffolds to explore their utility for treatment of SCI.  Types of 
scaffolds that are under investigation include: fibrin (Willerth, Arendas et al. 2006; 
Johnson, Parker et al. 2009), polymeric including poly(lactic-co-glycolic) acid (PLGA) 
poly L-lactic acid (PLLA) (Levenberg, Burdick et al. 2005), and poly(ethylene glycol) 
(PEG) (Mahoney and Anseth 2007), and electrospun fibers (Xie, Willerth et al. 2009). 
Along with cells many of these biomaterials can also encapsulate additional growth 
factors and therapeutic agents that can be released in a controlled fashion (Johnson, 
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Tatara et al. 2009) to aid in differentiation and cell migration, inhibit cell death, and 
facilitate axon extension. Transplantation of ES derived neural cells with biomaterial 
scaffolds into SCI models have also led to small, but significant, improvements in motor 
function (Johnson 2009). Yet, there is still much research to be done in this area. These 
studies are excellent models for future research on the types of cells, growth factors, and 
materials that will produce the best outcomes in SCI.  
1.2.5 Heterogeneity is a Challenge for Cell Therapies 
The central nervous system contains hundreds of different cell types. Each class 
of cells performs a specialized task which contributes to the overall function of the 
central nervous system. Disease or traumatic injury preferentially attacks certain cell types. 
Once we know which cells are affected, we can begin to investigate delivery of 
replacement cells as part of a therapeutic strategy. To be successful we need to 
experimentally determine which types of cells are most beneficial.   
Many cell types are lost in SCI, most notably motor neurons and 
oligodendrocytes, but there are also other cell types that may play a critical supporting 
role. As a starting point, two different types of ES derived therapeutic cells for SCI will 
be considered: relatively undifferentiated early neural stem cells and differentiated young 
motor neurons. Delivery of early neural stem cells offers several advantages.  Because 
early neural stem cells are able to proliferate they can help repopulate the cord, aiding in 
bridging the severed connections. Early neural stem cells will respond to endogenous or 
provided signals to differentiate and be directed to the needed therapeutic cell type(s). 
More than one type of therapeutic cell type can be delivered based on the differentiation 
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potential of the early neural stem cell. These advantages introduce the risk of several 
disadvantages. Early neural stem cells may continue to proliferate beyond what is needed, 
may not differentiate into the therapeutic cell type(s), or differentiate into undesirable cell 
types (Roy, Cleren et al. 2006), (Johnson 2009).  
As a potential alternative, young motor neurons have the advantage of being both 
a more homogeneous population of cells, and will not proliferate or generate undesirable 
cell types. However, there are also potential problems with delivery of differentiated cells. 
Because young motor neurons will not proliferate, enough cells need to be provided that 
will survive and become incorporated as functional units following the transplantation 
procedure. This is a concern due to the fragile nature of motor neurons and their delivery 
to an inhospitable injury site (Harper, Krishnan et al. 2004). In addition, there may be 
other cell types that are needed for survival and therapeutic gain which are not being 
supplied. In summary, both cell types described here offer potential benefits and pitfalls. 
We cannot determine a priori which will be best. The optimal cell types for therapeutic 
use must be determined by experimentation.   
To be able to experimentally determine the most beneficial cell type for 
delivery, we need to be able to both distinguish between cell types and have a means of 
isolating specific cell types.  Sections 1.3.3 and 1.3.4 describe approaches to perform these 
tasks. Improvements in the tools that are used to characterize and separate cells will 
address the challenge that cellular heterogeneity poses to the development of tissue 
engineering strategies. 
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1.3 Cell Fate Characterization 
Cell fate characterization is an important part of any tissue engineering strategy 
that incorporates ES cells.  The properties of the ES cells should be known, and methods 
for measuring the transition of pluripotent ES cells to the desired therapeutic cell fate 
must to be developed. For use of ES cells in therapeutic applications, we must be able to 
define measurable characteristics to monitor the pluripotent state and differentiation. 
Candidate characteristics include: epigenetic marks, mRNA expression, protein 
expression, and metabolite profiles.  Recent advances in genomics, PCR, and sequencing 
technologies make nucleic acid based analyses particularly attractive.  
1.3.1 mRNA Profiling   
Transcription of RNA marks one of the key steps in determining cellular fate. 
The mRNA encodes the information necessary for synthesis of proteins that are 
necessary for the cell to generate and maintain phenotype.  The presence or absence, and 
abundance of particular mRNAs will determine cellular phenotype. For example, the 
mRNA profile of an ES cell is very different from a neuron (Abranches, Silva et al. 2009).  
Biological tissues contain multiple cell types arranged in highly organized 
structures.  For tissue engineering mRNA profiling can be used to first identify the 
characteristics of the needed therapeutic cell type(s). Once the desired mRNA profile is 
known it can then be used as a quality control standard for the production of therapeutic 
cells from ES cells. An ideal technology for mRNA profiling in tissue engineering would 
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have three characteristics. It must be able to measure mRNA for many genes in a sample 
containing single cells or small numbers of cells and also must be quantitative. Standard 
mRNA expression profiling techniques such as microarrays, northern analysis, or RT-
PCR do not meet these criteria. New digital methods (section 1.3.3, Chapter 2) are likely 
to lead to advances in mRNA profiling technologies. Advances in mRNA profiling 
technology will be important to advance the use of ES cells in tissue engineering. 
1.3.2 DNA Methylation Analysis  
DNA methylation analysis is a complementary and alternative approach to 
mRNA expression analysis for characterizing cell fate (Baron, Turbachova et al. 2006). 
Mammalian DNA contains cytosine residues that are marked by covalent addition of a 
methyl group on the 5-carbon. At the time this thesis was initiated, DNA methylation 
was thought to function in silencing gene expression (Wolf, Jolly et al. 1984; Watt and 
Molloy 1988; Boyes and Bird 1991; Li, Beard et al. 1993; Panning and Jaenisch 1996; 
Walsh, Chaillet et al. 1998). Therefore, genes silenced during differentiation would 
become methylated in tissues where they are not needed. Consequently, changes in 
methylation patterns could be used to monitor differentiation of ES cells to a desired cell 
type. 
Perceptions of the functional role of DNA methylation are changing (see chapter 
3, Reviewed by (Suzuki and Bird 2008) as increased methylation data has become 
available through high throughput sequencing platforms (section 1.3.3). DNA 
methylation is no longer thought to be a definitive silencer. However, DNA methylation 
has several attributes that make it an attractive method to characterize cells. Foremost, 
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DNA methylation can be measured with base-pair precision using bisulfite treatment and 
PCR (Frommer, McDonald et al. 1992; Clark, Harrison et al. 1994). This technology has 
facilitated discovery of cell and tissue specific DNA methylation profiles for individual 
neural genes (Takizawa, Nakashima et al. 2001) and on a genome wide level (Eckhardt, 
Lewin et al. 2006; Illingworth, Kerr et al. 2008). For example, the promoter of Oct3/4, a 
critical marker of ES cell pluripotency, becomes methylated when ES cells are 
differentiated (Fouse, Shen et al. 2008); (Gidekel and Bergman 2002); (Hattori, Nishino et 
al. 2004); (Li, Pu et al. 2007) and unmethylated when fibroblasts are reprogrammed to a 
pluripotent cell (Takahashi and Yamanaka 2006; Takahashi, Tanabe et al. 2007; Wernig, 
Meissner et al. 2007). While the function of methylation is not well understood, 
correlation of methylation status and phenotype may be useful in a diagnostic context. 
DNA methylation profiles could provide a diagnostic marker that would open the 
way for a high-resolution analysis of cell fate. After cell type and tissue specific 
methylation profiles are identified, they could be used as criteria to monitor the quality of 
therapeutic cells by their differentiation status.  Therefore, discovery of cell type specific 
methylation profiles and development of DNA methylation assays have the potential to 
further the use of ES cells in tissue engineering research. 
1.3.3 Digital Methods for mRNA Profiling and Methylation Analysis  
Digital PCR relies on two principles: segregation of DNA molecules and clonal 
amplification by PCR to quantitatively detect single molecules. Messenger RNA can be 
treated in a similar fashion once RNA is reverse transcribed into complementary DNA 
(cDNA). The first embodiment of this method used dilution of DNA into a well plate to 
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separate molecules (Vogelstein and Kinzler 1999). Subsequently, gel matrices (Mitra and 
Church 1999; Chetverina, Samatov et al. 2002) and bead based emulsions (Dressman, 
Yan et al. 2003) have been used to segregate DNA molecules.  Capitalizing on the 
extraordinary amplification power of PCR, colonies of DNA with identical sequence are 
obtained from each molecule. The sequence of these colonies can then be interrogated in 
numerous ways (Ronaghi, Uhlen et al. 1998; Vogelstein and Kinzler 1999; Mitra, 
Shendure et al. 2003) including high-throughput sequencing. Due to their sensitivity, 
digital methods are uniquely positioned for profiling stem cells ((Rieger, Poppino et al. 
2007), See chapter 2).  At the time this thesis was initiated digital PCR strategies were just 
beginning to be investigated for mRNA expression (Warren, Bryder et al. 2006; Kim, 
Porreca et al. 2007) and methylation analysis (Taylor, Kramer et al. 2007; Korshunova, 
Maloney et al. 2008). Currently, digital PCR joined to low-cost, high-throughput 
sequencing technologies sold by companies such as Illumina, Roche (454), and Applied 
Biosystems (SOLiD) have set the new standard for mRNA profiling for research and 
industry.  These new methods are already providing powerful tools to gain insights into 
cell fate and will become critically important in the development of tissue engineering 
strategies. 
1.4 Cell Separation 
Despite considerable progress in directing stem cells to specific lineage by the 
application of growth factors, the population of differentiated cells is typically still 
heterogeneous. For therapeutic applications of ES cells, it will be important to enrich for 
the desired cell types and remove pluripotent and other rapidly dividing cells which may 
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have adverse clinical effects. Cell separation technologies are a necessary part of the 
future of the tissue engineering field (Palsson and Bhatia 2004).   
Cell separation technologies that are able to provide a high level of purity and 
yield are desired for therapeutic applications. Separation based on physical properties 
such as microdissection or density centrifugation give moderate to good purity but do not 
scale. Biological separation using surface markers with immuno-affinity allows for high 
yield, but often low purity (Schweitzer, van der Schoot et al. 1995; Corti, Nizzardo et al. 
2009).  Individual cells can be separated by surface markers and genetically engineered 
cells containing reporter genes can be selected with fluorescence activated cell sorting 
(FACS). Using the FACS allows for purification of cells with multiple characteristics, but 
operates at relatively low throughput (Palsson and Bhatia 2004; Murry and Keller 2008). 
While not widely used, selection using antibiotics and cells engineered with corresponding 
resistance gene have shown the ability to yield clinically relevant numbers of cells in 
bioreactors at high purity (Zandstra, Bauwens et al. 2003).   
1.5 Concluding Remarks 
This thesis is motivated by the potential of stem cells as a source of replacement 
cells in cellular and tissue engineering therapeutics for treatment of neurodegenerative 
disease and injury. Because the nervous system is comprised of hundreds of cell types 
which are differentially affected by disease and injury,  it will be necessary to 
experimentally determine which cell types are most beneficial as part of a therapeutic 
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strategy. For this purpose tools are needed that can both define heterogeneity and purify 
the desired cell types.  
This thesis will detail the development of three tools to advance the use of stem 
cells as part of tissue engineering approaches for neurodegenerative disease and spinal 
cord injury.  The first two studies will describe the application of two nucleic acid-based 
approaches to define cell fate. In chapter two, a digital PCR technology, called polonies, is 
applied to quantitatively measure mRNA levels from several key stem cell genes in small 
numbers of ES cells. To explore DNA methylation as a way to characterize 
differentiation from ES to neural cells, chapter three will measure DNA methylation 
surrounding genes that are instructive to pluripotency and neural cell fate in ES cells, ES 
derived neural cells, and non-neural tissues. Chapter four develops an approach to purify 
subsets of neural cells.  ES cells are genetically engineered to permit drug selection of a 
subset of ES derived neural cells. Overall, this thesis contributes tools to define and limit 
cellular heterogeneity which will be useful in the development of cellular and tissue 
engineering therapeutics for neurodegenerative disease and injury.  
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Chapter 2 
  
Polony Gene Expression Analysis of  
Stem Cells 
 
2.1 Abstract 
 
Expression profiling of stem cells is challenging due to their small numbers and 
heterogeneity. The PCR colony (polony) approach has theoretical advantages as an assay 
for stem cells but has not been applied to small numbers of cells. An assay has been 
developed that is sensitive enough to detect mRNAs from small numbers of ES cells and 
from fractions of a single mouse blastocyst. Genes assayed include Oct3, Rex1, Nanog, 
Cdx2 and GLUT-1. The assay is highly sensitive so that multiple mRNAs from a single 
blastocyst were easily detected in the same assay. In its present version, the assay is an 
attractive alternative to conventional RT- PCR for profiling a small population of stem 
cells. The assay is also amenable to improvements that will increase its sensitivity and 
ability to analyze many cDNAs simultaneously.   
 
Chapter 2 has been adapted from the following published manuscript: 
Rieger, C., Poppino, R., Sheridan, R., Moley, K., Mitra R., and D. Gottlieb. (2007). 
"Polony analysis of gene expression in ES cells and blastocysts." Nucleic Acids Res 
35(22): e151. 
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2.2 Introduction 
 
Stem cells are currently the focus of intense interest because of their importance 
in normal development and adult physiology as well as their potential application in 
clinical medicine. Expression profiling of stem cells poses a special challenge and lack of 
appropriate methods constrains progress in many branches of stem cell research. The 
challenge arises because stem cells occur as small populations surrounded by other cell 
types and because even the stem cell populations themselves are heterogeneous and 
encompass multiple cell populations. An ideal profiling method would have three 
capabilities. The first is the sensitivity to assay mRNAs in small populations and single 
cells and thus deal with heterogeneity. Second, because cell fate is determined by sets of 
genes rather than any single gene, the method must allow parallel analysis of multiple 
genes. Finally the method must be quantitative, since levels of expression rather than 
mere presence or absence of transcripts determines phenotype. While multiple expression 
analyses of stem cells based on PCR have been published, no method fulfils all these 
criteria (Chiang and Melton 2003; Tietjen, Rihel et al. 2003; Bengtsson, Stahlberg et al. 
2005; Hartmann and Klein 2006; Tang, Hajkova et al. 2006). The method of PCR colony 
(polony) analysis differs in important ways from conventional PCR and has potential to 
be very useful for profiling stem cells.  
In polony (also called molecular colony (Chetverina, Samatov et al. 2002)) 
analysis, individual DNA molecules are amplified clonally in a polyacrylamide gel matrix 
(Mitra and Church 1999; Zhu, Shendure et al. 2003). Analysis is very efficient, with 80% 
of the input DNA molecules forming polonies, so the method is inherently very sensitive 
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(Mitra and Church 1999). All polonies signify one starting template DNA molecule so 
variations of amplification efficiency do not influence the final count of input templates. 
Cross- interference of different amplicons is largely avoided, since the reactions are 
effectively isolated from one another by the gel matrix. The DNA sequence of individual 
polonies can be ascertained by either sequence-specific fluorescent hybridization probes 
or an in situ sequencing procedure, opening the way for parallel multigene analysis (Mitra, 
Shendure et al. 2003). Because of these features, the polony method is an excellent 
candidate approach for profiling stem cells. However, previous expression studies with 
polonies have used relatively large starting samples of cells (Kim, Porreca et al. 2007) so it 
is not known if the technique can be applied to small numbers of cells and be useful for 
stem cell profiling. 
In this report we demonstrate that the polony method can be used on small 
numbers of stem cells including ES cells and blastocysts. A method for isolating RNA 
and synthesizing cDNA from small samples was coupled with polony analysis and the 
sensitivity of the overall approach and the ability to do parallel analyses of multiple genes 
was evaluated. Our results represent significant progress towards the ideal profiling 
method described above and will encourage further technical developments of the polony 
approach. 
2.3 Materials and Methods 
 
ES cell culture 
 All ES cell experiments were done with the RW4 line of ES cells derived from 
Sv129 mice. Undifferentiated (ES) cells were grown on gelatin-coated tissue culture 
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plastic in the presence of leukemia inhibitory factor (LIF) using standard methods (Bain, 
Kitchens et al. 1995; Bain 1998).  In preparation for polony experiments, undifferentiated 
ES cells were trypsinized with 0.25% trypsin-EDTA (GIBCO) to detach cells from the 
surface, and counted using a hemocytometer. For the 1,000 ES cell isolation, cells were 
spun down and diluted to obtain a concentration of 500,000 cells/mL. 
Embryo Recovery and Culture 
Embryos were recovered as previously described (Moley, Chi et al. 1998).  In 
brief, three-week-old female mice (B6 x SJL F1, Jackson Laboratories; Bar Harbor, ME) 
were given free access to food and water and were maintained on a 12-hour light/dark 
cycle.  Female mice were superovulated with an intraperitoneal injection of 10 
International Units (IU)/animal pregnant mare serum gonadotropin (PMSG, Sigma; St. 
Louis, MO) followed 48 hours later by 10 IU/animal of human chorionic gonadotropin 
(hCG, Sigma; St. Louis, MO).  Female mice were mated with males of proven fertility 
overnight following the hCG injection.  Mating was confirmed by identification of a 
vaginal plug.  Mice were sacrificed 96 hours post hCG injection to recover embryos at the 
blastocyst stage (3.5 d.p.c).  Embryos were recovered by flushing dissected uterine horns 
and ostia with human tubal fluid medium (HTF, Irvine Scientific; Santa Ana, CA) 
containing 0.25% BSA (Bovine serum albumin fraction V, Sigma; St. Louis, MO). 
RNA Isolation 
Cells (either ES cells or blastocysts)  were delivered to PCR tubes containing 
either 10µg for blastocysts or 100µg for ES cells of Dynabeads Oligo (dT)25 (Invitrogen) 
in 20µL or 100µL lysis-binding buffer (100 mM Tris-HCl, pH 7.5, 500 mM LiCl, 10 mM 
EDTA, pH 8.0, 1% LiDS, 5 mM dithiothreitol (DTT)). Cells were lysed by pipetting up 
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and down five times in the lysis-binding solution. Tubes were rotated for 10 minutes at 
room temperature to promote hybridization of the polyA+ mRNA with the oligo(dT) tails 
of the Dynabeads. After hybridization of mRNA with Dynabeads, a series of washes was 
performed to prepare the mRNA for reverse transcription. Two washes were performed 
in wash solution A (10 mM Tris-HCl, pH 7.5, 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS).  
Next, Dynabeads were incubated in 100 µL wash solution B (10 mM Tris-HCl, pH 7.5, 
0.15 M LiCl, 1 mM EDTA) with 0.01% Tween-20 for 5 minutes to allow the beads to 
equilibrate.  This was followed by a second wash in wash solution B without Tween and a 
final wash in 10mM ice cold Tris-HCl, pH 7.5. In some experiments mRNA attached to 
the beads was used directly in an RT reaction. In others the mRNA was eluted in 10µL 
Tris-HCl by heating at 90°C for 2 minutes. 
cDNA Synthesis  
Reverse-transcription reactions were performed using the RETROscript kit 
(Ambion, Austin, TX). Final concentrations of components were as follows: 1x RT buffer 
(50mM Tris-HCl, pH 8.3, 75mM KCl, 3mM MgCl2, 5mM DTT), 5µM oligo(dT18), 500µM 
each dNTP, 0.5U/µL RNase Inhibitor, 5U/µL MMLV reverse transcriptase, .05 µg/µl 
BSA was added as a carrier. For cDNA synthesis reactions performed on mRNA 
hybridized to Dynabeads the oligodT primer was omitted.  cDNA synthesis reactions 
were carried out at 42°C on a roller for 1 hour. An RT-minus reaction was always 
prepared in parallel by substituting water for MMLV RT-enzyme. 
Primers 
The primers used are listed in Appendix A, Tables A1 – A3; all primers are from 
Integrated DNA technologies (IDT, Coralville, IA).  Primers were selected using Primer3 
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with the restriction of being within 800bp of the 3’ end. All polony reverse primers 
include an acrydite group (Ac) on the 5’ ends (Mitra and Church 1999). The 5’ end of the 
hybridization primers are covalently linked to a fluorescent dye (Cy5).   
Polony Reactions 
Polony reactions were prepared according to Mitra and Church (Mitra and 
Church 1999). Template cDNA was added to a liquid phase acrylamide gel mix 
containing PCR components. Templates were amplified using PCR within the gel. cDNA 
template or RT-minus suspension was added to a liquid-phase PCR mix (polony 
mastermix) [10mM Tris-HCl pH 8.3, 50mM KCl, 0.01% gelatin, 1.5mM MgCl2, 200µM 
dNTPs, 1 µM Forward Primer, 1µM Primer Reverse_Ac, 3.3U or 3.8U Jumpstart Taq  
(Sigma, St. Louis, MO), 9% Acrylamide, 0.05% Bisacrylamide (Sigma)].  Then, 0.667 µL 
of degassed 5% ammonium persulfate (Sigma) and 0.667 µl 5% temed (Sigma) were 
added to the polony mix to a total volume of 28µL or 40µL. Nineteen microliters of this 
solution was pipetted underneath a clean No. 2 coverslip (18 x 30 mm Fisher) on a bind-
silane (Sigma) treated Teflon coated oval well slide (Erie Scientific, Portsmouth NH).  
Slides were cycled using a PTC-200 thermal cycler (Bio-Rad, Hercules, CA) 
adapted for glass slides (16/16 twin tower block).  The following program was used: 
denaturation (2 min at 94°C) followed by 43 cycles of denaturation, primer annealing, and 
extension (30 s at 94 °C, 30 s at 56 °C, 30 s at 72 °C).  After cycling the Secure-Seal™ 
chamber was removed and slides were washed in hexane (Sigma) for 5 minutes to remove 
mineral oil and remaining adhesive.  Coverslips were removed and slides were washed 
twice in solution 1E (100mM Tris pH 7.5, 500mM KCl, 2mM EDTA, 0.01% Triton-X 
100) for 4 minutes with gentle shaking. 
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Hybridization for Polony Detection 
Slides were incubated in 70% formamide (Sigma) in 1X SSC at 70°C on a roller 
for 2 minutes to denature double stranded DNA.  Formamide was removed by washing 
with water for 3 minutes followed by washing with solution 1E. A blue Frame Seal 
chamber base (Bio-Rad) was applied to each slide and annealing mix was added (5.6µM 
hybridization probe in 125µL of 6x SSPE buffer with 1% Triton X-100). Slides were 
heated (2 minutes at 94 °C, 7 minutes at 56°C).   Frame seal chambers were removed 
quickly and slides were placed in wash1E to dilute away excess primer to limit non-
specific binding.  Slides were washed and stored in wash1E.  
Visualizing and Scoring Polonies  
 Polony slides were coverslipped, and imaged using a GenePix 4000B (Axon 
Instruments, Union City, CA) microarray scanner and GenePix software.  Optimal signal 
intensity for the Cy5 fluorophore was obtained for laser PMT gain of 700 (635 laser) and 
82 (532 laser). Images were saved as TIF and JPEG files. Polonies were counted manually 
using ImageJ software and cell counter applet.   
Competitive PCR 
DNA competitors with a 50bp deletion of the corresponding native amplicons 
were synthesized by standard methods. The competitors have the same terminal 
sequences as the native amplicons to ensure equal amplification. Forward primers, reverse 
primers and deletion primers are described in Table S4.  For polony and competitive PCR 
analysis, RNA was extracted in a series of reactions containing 2,000 ES cells and 100µg 
of Dynabeads in 100µL of lysis-binding buffer as previously described. RNA was eluted 
from Dynabeads in 20µL DEPC H20 and 4µL oligo(dT)18 and reverse transcription 
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performed as previously described in a total volume of 42µL. Competitive PCR reactions 
were carried out with a fixed amount of sample and varying amounts of competitor to 
determine the equivalence point. 
Model RNA  
To analyze the efficiency of RT mimic mRNAs were constructed. The mimic 
consists of the BNI5 yeast gene fused to a polyA+ tail taken from a region of the 
Xenopus elongation factor-1α gene (pTRI-XEF, Megascript kit, Ambion). The mimic 
was synthesized by knitting PCR followed by cloning into pBluescriptSKII(+) vector 
(Stratagene). RNA was transcribed from this plasmid by standard methods using T7 RNA 
polymerase. Model RNAs were purified by standard methods and quantified by OD260 
absorption. 
2.4 Results 
 
Polony technology has been used extensively to analyze genomic DNA and in a 
few instances cDNAs from large numbers of yeast or mammalian cells (Zhu, Shendure et 
al. 2003; Mikkilineni, Mitra et al. 2004; Kim, Porreca et al. 2007), but has not been used to 
profile gene expression from small numbers of cells. Our first question was whether 
polony analysis could be applied to small numbers of mammalian stem cells. Mouse ES 
cells were chosen because they offer a pure population of stem cells where the gene 
expression pattern is clearly related to cell fate choice (Boyer, Plath et al. 2006; Lee, 
Jenner et al. 2006). We also analyzed blastocysts, a stage of mammalian development 
comprised mainly of stem cells including a subset which corresponds to ES cells.  
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In the first experiment 1000 ES cells were used as the starting sample for isolating 
mRNA. Several methods of RNA extraction were investigated and it was found that 
hybridization capture of mRNA on oligo (dT)5 Dynabeads was particularly efficient. An 
illustration of the overall experimental methods is provided in Figure 2.1. 
 
Figure 2.1: Flow Chart of Typical Polony Gene Expression Experiment.  Cells (either 
1000 ES cells, single blastocysts or multiple blastocysts) were delivered to a lysis-binding 
solution containing oligo(dT)25 Dynabeads.  After cell lysis, mRNA was captured by 
hybridization of poly-A tails on the beads and mRNA was reverse transcribed into 
cDNA.  cDNA was added to non-polymerized polyacrylamide gel mix containing PCR 
components and deposited in an oval well on a microscope slide.  After polymerization 
of the gel, slides were thermocycled so that cDNA templates gave rise to polonies. 
Polonies were visualized by hybridization with a labeled gene-specific probe. 
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The mRNA from 1000 ES cells was captured on Dynabeads and added to a 
reverse transcriptase (RT) reaction with the Oligo-dT of the beads serving as primer. 
After cDNA synthesis, a small fraction of the beads was delivered to a polony slide with 
primers designed to amplify Oct3, a transcription factor involved in maintaining the 
pluripotency of ES cells (Pesce and Scholer 2001).  Each polony slide received the 
equivalent of 10 cells worth of cDNA or an equal volume of a control reaction lacking 
RT. Slides were thermocycled and then stained with a labeled hybridization primer for 
Oct3. In this and all subsequent experiments hybridization probes are internal to the 
amplifying primers and are labeled with Cy5 coupled to the 5’ terminus. It is crucial that 
the assays be highly specific for the intended transcript and not show false positives. As 
with any PCR method, there is the potential of primer dimers and other unintended 
amplified sequences. Our results are very likely to be free of this sort of error for two 
reasons. All experiments include RT control samples and these do not produce polonies. 
Second, scoring polonies by hybridization of an internal primer which does not share 
sequence with the amplifying primers prevents signals from primer dimmers and other 
unintended amplicons. Polonies were visualized on an Axon microarray scanner and were 
abundant, evenly distributed and clearly distinguishable from background on the slides 
with cDNA. Importantly, polonies were absent from the RT control slide demonstrating 
that cDNA rather than genomic DNA is detected (Figure 2.2).  
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 29 
To investigate reproducibility, an experiment with two independent RT reactions 
was performed. Each RT reaction was assayed on 4 slides and the number of Oct 3 
polonies on each slide were counted (Table 2.1).  
 
Table 2.1: Oct3 Polony Counts from Slides Containing the Equivalent of 10 ES Cells 
 
mRNA was isolated from 1,000 ES cells and reverse transcribed to cDNA in 2 separate 
reactions.  10 ES cell equivalents of cDNA from each synthesis was delivered to 4 
polony slides. After amplification, polonies were visualized by an Oct3 gene-specific 
hybridization probe. Scans of slides 1 and 2 appear in Figure 2. Oct3 polony counts 
ranged from 292 to 655 polonies per slide with an average of 499 per slide, equivalent to 
an average of 50 polonies per ES cell. Slide 9 is an RT control and does not contain 
polonies.    
 
 
The mean of all 8 slides was 499 polonies with a standard deviation of 116; this is 
equivalent to a mean of 50 Oct3 polonies per cell. As discussed below this is a minimum 
estimate of the number of mRNAs per cell as it does not take into account the efficiency 
of mRNA isolation and conversion to cDNA. We conclude that the polony approach 
allows the assay of expression from small numbers of ES cells.  
 30 
Having demonstrated that polonies can detect mRNA from small numbers of ES 
cells, we wanted to see if they could be used to detect mRNAs in a normal biological 
structure that contains stem cells and is made up of a small number of cells. We chose the 
mouse blastocyst since it is an intensely studied stage of mammalian development, is easily 
obtainable, and is comprised of only 75-100 cells (Chisholm, Johnson et al. 1985; Johnson 
and McConnell 2004). About 40% of the cells are in the inner cell mass (ICM) and 
phenotypically resemble ES cells. The transcription factor Oct3 is exclusively expressed in 
the ICM (Carayannopoulos, Schlein et al. 2004). In a range-finding experiment, 10 mouse 
blastocysts were pooled, their mRNA isolated, and cDNA synthesized. Polony assays for 
Oct3 were conducted on two slides each containing cDNA equivalent to one half of a 
blastocyst (Table 2.2).  
 
 
Table 2.2: Oct3 Polony Counts from Pooled and Individual Blastocysts 
 
 
mRNA was isolated from a pool of 10 blastocysts and diluted so that the mRNA 
equivalent to one half of a blastocyst was delivered to slides 1 and 2. Next, mRNA 
isolated from a single blastocyst was divided between slides 3 and 4. Two RT control 
slides contained mRNA from the equivalent of 5 blastocysts.  Oct3 polony counts from 
the pooled blastocyst sample are in good agreement with the individual blastocyst 
sample. Data demonstrates that analysis from one half of a blastocyst is feasible.  
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There were 967 and 901 polonies on the two slides for a total of 1868 polonies per 
blastocyst. Next, mRNA from a single blastocyst was isolated, reverse transcribed and 2 
slides prepared. The average of these slides detected 1728 polonies per blastocyst.  Two RT 
controls were done with the mRNA equivalent of five blastocysts; no polonies were 
present. We conclude that the polony method is sensitive to the level of a single blastocyst 
and that the entire analysis from mRNA preparation through polony analysis is scaleable in 
the range of one to ten blastocysts. The sensitivity of the polony assays compares very 
favorably with conventional RT-PCR analysis of expression in blastocysts, where multiple 
blastocysts are pooled to detect gene expression (Carayannopoulos, Schlein et al. 2004; 
Riley, Heeley et al. 2004). For some genes, however, expression of multiple genes can be 
measured from a single embryo (Zhang, Tam et al. 2006). 
In order for the assay to be useful, it is essential to know the sample-to-sample 
variability due to cDNA synthesis and polony reactions. In this and all subsequent 
experiments we used two minor refinements of the previous protocol: mRNA was eluted 
from the beads prior to cDNA synthesis and the amount of Taq per slide was increased 
threefold. Taken together these two steps increased polony counts by about 30% (data not 
shown). To measure variability, mRNA was isolated from a pool of five blastocysts and 
split into three sub-pools, each the equivalent of a single blastocyst  (Figure 2.3).  
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Figure 2.3: Analysis of Variation of RT and Polony Generation Steps. (a) Flow chart of 
the experiment. Five blastocysts are used in a single mRNA prep and one blastocyst 
equivalent is used in three separate RT reactions. Each RT reaction is analyzed on 3 
separate polony slides (P1-3) for Oct3. (b) Bar graph where each bar is the average number 
of polonies for three slides from the same cDNA synthesis. The error bars are the standard 
deviation. ANOVA indicates that independent cDNA preparations are indistinguishable 
(P>.05) 
 
 
These were reverse-transcribed in parallel, and cDNA analyzed for Oct3 transcripts in 
three polony reactions for each reverse transcriptase reaction. The variation between the 
polony numbers on replicate slides with the same reaction was acceptable, with the 
standard deviation being no more than 17.7 % of the mean.  There was also good 
agreement between the means for the three different cDNA syntheses which differed by 
no more than 23%. An ANOVA analysis revealed that the different cDNA reactions were 
comparable to one another (p>0.05) with an overall average value of 3213+/-462 polonies 
per blastocyst. In conclusion, sample-to-sample variability is comparable to other widely 
used assays.   
 33 
The ability to measure expression of multiple genes from a single sample is highly 
desirable, and we next investigated whether the polony assay could detect expression of 
multiple genes from a single blastocyst. We chose two other transcription factors expressed 
in ES cells and the blastocyst inner cell mass (ICM): Nanog and Rex1 (Rogers, Hosler et al. 
1991; Mitsui, Tokuzawa et al. 2003). Gene-specific amplification and hybridization primers 
were designed for these mRNAs and validated with ES cells (data not shown). Next, 
individual blastocysts were assayed. RNA was extracted and cDNA synthesized by the 
same method as above, and the cDNA from each blastocyst split and delivered to three 
individual slides with primers for either Oct3, Nanog or Rex1, and the slides assayed with 
the appropriate gene-specific hybridization probe. As shown in Figure 2.4, all reactions 
yielded polonies; counts from this experiment are given in Table 2.3.  
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Table 2.3: Multigene Analysis of a Single Blastocyst 
 
 
Three individual blastocysts were analyzed for 3 genes: Oct3, Nanog and Rex1. Three 
separate polony reactions were performed using mRNA from each blastocyst. The 
numbers in the table represent average and standard deviations for each gene. Gene 
specific hybridization probes were used to detect and quantify polonies 
 
 
Oct3 gave the highest number of polonies; the number of Oct3 polonies per 
blastocyst was consistent with those of previous experiments. Nanog had the lowest 
number (~10% of Oct3) and Rex1 about twice as many as Nanog. The lower number of 
polonies for Nanog and Rex1 might mean that there are fewer mRNAs per blastocyst than 
Oct3. Alternatively, it could be because their isolation is less efficient or that cDNA 
synthesis is less efficient. We conclude that expression of at least three genes from a single 
blastocyst can be readily detected. This is in contrast with many current experiments with 
standard RT-PCR that require pooling multiple blastocysts (Carayannopoulos, Schlein et al. 
2004; Riley, Heeley et al. 2004).  
Blastocysts contain two layers termed the inner cell mass (ICM) and the 
trophectoderm. Oct3, Nanog and Rex1 are all expressed in the blastocyst ICM. To test the 
generality of the polony method we assayed expression of Cdx2, a gene selectively 
expressed in the trophectoderm (Strumpf, Mao et al. 2005; Deb, Sivaguru et al. 2006). Four 
individual blastocysts were analyzed for Cdx2 and Oct3 (Table2. 4).  
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Table 2.4: Analysis of Trophectoderm Gene Cdx2 
 
 
RNA was extracted from each of four blastocysts and reverse transcribed separately. 
Each cDNA was split and analyzed for Cdx2 (2 slides) and Oct3 (1 slide). Polonies per 
blastocyst and the average and standard deviation are indicated. 
 
 
 
Cdx2 polonies were present in all four blastocysts and there was a large variation 
among the four blastocysts with a range from 809 to 2105 Cdx2 polonies. The range for 
Oct3 was 2268 to 4305 which is consistent with previous experiments. We conclude that 
the polony approach can detect expression of a gene that is specifically expressed in the 
trophectoderm lineage of the blastocyst. All of the genes assayed above are for 
transcription factors and it is desirable to show that polonies can detect another class of 
genes. We therefore assayed the expression of GLUT-1, a membrane protein that is one of 
the primary glucose transporters in blastocysts (Figure 2.5) (Heilig, Saunders et al. 2003).  
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Figure 2.5: GLUT-1 Expression Assayed by Polonies. (a) GLUT-1 and Oct3 polonies 
per slide for six individual blastocysts.   Each data point represents an average of two 
replicate slides for GLUT-1 and one slide for Oct3. All slides contain one-fifth of the 
cDNA from a single blastocyst.  (b) Comparison of GLUT-1 and Oct3 polonies per 
blastocysts for averaged individual samples. 
 
 
GLUT-1 assays were done on six individual blastocysts and Oct3 was measured as 
a control. GLUT-1 polonies are present in each blastocyst with an average of 348 ± 84 
polonies/blastocyst. The blastocysts had 3340 ± 674 polonies for Oct3, in accordance with 
previous experiments. We conclude that all the blastocysts tested express GLUT-1 and that 
the polony method is suited for analysis of this gene. 
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In order to further validate the use of polonies for small numbers of cells a direct 
comparison with an established PCR method was performed. Competitive PCR was 
chosen as the standard method because of its sensitivity and rigorous quantitative design 
(Zentilin and Giacca 2007). Assays were done on ES cells for Oct3, Nanog and Rex1 
expression by polonies and competitive PCR and the results compared (Figure 2.6).  
 
 
Figure 2.6: Polonies and competitive PCR for three genes. (A) Polonies per slide and 
per ES cell equivalent for Oct3, Nanog, and Rex1.  The average number of polonies and 
standard deviation of three replicate slides containing 10.4 ES equivalents are shown. 
Calculated number of polonies per cell for each set of slides is indicated. (B) Competitive 
PCR for each of three genes. DNA competitors with 50-bp deletions were generated for 
Oct3, Nanog, and Rex1.  Competitive PCR reactions with the indicated number of ES cell 
cDNA equivalents and varying amount of competitor is shown.  
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Polonies were counted on slides containing cDNA from 10.4 ES cell equivalents 
for the three genes. Average and standard deviation of polony counts for three replicate 
slides and calculated polonies per ES cell equivalent are shown in Figure 2.6.  The polony 
method shows an average of 67 Oct3 cDNAs per cell, 26 Nanog cDNAs per cell, and 43 
Rex1 cDNAs per cell.  Competitive PCR gels for each of the three genes are also shown in 
Figure 2.6.  Note that the number of ES cell equivalents used to obtain an equivalence 
point using PCR differed for each of the three genes. Using competitive PCR we obtain an 
estimate of 118 Oct3 cDNAs per cell, 38 Nanog cDNAs per cell and 60 Rex1 cDNAs per 
cell.  The number of polonies per ES cell is thus similar to the number of cDNAs 
measured by competitive PCR for each of the three genes. RT controls for each gene using 
competitive PCR and polonies showed no background. In summary, polony assays and 
competitive PCR assays give comparable results 
The numbers of polonies per cell is less than the actual number of mRNAs per cell 
due to inefficiencies in extracting mRNA and reverse transcription of mRNA to cDNA.  
Determining the efficiency from RNA to cDNA (reverse transcription) is a step towards 
extrapolating polony counts to actual number of mRNAs present in a cell.  To this end a 
model RNA was constructed, a known amount reverse transcribed and the efficiency of 
the reaction determined with polonies (Figure 2.7).  
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Figure 2.7:  Efficiency from RNA to Polony. The number of starting RNA molecules is 
plotted against polony output for three levels of RNA input. The number of polonies 
increased linearly with the number of RNA molecules added to the polony reaction. 
Polony counts from each slide are shown by a gray box. Mean values and error bars 
(standard deviation) for each set of three slides at a particular dilution are shown in black.   
 
 
A plasmid for generating model RNA was constructed by joining a yeast gene 
(BnI5) to the poly(A+) rich region  from the Xenopus elongation factor-1α  gene. The 
model RNA (1.6kb containing A70) was synthesized by T7 polymerase. For three dilutions 
of model RNA, the number of polonies increased linearly with increasing amount of 
template (Figure 2.7). RNA template conversion to polony ranged from 4.8%-6.1% on 
individual slides and averaged 5%.  Control polony slides without RNA did not produce 
polonies proving that the polony reaction is specific to the model RNA; RT controls were 
also negative.  To explore the generality of this finding, polonies for other regions of this 
model RNA were tested. Efficiency from RNA to polony for these other amplicons was 
similar (data not shown).  These data are in good agreement with measurements of RT 
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efficiency in the literature (Dufva, Svenningsson et al. 1995). Recently, differences in the 
efficiency of reverse transcription among templates have been shown (Warren, Bryder et al. 
2006), although the reasons for the variability of the RT step have not been discovered. 
2.5 Discussion 
 
The polony method of analysis was adapted for use with small numbers of stem 
cells. The method is sensitive, can be applied to most genes, and allows a degree of 
multiplexing; it gives comparable results to competitive PCR, an established method for 
quantifying cDNAs (Zentilin and Giacca 2007). The approach is also amenable to future 
refinements that will extend its powers.  
The method is sensitive enough to detect mRNAs in fractions of a single mouse 
blastocyst which is comprised of only 75-100 cells. Specifically we have detected mRNAs 
in as little as 1/5 of a single blastocyst. In the case of Oct3 expression is confined to the 
ICM, which is comprised of about 35 cells, demonstrating the method is sensitive to 7 cells 
(1/5 of 35 cells) for this particular RNA.  It is significant that the number of Oct3 polonies 
per ES cell (~50) predicts that there would be about 1750 polonies per blastocyst 
(50/cellX35 ICM cells/blastocyst) a number close to what is measured. The generality of 
the method was demonstrated by performing assays on five separate genes representing 
two classes: transcription factors and a membrane transporter. They also include genes 
exclusive to the ICM (Oct3 and Nanog), a mRNA expressed in both ICM and TE (Rex1) 
and a mRNA expressed specifically in the TE (Cdx2) (Deb, Sivaguru et al. 2006). Taken 
together, these results suggest the method will be applicable to most genes of interest. The 
number of mRNAs present per cell is likely to be greater than the number of polonies due 
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to losses of mRNA in extraction and inefficiency in conversion of mRNA to cDNA by 
reverse transcriptase. Future developments of the method are needed to discover the 
efficiencies of the steps leading up to polonies.  
 In this study we measured the mRNA from three genes from individual blastocysts 
by performing parallel assays on fractions of the cDNA from a single blastocyst. Polonies 
for multiple templates can be analyzed on the same slide by including multiple primer pairs 
(Mitra, Butty et al. 2003) so it is likely that as many as ten genes can be amplified by a 
simple extension of the method we used. Much greater increases in the number of genes 
that can be assayed might be achieved by using universal amplifying primers and applying 
fluorescence in situ sequencing of the polonies (Mitra, Shendure et al. 2003). Thus future 
enhancements of our method could easily assay dozens of genes per blastocyst. 
In summary, the results of these studies show that the polony approach may be 
applied to the problem of stem cell expression profiling and should encourage efforts to 
further develop this system for the special needs of stem cell biology.    
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Chapter 3 
  
From ES to Neural Cells:  
DNA Methylation as a Marker of  Neural 
Cell Fate 
 
3.1 Abstract 
 
The aim of this work was to test the hypothesis that DNA methylation represses 
transcription in genes involved in neural cell fate specification. We investigated the 
correlation between CpG methylation and silencing of gene expression by mapping 
methylation in key developmental and neural fate determining genes in expressing and non-
expressing cells and tissues. The direct bisulfite sequencing method employed mapped 
methylation loci more quickly and cheaply than conventional clonal bisulfite sequencing, 
appropriate for our semi-quantitative focused analysis of a few genes along a pathway. We 
found that Oct3/4 and Pgk1 promoter methylation was correlated with silencing, but 
methylation status of neural fate determining genes Sox1, Olig1, and Olig2 was not 
indicative of expression. This analysis showed that DNA methylation of neural fate 
determining genes was not associated with transcriptional repression, refuting the 
hypothesis. The leading hypothesis for the function of DNA methylation is under question 
and tools to uncover its role have not been developed. 
 
Deany Delaney assisted with experiments performed in Chapter 3.  She performed differentiations and 
prepared DNA. Methylation analysis was done autonomously.  
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3.2 Introduction 
 
DNA methylation is both precisely distributed and dynamic in the mammalian 
genome. In mammals DNA methylation is found exclusively on the 5-carbon of cytosine 
residues and is confined to CpG dinucleotides, a cytosine joined by a phosphodiester bond 
to a guanine. Methylation at CpG sites is symmetric; CpGs are either methylated or 
unmethylated on both strands (Bird 1978). Overall, CpG dinucleotides are 
underrepresented, present at one-fourth of expected frequency based on overall base 
compositions (Bird 1980; Jabbari and Bernardi 2004), and are highly methylated with 60-
90% of CpG sites methylated (Ehrlich, Gama-Sosa et al. 1982; Ehrlich 2003). Genome-
wide methylcytosine levels vary significantly from 0.7 – 1% in different cell types with 
somatic tissues having higher overall methylation levels than both germ cells and placental 
tissues (Ehrlich, Gama-Sosa et al. 1982; Ehrlich 2003). Not only is DNA methylation 
essential for proper embryonic development (Frommer, McDonald et al. 1992; Li, Beard et 
al. 1993; Okano, Bell et al. 1999), periods of demethylation and remethylation occur during 
specific stages of early embryonic development (reviewed by (Ehrlich 2003)). Because 
DNA methylation is necessary for proper development, and actively changing during 
development, as well as exhibiting tissue specific differences, it was hypothesized that 
methylation was involved in the regulation of cell fate.  
A prevailing hypothesis in the field is that DNA methylation functions to silence 
transcription. Many studies have shown that DNA methylation correlates with decreased 
transcription and gene expression. Artificially methylated promoters show decreased 
transcription factor binding in cell extracts (Watt and Molloy 1988; Boyes and Bird 1991) 
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and decreased expression when transfected into cells (Boyes and Bird 1991). Embryonic 
cells methylate retroviral elements rapidly silencing active retroviruses (Jahner, Stuhlmann 
et al. 1982).  In imprinting, the silent allele is preferentially methylated while the 
unmethylated allele is actively transcribed (Li, Beard et al. 1993). Expression of Xist, the X-
inactivation RNA, is also silenced by methylation (Panning and Jaenisch 1996), and CpG 
Islands are methylated on the silent X chromosome (Wolf, Jolly et al. 1984). Expression is 
restored from inactive retroelements (Walsh, Chaillet et al. 1998), imprinted alleles (Li, 
Beard et al. 1993), X-linked and developmental genes (Fouse, Shen et al. 2008) when 
methylation is inhibited, when cells are treated with 5-deoxyazacytidine or have knocked-
out DNA methyltransferases, providing strong evidence that methylation is correlated to 
gene silencing.  
Therefore, there is great interest in mapping DNA methylation genome-wide and 
in localized regions in various cell types. Initial studies digested of genomic DNA with 
methylation sensitive restriction enzymes revealing CpG sites, are unevenly distributed into 
two distinct populations in the mammalian genome: CpG Islands, defined as unmethylated 
CpG-rich DNA (Bird, Taggart et al. 1985) and heavily methylated rest of the genome. With 
the availability of DNA sequence data, CpG Islands were redefined in silico, as CpG-rich 
DNA independent of methylation status, based on sequence GC content (>50%) and 
observed CpG frequency (obs /expect >0.6) over a length window of 200 bases or greater 
((Gardiner-Garden and Frommer 1987), now >500bp). CpG islands were found to be 
associated with the promoter regions of housekeeping genes and 56% of human genes 
(Gardiner-Garden and Frommer 1987; Antequera and Bird 1993); these regions were 
typically unmethylated and associated genes were transcribed. Methylation mapping of 
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specific genes within the context of developmental pathways also provided support for the 
role of DNA methylation in silencing. Mapping Glial Acidic Fibrillary protein (GFAP), 
revealed an unmethylated CpG site in its promoter in astrocytes, which expressed the gene, 
and the same site was methylated in neurons and other non-expressing tissues (Takizawa, 
Nakashima et al. 2001), providing additional support for the hypothesis that methylation is 
involved in silencing.  
Mapping DNA methylation was revolutionized by the bisulfite conversion method 
and PCR (Frommer, McDonald et al. 1992; Clark, Harrison et al. 1994) enabling analysis of 
localized regions at single base resolution. With the completed human and mouse genomes, 
genome-wide methylation mapping is now being revisited using direct bisulfite sequencing 
(Eckhardt, Lewin et al. 2006). Representative regions of the genome have been mapped by 
first performing enrichment by affinity (Illingworth, Kerr et al. 2008) or digestion with 
methylation-sensitive restriction enzymes followed with bisulfite treatment and PCR. 
Methylation status containing sequence information is then obtained by application of PCR 
products to arrays (Shen, Kondo et al. 2007) or to short-read sequencing reactions 
(Meissner, Mikkelsen et al. 2008). This recent flood of genome-wide methylation data is 
revealing exceptions to once held generalizations in the field (Reviewed in (Suzuki and Bird 
2008)).  
The coverage and scope of genome-wide methylation maps are rapidly growing, yet 
these maps are incomplete. Focused methylation mapping still needs to be performed to 
elucidate the relationship between gene and tissue specific methylation patterns and gene 
regulation within the context of specific pathways. Traditionally, bisulfite treatment and 
gene specific PCR are coupled with cloning of PCR fragments and a small number of 
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clones are sequenced to get a quantitative estimate of methylation in a gene of interest. 
Direct bisulfite sequencing, where PCR products obtained following bisulfite treatment are 
sequenced directly, is a quick and cheap alternative for assaying methylation in a small 
number of loci in carefully chosen tissue types and provides a semi-quantitative picture of 
methylation for the pathway of interest.  
The aim of this work is to test the hypothesis that DNA methylation is associated 
with repressed transcription in genes involved in neural cell fate. We investigated the 
correlation between CpG methylation and silencing of gene expression by mapping 
methylation in several regions of key developmental and neural fate determining genes in 
expressing and non-expressing cells and tissues by direct bisulfite sequencing. Two genes 
studied here support the hypothesis. The promoter of Pgk-1, a constitutively expressed 
housekeeping gene, is unmethylated in all cells and tissues; and the promoter of Oct3/4, a 
pluripotency gene, is unmethylated in ES cells where it is expressed, and becomes 
increasingly methylated in differentiated cells and tissues where Oct3/4 is silenced. The 
three neural fate determining genes analyzed: Sox1, Olig1, and Olig2 do not support the 
hypothesis as the regions mapped were largely unmethylated in cells and tissues that do not 
express these genes. The current study adds to the growing epigenome map and refutes the 
leading hypothesis that DNA methylation marks repressed transcription. Currently, there 
are no strong alternative hypotheses for the function of DNA methylation. 
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3.3 Materials and Methods 
 
ES cell culture 
All ES cell experiments were done with the RW4 line of ES cells derived from Sv129 mice. 
A set of experiments with cell line G-Olig2, where GFP has been knocked into the Olig2 
locus of RW4 ES cells (Xian, McNichols et al. 2003), was also performed. Undifferentiated 
(ES) were cells were grown in DMEM supplemented with 10% Fetal Bovine Serum (FBS, 
Sigma), 10% Newborn Bovine Serum (NCS, Sigma) and supplemental nucleosides on 
gelatin-coated tissue culture plastic in the presence of leukemia inhibitory factor (LIF 
1000U/ml, Invitrogen) and beta-mecaptoethanol (0.11mM, Sigma) (Bain, Kitchens et al. 
1995; Bain 1998). 
Neural differentiation 
To generate neural cultures, undifferentiated ES cells were washed twice with 
DMEM/F12 medium and scraped off the bottom of flasks in the presence of 6mL DFK5. 
Cell clumps were triturated and then cultured for 2 days in 10ml of M-DFK5 medium in 
non-adhesive agarose coated tissue culture treated dishes. M-DFK5 medium consists of 
DMEM/F12 supplemented with 1X non-essential amino acids (NEAA, Invitrogen), 1x 
nucleosides, 0.1mM beta-mercaptoethanol, 50ug/mL transferin (Sigma), 5ug/mL insulin 
(Invitrogen), 30nM Na-selenite (Sigma) and 5% Knockout serum replacement (Invitrogen) 
as previously described (Bain, Kitchens et al. 1995; Bain 1998; Zhang, Horrell et al. 2008). 
EBs were transferred to 6 well gelatin coated dishes in M-DFK5 in the presence of retinoic 
acid (RA 2uM) and sonic hedgehog agonist (Shh 30nM, Curis Inc) for 4 days to generate 
neural cultures.  
 49 
Hematopoetic differentiation  
Hematopoietic precursors were generated by switching undifferentiated ES cells 
from DMEM to ES-IMDM media two days prior to differentiation. ES-IMDM media 
consists of IMDM supplemented with 15% FBS, 1% NEAA, 1% L-Glutamine 
(Invitrogen), Monthioglyceriol (MTG .15mM, (Sigma)) and LIF (1000U/ml). To begin 
differentiation, ES cells were washed in HEPES and then trypsinized (0.25% 
Trypsin/EDTA(Sigma)) for 1-2 minutes until cells just started to detach from the surface. 
FBS (1mL) and IMDM (5ml) were added to stop the action of trypsin. Cells were then 
washed with IMDM, resuspended in 5ml IMDM with 10% FBS, and 20,000 cells were 
added to an agarose coated dish containing 10ml of B-differentiation media and grown for 
6 days. B-differentiation media consists of IMDM supplemented with 15% FBS, 1% 
Ascorbic acid (Sigma), 2mM L-glutamine, 0.039uL/mL MTG, Bone morphogenic protein 
(BMP-4 (10ng/mL) (R&D Systems)), and Vascular Endothelial Growth Factor (VEGF 
(5ng/mL) (R&D Systems)) (Lugus, Chung et al. 2007).  
Fluorescence activated cell sorting of G-Olig2 cells  
G-Olig2 ES cells were differentiated into neural precursor cells for either 4 or 6 
days as described and then sorted on the MoFlo or Turbo sorter (Flow cytometry core, 
Washington University School of Medicine). The highest expressing cells (20%) were 
sorted from the lowest (20%) expressing cells and DNA was harvested.  
Isolation of DNA from Cells and Tissues  
Cells were harvested by trypsinization at appropriate differentiation stage. DNA 
was isolated from 1-2 million cells per reaction. Approximately, 70-150mg of heart, liver, 
and lung tissue were harvested from an anesthetized mouse. For all samples DNA was 
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purified using the ArchivePure DNA purification kit (5 Prime) according to manufacturer’s 
instructions.  
Construction of in vitro methylated template  
Plasmid pBluescriptIISK+ was used to construct mock unmethylated and 
methylated templates to assess the efficiency of bisulfite treatment. An initial PCR reaction 
was performed to obtain a linear unmethylated template. This linear template was gel 
purified to remove primers using a Qiaquick gel purification kit (Qiagen) and then 
methylated at CpG sites in vitro at 37°C for two hours using m.SSSI methyltransferase 
(New England Biolabs). The reaction was conducted in 10 mM Tris-HCl, 50 mM NaCl, 1 
mM Dithiothreitol pH 7.9 @ 25°C in the presence of s-adenosylmethionine (SAM 160uM). 
The methylated template was then cut with BstUI which is sensitive to methylated CpG, 
and full-length methylated template was gel purified (Qiagen). Controls verifying the 
methylation specificity of m.SSSI and cofactor SAM were performed in parallel. Primers 
for construction and validation are given in Appendix C, Table C.1.  
Treatment with Sodium Bisulfite  
DNA was treated with sodium bisulfite using EZ DNA methylation kit (Zymo 
Research). Modified conversion conditions were applied. Approximately 500ng of DNA 
were added to 7.5ul of M-Dilution buffer in a total volume of 50ul and incubated at 42ºC 
for 30 minutes to denature the DNA. Following denaturation, 97.5ul CT conversion 
reagent (resuspended in 750uL H
2
0 and 185uL M-dilution Buffer) were added and bisulfite 
treatment was performed overnight in a thermocycler for 16 cycles of 95 ºC for 30 seconds 
and 50 ºC for 1 hour. DNA was stored at 4 ºC until washing and desulphonation were 
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completed the following morning according to manufacturer’s instructions. Bisulfite 
treated DNA was eluted from spin columns in 20ul of 10mM Tris 1mM EDTA.  
PCR Amplification and Purification  
PCR was carried out on 7-9uL (~140-180ng) of bisulfite treated DNA in a total 
reaction volume of 120ul using primers indicated in Appendix C, Tables C.1 and C.2. Gene 
specific PCR primers were designed using MethPrimer (Li and Dahiya 2002), a program 
based on Primer3 to design bisulfite specific PCR primers 
(http://www.urogene.org/methprimer/), and perl scripts were used to append universal 
sequencing tails. PCR reactions were performed in 1X Jumpstart Taq buffer with MgCl
2 
at 
a final concentration of 1.5mM, Jumpstart Taq polymerase, 0.5uM each primer, 200uM 
dNTP mix, and Jumpstart Taq to 0.05U/ul supplemented with BSA (1X) and Betaine 
(1.6M). Thermocycling parameters were as follows: 94 ºC for 2 minutes, 94 ºC for 30 
seconds, 50 ºC for 30 seconds, 72 ºC for 1 minute for 43 cycles with a final extension of 72 
ºC for 5 minutes. PCR products were concentrated and purified from primers using a 1.5% 
agarose gel and Qiaquick gel purification kit (Qiagen) according to manufacturer’s 
instructions, or gel purified by pipette from a 1.5% agarose gel with a 0.2% low melting 
temperature agarose window (Ma and Difazio 2008).  
Sequencing and Analysis  
Gel-purified PCR products (~8ng) were sent for sequencing at PNACL facility at 
Washington University School of Medicine. DNA was sequenced using ABI V1.1 from 
both ends. Trace files and called bases were downloaded from the PNACL server. Several 
commercially available and custom software programs were used to analyze data. First, 
traces were viewed in Gap4 databases assembled using Pregap4 from the Staden Package 
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((Staden, Beal et al. 2000) http://staden.sourceforge.net/). Following visual inspection, 
called sequences were analyzed using a combination of Perl scripts and ClustalX 
((Thompson, Higgins et al. 1994), http://bips.u-
strasbg.fr/fr/Documentation/ClustalX/#R) to align called bases with a known reference 
sequence and quantify bisulfite conversion. Further sequence analyses were performed 
using CpG Viewer ((Carr, Valleley et al. 2007), http://dna.leeds.ac.uk/cpgviewer/), which 
facilitated alignment and visual inspection of traces, called bases, and construction of 
lollipop diagrams. CpG dinucleotides were called methylated when the highest peak and 
called base at a particular position was cytosine followed by guanine in the sense direction 
and unmethylated when the highest peak and called base was thymine followed by guanine 
in the sense direction. A site was considered heterogeneous when reads from sense and 
antisense directions disagreed; most often this was a result of dual peaks (C/T) of near 
equal height. 
3.4 Results 
 
We investigated promoter CpG methylation status of three genes to test the 
hypothesis that promoter methylation is correlated to gene silencing in neural lineage 
specification. Methylation was mapped in loci of a housekeeping gene, Pgk-1 and several 
developmental regulatory genes, Oct3/4, Sox1, Olig1, and Olig2 in expressing and non-
expressing tissues; we expected all cells and tissues that did not express a particular gene to 
be methylated. We began by first evaluating the direct bisulfite sequencing method, so that 
it could be applied to methylation analysis of biological samples.  
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3.4.1 Direct bisulfite sequencing is sensitive and specific, but does  
not quantify heterogeneity  
 
To examine the sensitivity and specificity of the direct bisulfite sequencing method, 
a model linear 2.5kb template with known methylation status was analyzed. Sequencing was 
performed on 5 regions of unmethylated, unmethylated bisulfite treated, and in vitro CpG 
methylated bisulfite treated template using 5 amplicons of approximately 300bp, the same 
size as were used in the gene specific studies described. The efficiency of bisulfite 
conversion [#C’s converted to T’s / total number of C’s sequenced] and extent of 
protection by methylation [#CpG protected / total # of CpG’s sequenced] was 
determined using called sequences and shown in Table 3.1. 
 
Table 3.1 In vitro methylation experiment 
 
 % Bisulfite 
Conversion 
% Methylation 
Unmethylated    17 / 768 = 0.022 185 / 188 = 0.984 
Unmethylated and bisulfite treated 779 / 782 = 0.996     0 / 196 = 0 
CpG methylated and bisulfite 
treated 
587 / 786 = 0.747 190 / 195 = 0.974 
 [#C’s converted to 
T’s / total number 
of C’s sequenced] 
[#CpG protected / 
total # of CpG’s 
sequenced]  
 
The unmethylated, untreated template shows the rate of sequencing errors (false 
positives) that falsely predict conversion (0.022) and CpGs that should have been measured 
(1-0.984= 0.016, false negatives). Bisulfite conversion is very efficient, converting 0.996 of 
cytosines to called thymines. The method was also very sensitive in detecting completely in 
vitro methylated template, as the percent of CpGs measured is close to that of the 
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unmethylated, untreated template (185/188 unbisulfite treated, 190/195 methylated and 
bisulfite treated, p>0.1 binomial test). Methylation specific to CpGs will protect against 
bisulfite treatment 97% of the time while 99% of unmethylated CpGs will be converted in 
the presence of methylated CpGs (587/591 cytosines that are not CpGs are converted in 
M. SSSI methylated template). Errors generally occurred within the low-quality, first 50bp 
of sequences and must be taken into account when analyzing direct bisulfite sequencing 
data from biological samples. These errors can be further minimized by sequencing 
overlapping reads from both directions. Use of universal sequencing tails facilitated easy set 
up of sequencing reactions and improved amplification efficiency and sequence quality. 
This study shows that the direct bisulfite technique employed is very effective at detecting a 
completely methylated template. A thorough quantitative analysis based on mixtures of 
methylated and unmethylated templates, mimicking actual biological conditions was not 
performed. However, this analysis gave a strong indication that the direct bisulfite method 
was sensitive and specific enough to perform analysis on biological samples. 
3.4.2 Promoter methylation correlates to silenced Oct3/4, but not Olig2 
 
In the first study, direct bisulfite sequencing was used to measure methylation in 
promoter regions of Pgk1, Oct3/4, and Olig2 genes in ES, ES derived neural (neural), and 
ES derived hematopoietic (blood) cells, and adult mouse heart, lung, and liver tissue. 
Isolated DNA was treated with sodium bisulfite and amplified by PCR. PCR products were 
gel purified and sequenced (Figure 3.1). PCR primers for the promoter analysis are given in 
Appendix C, Table C.2.a.  
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Figure 3.1: Methods for direct bisulfite sequencing. DNA is isolated from cells and 
tissues treated with sodium bisulfite. Methylated cytosines are protected whereas 
unmethylated cytosines are converted to uracils. Regions of interest are then PCR amplified 
with gene specific primers. Purified PCR products were Sanger sequenced. Traces show 
unmethylated CpGs as TpGs and methylated CpGs as CpGs. At heterogeneous sites, 
methylation status is determined by the tallest peak at each CpG dinucleotide. In lollipop 
diagrams methylated CpGs are filled circles and unmethylated CpGs are open circles. 
 
 56 
The three genes studied have unique structures (Figure 3.2) and different 
expression profiles.  
 
 
Figure 3.2: Structures of all genes studied: Pgk-1, Oct3/4, Sox1, Olig1, and Olig2. 
Exons are indicated by black rectangles with 5’ and 3’ untranslated regions by slightly 
smaller rectangles shown. Introns are shown by lines connecting exons. Called CpG 
Islands (UCSC browser) are shown in green. Regions of interest are given by red bars. 
Proximal promoter regions are denoted by an asterisk (*). Numbers over regions of interest 
correspond to regions described in the text. The total CpG sites assayed are indicated.  
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The Pgk-1 gene encodes the enzyme 3-phosphoglycerate kinase, a house-keeping 
gene located on the X chromosome where it is constitutively transcribed in all tissues from 
the active X (McBurney, Sutherland et al. 1991). Oct3/4, a transcription factor and 
pluripotency regulator, is expressed in the inner cell mass of the blastocyst and in ES cells. 
Oct3/4 plays an important role in development turning off as cells acquire somatic 
phenotypes (Pesce and Scholer 2001). On the other hand, Olig2 is a transcription factor 
expressed in the developing nervous system in oligodendrocyte precursor cells and in 
oligodendrocytes of the mature nervous system ((Lu, Yuk et al. 2000); Reviewed in (Ligon, 
Fancy et al. 2006)); Olig2 is not expressed in pluripotent cells. Expression of Olig2 is highly 
specific to subsets of cells at each stage of nervous system development (Takebayashi, 
Nabeshima et al. 2002).  
Promoter CpG methylation was investigated in three genes: Pgk-1, Oct3/4 and 
Olig2 by direct bisulfite sequencing. Bisulfite sequencing traces revealed complete 
conversion of non-CpG cytosine residues in all three genes, indicating effective bisulfite 
treatment. Pgk1 and Olig2 promoters were unmethylated at all CpG sites examined in all 
cells and tissues. Only the Oct3/4 gene showed differential methylation across the different 
cell types (Figure 3.3).  
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Figure 3.3: Promoter region methylation of Oct3/4, Olig2, and Pgk-1 in cultured cells 
and mouse tissues. Lollipop diagram of methylation in ES, ES derived neural, ES derived 
hematopoietic cells, heart, liver, and lung tissues by direct bisulfite sequencing. Partially 
filled circles indicate replicate reads with different calls. Oct3/4 promoter shows increased 
methylation in differentiated cells and near complete methylation in tissues whereas Olig2 
and Pgk-1 promoter regions remain unmethylated in all cells and tissues.  
 
 
Of the 16 Oct3/4 CpG sites assayed, all were unmethylated in ES cells. Blood 
progenitors showed methylation heterogeneity at three Oct3/4 sites (-167, -105, -101) 
proximal to the transcription start site. Heterogeneous bases, indicated by half filled circles 
are where dual C/T peaks were present and called bases differed in forward and reverse 
sequences (Figure 3). Neural cells had seven Oct3/4 methylated sites (-167 – 
 -107, 3, 18), two heterogeneous sites (-253,-229), and four called unmethylated sites that 
showed some methylation (-265, -49, +37, +42). The remaining three distal downstream 
sites (-409,-360,-298) have no evidence of methylation. The Oct3/4 promoter became 
increasingly methylated in adult tissues where Oct3/4 is silenced. For heart, liver, and lung 
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tissue 13/16, 15/16, and 13/16 CpGs showed methylated sites, with methylation spanning 
the entire promoter region. Heart tissue had many called methylation sites showing a 
mixture of methylated and unmethylated CpGs. Liver had the strongest methylation signal 
with 15/16 sites producing methylated CpGs. Even the only called unmethylated site (+37) 
showed a moderate dual C/T peak. The Oct4 promoter was also highly methylated in lung 
tissue with methylation detected at 13/16 sites, one heterogeneous CpG site (+42), and the 
remaining two unmethylated CpGs (-49, +37) showing dual C/T peaks, with the thymine 
peak slightly taller than the cytosine peak. In conclusion, our Oct3/4 results support the 
established hypothesis that DNA methylation is associated with transcriptional repression; 
Oct3/4 becomes methylated when the gene is no longer expressed, as pluripotent cells 
differentiate into the somatic lineages of the body.  
 
3.4.3 The Olig2 promoter is not methylated in Olig2 expressing and  
non-expressing neural cells  
 
 
Since methylation was not observed in the Olig2 promoter region in heart, liver, 
and lung tissues that have silenced Olig2, an additional study was conducted with G-Olig2 
ES cell line to definitively determine if methylation is correlated to Olig2 expression in ES 
derived neural cells. Olig2 expression is easily monitored by GFP expression in the G-
Olig2 cell line so that methylation could be measured in neural cells that expressed and did 
not express Olig2. G-Olig2 ES cells underwent neural differentiation in the presence of 
retinoic acid and sonic hedgehog agonist for 4 or 6 days as previously described. A sub-
population of the neural cells, approximately 50%, were bright green under the 
fluorescence microscope indicating Olig2 was being expressed in agreement with 
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previously published results (Xian, McNichols et al. 2003). FACS sorting was used to 
separate Olig2 expressing from non-expressing cells and Olig2 promoter methylation was 
assayed. Like the cells and tissues studied in Figure 3.3, both Olig2 expressing and non-
expressing neural cell populations showed no methylation in the Olig2 promoter region, 
refuting the hypothesis that methylation is associated with silenced Olig2 transcription and 
showing that methylation is not associated with Olig2 expression.  
 
3.4.4 The Olig2 locus is hypomethylated in normal cells and tissues 
 
 
Since Olig2 promoter methylation was not found in any cells or tissues assayed, we 
hypothesized that alternative regions may be responsible for methylation correlating with 
Olig2 regulation. Like Olig2, Sox2 is transcription factor expressed in the developing 
central nervous system involved in neural differentiation; its promoter does not have 
methylation correlated to silencing. Rather, methylation of an upstream epigenetic 
enhancer 4kb upstream is correlated to cell type specific Sox2 expression (Sikorska, Sandhu 
et al. 2008). Gene body methylation and methylation of 3’UTR regions have also been 
shown to occur and correlate to silencing in some genes (Suzuki and Bird 2008).  
We proceeded to map methylation across the Olig2 locus in ES derived neural cells 
and in heart, liver, and lung tissues by direct bisulfite sequencing. Results of the analysis are 
shown in Table 3.2. Primers for analysis are given in Appendix C, Table C.2.b. 
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As shown in Table 3.2, bisulfite sequencing revealed that the Olig2 locus is largely 
unmethylated, as an additional 182 CpG sites were surveyed and only 2 methylated CpG 
sites were detected. Liver tissue and neural cells both had a methylated CpG at (-4795). The 
neural cells also had methylation heterogeneity at (-1426) whereas all cell types were 
unmethylated at this CpG site. In conclusion, there was no correlation between Olig2 
silencing and methylation status, refuting the hypothesis that methylation is correlated with 
silencing.  
 
3.4.5 Methylation of neural transcription factors Sox1 and Olig1 does 
not correlate to silencing  
 
Although methylation was minimal across the Olig2 locus, there is evidence that 
DNA methylation of neural genes, such as brain-derived neurotrophic factor (BDNF) 
(Martinowich, Hattori et al. 2003) and in the astrocyte lineage GFAP (Takizawa, 
Nakashima et al. 2001), plays a role in cell fate specification. The next set of experiments 
focused on determining if methylation was at all correlated to gene silencing in non-
neuronal cells and tissues in Sox1, a transcription factor instrumental in establishing early 
neural fate, and Olig1, a transcription factor closely related to Olig2 and oligodendrocyte 
precursor marker.  
Sox1 is a transcription factor expressed in dividing neural cells. These neural 
progenitors are cells that are competent to become neurons; upon differentiation Sox1 is 
down-regulated (Pevny, Sockanathan et al. 1998; Kiefer 2007). Sox1 only has one exon 
which also coincides with a called CpG Island. Methylation was mapped in four regions 
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spanning the Sox1 locus (Figure 3.2). Primers are given in Supplemental Table C.2.c. A 
summary of all CpGs mapped is provided in Table 3.3.  
 
Table 3.3: Sox1 methylation in cells and tissues 
 
ROI 1 2 3 4 
Location 
[start 
end] 
-3725 
 
-3412 
-1609 
 
-1312 
316 
 
635 
2866 
 
3183 
ES cells -------- 7/7 0/23 5/5 
Neural Cells 2/7 8/8 0/23 0/5 
Heart 0/9 0/7 0/23 0/5 
Liver 0/9 1/6 0/19 0/5 
Lung 0/9 0/7 0/23 0/5 
# sites 9 8 23 5 
Fractions given are the number of methylated CpGs/ 
total number of CpGs read  
 
As shown in Table 3.3, Sox1 upstream regions contained methylated sites in ES 
and neural cells, whereas the amplicon in the 5’UTR and called CpG island region was 
highly unmethylated in all tissues. The 3’UTR region, downstream of the CpG island, only 
showed methylation in ES cells. Detailed lollipop diagrams of differentially methylated sites 
are shown in Figure 3.4.  
Neural cells show methylation at heterogeneous sites -3740 and -3745, while all 
other tissues are unmethylated; ES cells were not analyzed. The second upstream region 
contains the majority of differentially methylated sites with ES and neural cells having a 
high degree of methylation. In particular a pair of CpG sites, at -1489 and -1486 bases 
upstream, are highly methylated in ES and neural cells while -1489 is heterogeneous in 
liver; both sites (-1489, -1486) largely unmethylated in other tissues. Heterogeneity is seen 
at -1423 and -1384 with methylation being dominant in ES and neural cells and 
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unmethylation dominant in the tissues. The upstream triplet of CpG sites surrounding -
1346 also showed methylation in ES and neural cells. Finally, unlike any of the other cell 
types and tissues analyzed ES cells had heterogeneously methylated sites covering the entire 
region in the 3’UTR, as five of the five sites were called methylated in separate reads 
(Figure 3.4). To summarize, methylation of the Sox1 locus did not occur in tissues that had 
silenced the Sox1 gene, refuting the hypothesis that methylation is correlated with 
transcriptional repression.  
 
a. 
 
 
b. 
 
 
Figure 3.4: Methylation mapping of neural genes Sox1 and Olig1. a) Lollipop diagram 
for Sox1 differentially methylated regions. b) Lollipop diagram for Olig1 differentially 
methylated regions. Detailed methylation data is provided in Tables 3.3 and 3.4. Structural 
maps of both genes are provided in Figure 3.2.  
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Olig1 is a transcription factor involved in neural development. The gene is located 
40 kb downstream of Olig2 in mice and in humans and is thought to have arisen out of a 
gene duplication event. Olig1 differs from Olig2 structurally in that it only has one exon 
(Figure 3.2). By itself, Olig1 promotes the formation of oligodendrocyte progenitor cells 
and mature oligodendrocytes in culture and in developing mice(Lu, Sun et al. 2002), but 
also functions in concert with Olig2 in establishing motor neuron and oligodentrocyte 
lineages in the primitive neural tube (Lu, Yuk et al. 2000; Ligon, Fancy et al. 2006).  
Direct bisulfite sequencing was used to measure methylation of seven regions that 
span the Olig1 locus (Figure 3.2). Primers are given in Appendix C, Supplemental Table 
C.2.c. Based on the hypothesis, we expected to find that tissues that did not express Olig1, 
i.e. lung, liver, and heart would be highly methylated. We found that this was not true. An 
overview of all the sites analyzed is provided in Table 3.4. 
Table 3.4: Olig1 methylation in cells and tissues 
 
ROI 1 2 3 4 5 6 7 
Location 
[start 
end] 
-2235 
 
-1955 
-1324  
 
-1009 
-647 
 
-399 
202   
 
450 
883 
 
1140 
1149 
 
1454 
1756 
 
2106 
ES cells 6/6 8/9 3/5 ------ 0/8 0/16 1/13 
Neural cells 5/5 8/9 3/5 0/14 0/9 0/15 0/20 
Heart 5/5 8/9 0/5 0/20 0/9 0/15 0/20 
Liver 6/6 6/9 0/5 0/15 0/9 0/15 0/24 
Lung 6/6 7/9 0/5 0/20 0/12 0/16 0/24 
# sites 6   9   6 20 13 16 24 
Fractions are number of methylated CpGs/ total number of CpGs read.  
 
Methylation was found in three regions upstream of the Olig1 transcription start 
site (Figure 4b) while all regions within the gene were highly unmethylated. The first region 
of interest analyzed (-2235 - -1955) showed methylation at all CpG dinucleotides analyzed. 
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The first three and last CpG dinucleotides were highly methylated (-2208,-2196,-2154, -
1978). Dual C/T peaks were apparent at -2112, -2045 and in ES, neural heart, and lung 
samples, however methylation was called. Differential methylation was found in regions 2 
and 3. A more detailed look at the status of particular sites is provided in Figure 4b. The 
second region (-1324 - -1009) showed a majority of methylated sites in all of the tissues, 
ranging from 6/9 in liver tissue to 9/9 sites called methylated in ES and neural cells and 
heart tissue. Heart tissue has the only called methylated CpG at -1123. In all of the tissues 
that site presents as a heterogeneous peak, with the rest of the tissues being more 
unmethylated at that site. The most highly methylated sites in all tissues were -1227 and -
1225 which form a CGCG site. The final CpG site analyzed in region 2 at position -1064 
displays methylation heterogeneity in ES and neural cells, but is distinctly unmethylated in 
heart, liver, and lung tissues. The upstream region proximal to the Olig1 promoter (-647 -
399) contained three sites that differed in methylation status (-503, -484,-466), being 
methylated in ES and neural cells and unmethylated in heart, liver, and lung tissue. The first 
and last of these three are heterogeneous and more highly methylated (-503, -466), while 
the other (-484) shows a strong clear methylation signal. One read from ES cells showed 
one methylated site (1954) in region 7 in a very CpG rich area in the 3’ UTR of Olig1. 
Heterogeneity was apparent in five CpG sites from (1948-1958). This may be due to true 
methylation at all of these loci or protection from bisulfite treatment at unmethylated 
CpGs by neighboring methyl groups (Warnecke, Stirzaker et al. 2002). A repeat of this read 
would provide more information as only 13 of the 24 CpGs could be analyzed. There is no 
simple correlation between methylation of the Olig1 promoter region and silencing of the 
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Olig1 gene. Methylation measurements of the Olig1 gene refute the hypothesis that 
methylation is associated with transcriptional silencing of Olig1.  
3.5 Discussion 
 
The precise spatial and temporal regulation of gene expression is essential for 
development of a functional organism. DNA methylation is also necessary for proper 
development and exhibits tissue specific differences. These two observations led to 
investigations which have shown a strong correlation between DNA methylation and 
transcriptional silencing (Boyes and Bird 1991), and the emergence of the hypothesis that 
DNA methylation was involved in the regulation of cell fate by functioning to silence genes 
during development once fate decisions have been made and gene expression is no longer 
needed.  
We tested the hypothesis that DNA methylation is correlated with repressed 
transcription in genes involved in neurogenesis by mapping methylation in loci of a 
housekeeping gene and several developmental regulatory genes in expressing and non-
expressing tissues, expecting all cells and tissues that did not express a particular gene to be 
methylated. We found two genes that fit this hypothesis, a housekeeping gene Pgk-1 
(Hansen and Gartler 1990) and pluripotency regulator Oct3/4 [(Pesce and Scholer 2001; 
Gidekel and Bergman 2002; Hattori, Nishino et al. 2004; Li, Pu et al. 2007; Yeo, Jeong et 
al. 2007; Zhang, Siu et al. 2008)], in agreement with previous studies. On the other hand, 
methylation maps of neural lineage genes in non-neural tissues obtained in this study 
contradicted the hypothesis.  
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Sox1 is the earliest transcription factor expressed specifically in neural cells. Sox1 
expressing cells are dividing neural progenitors that are competent to become neurons 
upon differentiation and Sox1 down-regulation (Pevny, Sockanathan et al. 1998; Kiefer 
2007). All Sox1 non-expressing tissues, heart, liver, or lung, assayed were largely 
unmethylated in the upstream regions and throughout the gene contrary to the hypothesis. 
Methylation was found ~1.4kb upstream of the Sox1 transcription start site in ES cells and 
in neural cells. Two methylated CpG sites were also found in only neural cells (~3.5kb 
upstream); ES cells were not analyzed for this region. Methylation was only observed in ES 
cells in the 3’UTR of Sox1 which also was an unanticipated finding. To summarize, 
methylation is not correlated to silencing of Sox1 expression.  
Olig1 and Olig2 are transcription factors expressed in the developing nervous 
system in oligodendrocyte precursor cells and in oligodendrocytes of the mature nervous 
system (Lu, Yuk et al. 2000; Ligon, Fancy et al. 2006). Of all of the cells assayed in this 
study, Olig1 and Olig2 expression is limited to a subset of ES derived neural cells, 
therefore if methylation represses transcription of Olig1 or Olig2 according to the 
hypothesis, we would expect some methylation of the Olig1 and Olig2 promoters in neural 
cells, and complete methylation in all other cell types. Olig2 was largely unmethylated in all 
cells and tissues while Olig1 methylation profile was more complex.  
Methylation analysis of the Olig1 locus showed regions that were completely 
methylated in all cells and tissues (~2kb upstream), had some methylated sites in all cells 
and tissues (~1.2 kb upstream), were methylated in ES and neural cells and not in adult 
tissues (~500bp upstream), or were completely unmethylated in all cells and tissues (body 
of the gene). The two upstream regions that had methylation in all cells and tissues (~1.2kb 
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and ~2kb upstream) support the hypothesis, as cells and tissues that do not express Olig1 
are methylated. While all sites in the ~2kb upstream region were methylated in all tissues, 
the degree of methylation differs between tissue types in the ~1.2kb upstream region, with 
some sites being methylated, heterogeneously methylated, and unmethylated in different 
tissues. The ES derived neural cells containing a subset of Olig1 expressing cells are also 
methylated in these two regions, refuting the hypothesis. It is possible that the direct 
bisulfite PCR method employed here is not sensitive enough to pick up the heterogeneity 
of the ES derived neural cells, therefore analysis of a pure Olig1 expressing population of 
cells or use of a more quantitative method might resolve Olig1 expressing cells as 
unmethylated in this region and support the hypothesis. Analysis of the region immediately 
upstream of the Olig1 transcription start site, ~500bp , showed that methylation in this 
region was not correlated to silencing of Olig1 as heart, liver, and lung tissue were 
unmethylated in this region. In summary, our analysis shows that methylation is not 
associated with Olig1 silencing.  
Like Olig1, Olig2 expression is limited to a subset of ES derived neural cells. 
Therefore if methylation represses transcription of Olig2 according to the hypothesis, we 
would expect some methylation of the Olig2 promoter in neural cells, and complete 
methylation in ES cells, and heart, liver, and lung tissues. There was no DNA methylation 
in the Olig2 promoter region, 500bp upstream to 100bp downstream of transcription start 
site, in cells and tissues that express and do not express Olig2. Recent work by other 
groups confirms our results that the Olig2 promoter is not methylated in tissues that do 
not express Olig2 (Meissner, Mikkelsen et al. 2008). In addition, Olig2 promoter 
methylation was observed in acute myeloid leukemia blood cells while normal blood cells 
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were unmethylated (Kroeger, Jelinek et al. 2008), indicating that methylation of the Olig2 
promoter may be a sign of disease. We conclude that Olig2 promoter methylation is not 
correlated to Olig2 silencing and does not appear to have any involvement in regulating 
Olig2 transcription in normal cells and tissues.  
Surprisingly, the entire Olig2 locus, from 6kb upstream through the body of the 
gene, was hypomethylated in the neural cells and in all tissues. Only two CpG sites 
upstream of Olig2 were methylated in neural cells and liver tissue and unmethylated in all 
other tissues. Recent restriction based illumina mapping also showed low levels of 
methylation directly upstream (~5kb) of Olig2 in ES and neural progenitors (Meissner, 
Mikkelsen et al. 2008). In addition, high levels of methylation ~14kb upstream in ES and 
neural cells and differential methylation with ES cells being methylated and neural 
progenitors largely unmethylated were found ~90 kb upstream of Olig2, far outside the 
scope of this study. In summary, methylation of the Olig2 locus is not correlated with 
Olig2 silencing and neural cell fate specification.  
There are several alternative hypotheses for the role of methylation in gene 
regulation including: silencing of retroviral insertion elements, marking proliferative status 
in a cell line, or activating transcription. Silencing of retroelements by methylation is the 
most widely accepted of these. Retroviral insertion elements are preferentially methylated 
in order to protect the organism ((Jahner, Stuhlmann et al. 1982; Walsh, Chaillet et al. 
1998). ;Reviewed in (Hoelzer, Shackelton et al. 2008)). The analyzed region of the Olig1 
locus contains several retroviral insertion elements, one LINE, three SINES, and one LTR, 
and a large (6.8kb), nearly complete retroviral LTR element between Olig2 and Olig1 on 
chromosome 16, 21kb upstream of Olig1. Two of the three regions with methylation 
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mapped in this study correspond to a repetitive element. Olig1 region 2 (~1.2kb upstream) 
partially maps to a SINE element (-1446 – -1244), and the first 2 CpGs, corresponding to 
the SINE element, were methylated or heterozygously methylated in all cells and tissues. 
Olig1 region 3 (~500bp upstream) encompasses a LINE element (-593- -497) where there 
was methylation in ES and neural cells, but not in any of the adult tissues. An Alu sine 
element (-438—351), known for methylation (Reviewed in (Hoelzer, Shackelton et al. 
2008)), was nearby to mapped region 3, but the CpG site in it (-365) was not mapped. In 
the limited scope of this study, the data support the association of retroviral insertion 
elements with methylation, however methylation of the Olig1 locus was not limited to 
retroviral elements.  
Genome-wide methylation has been observed to increase in propagated cell lines 
over freshly isolated primary cultures, possibly as a result of in vitro culture conditions 
(Antequera, Boyes et al. 1990; Meissner, Mikkelsen et al. 2008). Our analysis shows some 
evidence for this in the methylation patterns in the Sox1 and Olig1 loci. Methylation was 
observed ~1.4kb upstream of the Sox1 transcription start site in ES cells and in neural 
cells. Similarly, in the Olig1 promoter region ES and ES derived neural cells were 
methylated at the same 3 sites, while all tissues were unmethylated. The two methylated 
CpGs only found in neural cells ~3.5kb upstream directly contradict the correlation 
between methylation and repression. Upon further analysis, if ES cells are not methylated 
in these two sites and methylation is specific to neural progenitors, methylation may be 
playing an alternative role as a transcriptional activator (Chahrour, Jung et al. 2008). Our 
study provides limited evidence to support the methylation as proliferative mark or 
transcriptional activator hypotheses.  
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There are structural and functional clues as to why the Oct3/4, Sox1, and Olig1 
genes are able to recruit methyltransferases and Olig2, especially the promoter, does not. 
Unlike Oct3/4, which has a high GC content (59%), but low CpG density 
(observed/expected=0.34), the Olig2 promoter is associated with a called CpG Island and 
the analyzed region has a GC content of 61% and a CpG observed/expected of 0.76 
similar to Pgk-1 (62%, 0.71) which is also associated with a called CpG Island and 
unmethylated on the active X in all tissues. All methylated regions in neural genes Sox1 and 
Olig1 found in this study did not fit the CpG Island criteria. Other groups have also found 
the majority of CpG Island promoters (87.9%) remain unmethylated in all tissue types, 
whereas 50% of the non-CpG Island 5’UTRs were methylated (Eckhardt, Lewin et al. 
2006). This study also provides support for the prevailing idea that areas of high CpG 
density, CpG islands, are unmethylated, which may have the function of providing 
protection from mutagenesis to these critical regions (Bird 1980). The Olig2 promoter 
region analyzed also contains 2 Sp1 sites. A transcription factor involved in early 
development, binding sequences (GGCGG) and lack of methylation at these sites allows 
for binding and transcription. Functional assays of the Olig2 promoter region have shown 
non-specific transcription activity from a region 1.1kb upstream of the transcriptional start 
site (Zhang, Horrell et al. 2008). Lack of methylation at the Olig2 promoter would allow 
for non-specific transcriptional activity.  
The overall conclusion of this study is that there is no sensible hypothesis that 
unifies all of the data. For two genes, DNA methylation is associated with repression 
whereas for three genes it is not. Larger datasets, including genome-wide studies are also 
coming to the conclusion that the prevailing hypothesis is not correct and the function of 
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DNA methylation remains elusive (Meissner, Mikkelsen et al. 2008; Suzuki and Bird 2008). 
Determining what makes a particular locus amenable to methylation and measuring the 
effects of methylation on a particular gene depends on being able to selectively perturb 
methylation within its genomic context. Current technologies allow for genome-wide 
methylation disruption by methyltransferase knockout or chemical inhibitor, but tools to 
perform targeted methylation or methylation inhibition are still under development. 
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Chapter 4 
  
Engineering ES Cells for Drug Selection 
of  a Subset of  Neural Cells 
4.1 Abstract 
ES cells genetically engineered with drug resistance expressed under the control of 
a neural cell type specific promoter offers the potential to provide access to large numbers 
of well-defined neural cells for research and therapeutic applications. Two ES cell lines 
were generated where a puromycin acetyltransferase (PAC) gene was inserted into the 
Olig2 gene.  In both lines, PAC expression recapitulated the expression of the native Olig2 
gene to permit purification of a subset of ES derived neural cells by selection with 
puromycin. Selected neural cells were arranged in rosettes and expressed Olig2. In addition, 
continued culture and selection of purified Olig2 expressing cells was possible. This system 
enables convenient and cost-effective purification of large numbers of Olig2 expressing 
cells for biochemical analysis, transplantation research, and toxicity testing. A similar 
selection strategy may be applied to other neural subsets.  
 
David Lorberbaum and Julia Kuhn assisted with experiments performed in Chapter 4.  
They built the expression vector, performed targeting detection PCRs, and handled clones. 
The rest of the work was done autonomously.  
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4.2 Introduction 
 
The two fundamental properties of ES cells, the ability to self-renew and potential 
to differentiate, have raised exciting new possibilities for their use in biomedical research 
and applications in regenerative medicine. Methods have been developed to differentiate 
mouse ES cells into various neural lineages including: general neural(Bain, Kitchens et al. 
1995), ventral neural (Wichterle, Lieberam et al. 2002), retina(Zhao, Liu et al. 2006), 
cerebellum(Salero and Hatten 2007), and cerebral cortex (Gaspard, Bouschet et al. 2008).  
These methods are being extended to human ES cells (Thomson, Itskovitz-Eldor et al. 
1998), enabling human cells to become the focus of study of human biology and to 
recently discovered iPS cells (Takahashi, Tanabe et al. 2007; Wernig, Meissner et al. 2007), 
making it possible to develop patient specific models of disease.  Stem cell derived neural 
cells have shown promise as a tool to study the development of the nervous system 
(Abranches, Silva et al. 2009), to model neurodegenerative disease (Di Giorgio, Carrasco et 
al. 2007; Hochedlinger and Plath 2009), for development of cellular replacement therapies 
(Reviewed by Murray and Keller, 2008;  (Nayak, Kim et al. 2006), and as a testing ground 
for pharmaceuticals on neural cells ({Broom, 2006 #181; Murry and Keller 2008) 
Reviewed by (Rubin 2008)). 
The ability to generate large numbers of well-defined ES cell derived neural cells is 
critical for all of the applications described. ES derived neural cells recapitulate much of the 
complex biology and heterogeneity of the mammalian nervous system, both in terms of 
genetics and physiology (Bain, Kitchens et al. 1995; Wichterle, Lieberam et al. 2002).  
Given their origins as proliferating stem cells, generating large numbers of ES cell derived 
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neural cells is not a problem. However, limiting the differentiation of stem cells to the 
desired population of neural cells is a challenge. Two approaches to direct stem cell derived 
neural cells to specific lineages are the use of instructive growth factors and manipulating 
stem cell genetics by promoter-reporter constructs.  
ES cells have the potential to differentiate into all cell types of the body and 
without signaling factors will generate a very heterogeneous population that includes a 
small percentage of neural cells (Martin 1981). Instructive factors have been identified to 
direct ES cells to the neural lineage. Retinoic acid (RA) enriches for differentiation of ES 
cells along a general neural pathway: generating cultures of neurons, astrocytes, and 
oligodendrocytes (Bain, Kitchens et al. 1995). The combination of RA and sonic hedgehog 
(Shh) further limits the phenotypes of ES derived neural cells to the ventral nervous 
system, responsible for motor output (Wichterle, Lieberam et al. 2002), Figure 4.1A). Yet, 
even ventral neural cultures contain many cell types. Further definition of ES derived 
ventral neural cells can be based on the expression of transcription factors or other cell 
type specific marker genes. 
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Figure 4.1: Taking Clues from Embryonic Development to Direct Stem Cells into 
Ventral Neural Cells. (A)  ES cells can be differentiated to produce heterogeneous motor 
neuron progenitor (pMN) cultures by applying inducing factors retinoic acid and Shh 
(Wichterle 2002, Xian and Gottlieb 2005) (B) Diagram of the pMN domain, a region in the 
developing ventral spinal cord responsible for generating motoneurons and 
oligrodendrocyte precursor cells. (C) Olig2 is transcription factor expressed in the 
developing ventral spinal cord (Takebayashi, Yoshida et al. 2000). Olig2 expressing cells are 
multipotent and can differentate into motoneurons and oligodendrocyte precursors (based 
on (Rowitch, Lu et al. 2002)). (D) G-Olig2, an ES cell line with green fluorescent protein 
gene targeted to Olig2 in ES cells (Xian, McNichols et al. 2003; Xue, Wu et al. 2009), 
allows for easy visualization of Olig2 expression in pMN cells.   
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Olig2 is a basic helix-loop-helix transcription factor expressed in the ventral 
portion of the developing brain and spinal cord (Takebayashi, Yoshida et al. 2000; Ligon, 
Fancy et al. 2006), See Figure 4.1B). It is an important fate regulator in the central nervous 
system (Zhou and Anderson 2002). Olig2 expression defines a population of neural stem 
cells that differentiate into motoneurons and oligodendrocyte precursor cells (OPC). As 
depicted in Figure 4.1C, motoneurons shut off Olig2, but Olig2 expression persists in the 
OPC lineage (Lu, Sun et al. 2002; Wu, Wu et al. 2006).  
GFP knock-ins to the Olig2 gene have been particularly useful for observing and 
selecting for Olig2 expressing cells in heterogeneous ES derived neural cultures. In 2003, 
Xian et al (Xian, McNichols et al. 2003) generated a mouse Olig2 GFP knock-in ES cell 
line (G-Olig2). In G-Olig2 ES cells a promoterless green fluorescent protein gene (GFP) is 
inserted into the protein coding region of Olig2 so that the Olig2 promoter drives GFP 
expression.  Cells expressing Olig2 in the G-Olig2 line express GFP, and appear green 
using fluorescence microscopy. With the knock-in line, Olig2 expression became easily 
observable in ES derived neural cultures. In addition, Olig2 expressing cells could be 
purified from heterogeneous neural cultures by fluorescence activated cell sorting (FACS, 
(Xian, McNichols et al. 2003; Xian and Gottlieb 2004; Xian, Werth et al. 2005)). By 
monitoring GFP expression, chemical signals that induce Olig2 expression could be easily 
identified by simple observation, as depicted in Figure 4.1D. Also, expression profiles of 
homogeneous Olig2 expressing cells can be obtained (Xian, Werth et al. 2005; Shin, Xue et 
al. 2007). Because of the utility of the mouse ES GFP knock-in, an Olig2-GFP knock-in 
was made recently in human ES cells (R-Olig2, (Xue, Wu et al. 2009)). One of the main 
purposes of this work was to purify Olig2 expressing cells, so the properties of these cells 
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could be explored in biochemical experiments.  To that end, global gene expression 
analysis was performed on selected R-Olig2 at two time points during differentiation, 
revealing distinct expression profiles. In addition, R-Olig2 selected cells were transplanted 
into a rat spinal cord and differentiated into oligodendrocytes in vivo.  
The Olig2 GFP knock-ins have provided a useful tool for observing Olig2 
expression in the ES derived neural cells and a glimpse into the value of a genetically 
selected cell population for biochemical analysis and transplantation research. As the focus 
of research turns to relatively homogeneous cells, using GFP as a selector will limit the 
scope and scale of research. 
ES cells can be targeted with a drug resistance cassette to select for cells expressing 
a targeted gene (Klug, Soonpaa et al. 1996; Li, Pevny et al. 1998; Billon, Jolicoeur et al. 
2002; Ying, Stavridis et al. 2003; Zandstra, Bauwens et al. 2003). Drug selection works by 
utilizing a drug toxic to all cells and a gene encoding an enzyme that renders the drug non-
toxic. An ES cell knock-in is made where the inserted gene encodes an enzyme that 
renders the drug inactive. In the knock-in line, cells not expressing the targeted gene do not 
express enzyme and are killed by the drug.  In contrast, cells expressing the targeted gene 
make an enzyme which inactivates the drug, allowing only cells expressing the target gene 
to survive in the presence of drug.  
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Figure 4.2: Advantages of Drug Selection.  (A) Selection of Olig2 expressing neural cells 
is simple using the P-Olig2 cell lines. Puromycin is applied to P-Olig2 neural cultures, 
killing cells that are not expressing Olig2 and puromycin acetyltransferase (PAC). PAC 
expression protects Olig2 expressing cells, theoretically enriching cultures from 33% to 
100% of cells expressing Olig2. (B) Using a drug based selection allows for the researcher 
to obtain up to 100X more selected cells with the convenience of doing the selection in 
their own lab on their schedule. Project costs for selection are much lower using drug 
selection. Experiments using continuous selection are now simple instead of requiring 
multiple serial sorts.  
 81 
 
 
For studies on selected cells, drug selection provides many advantages over 
traditional GFP selection (Figure 4.2).  FACS selection with GFP lines limits selection to a 
specific time point whereas drug selection can be applied in a continuous manner.  Drug 
selection increases convenience with the benefit of decreasing cost. Selection can be 
performed in any laboratory at any time, thereby providing an easily accessible source of 
the selected cell population. In addition, parallel selection of multiple independent samples 
is challenging using FACS but facile using drug selection. In conclusion, using drug 
selection will enable research that is simply not feasible with GFP knock-ins. 
Not only will drug selection work on smaller research scales, but it will be favored 
over FACS selection to obtain large numbers of selected cells for screening assays in 
research and industry (Zandstra, Bauwens et al. 2003).  Drug selection dramatically 
increases the number of cells that can undergo selection, and decreases cost. Drug selection 
on 109 cells costs less than $100 and can be performed directly in culture vessels. Sorting 
the same 109 cells using FACS requires a dedicated FACS machine directly attached to a 
bioreactor operating around the clock.  Sorting 109 cells with a FACS would occupy the 
machine for two to eleven days depending on flow-rate [25,000/sec – 4,000/sec], and 
require a substantial project investment.   
Here we describe an approach using gene targeting to allow for drug selection of a 
subset of ES derived neural cells. The drug for selection was puromycin. Puromycin is an 
aminonucleoside antibiotic that is toxic to mammalian cells and will kill up to 99% of cells 
within two days (Watanabe, Kai et al. 1995).  ES cell lines (P-Olig2-1 and P-Olig2-2) were 
generated where the Olig2 gene was targeted with the gene encoding the enzyme 
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puromycin acetyltransferase (PAC, (Gomez Lahoz, Lopez de Haro et al. 1991)), which 
modifies puromycin making it non-toxic. P-Olig2 cells expressing Olig2 will express PAC 
and survive puromycin selection. The P-Olig2 ES cell lines allow for convenient, efficient, 
cost-effective purification of Olig2 expressing cells. The principle of drug selection 
described here will be applicable to other neural genes.  
 
4.3 Materials and Methods 
 
4.3.1 Construction of P-Olig2 Knock-In Vectors 
The Olig2 BAC 227 clone previously used by Xian et al. (Xian, McNichols et al. 
2003) was verified by PCR of 10 short amplicons spanning the Olig2 locus (Appendix 
D.2). All were purchased from IDT technologies (Coralville, IA). All primers used for the 
entire construction process are listed in the tables in Appendix D.1. 
Targeting vectors were constructed by a combination of recombineering and 
restriction enzyme based cloning as previously described (Wu, Ying et al. ; Xue, Wu et al. 
2009).  Because targeting vectors ranged in size from 12-20kb, to reduce the possibility of 
plasmid instability all bacterial strains were grown at 31ºC for the duration of the project. 
First, the Olig2 region was subcloned from its BAC into a kanamycin resistant plasmid 
(pStartK,  (Wu, Ying et al. 2008)) using red recombination (Figure 4.3A). The rescue 
plasmid pStartK was amplified by PCR using primers tailed with 50bp of homology to the 
Olig2 region. The homology region was carefully screened to eliminate regions of repetitive 
sequence. Linear product was electroporated into recombinogenic Olig2 BAC 227 cells and 
recombinants were selected with kanamyacin.  The resulting clones were screened by 
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looking for single band following mini-prep, and verified by restriction digests (Appendix 
D.2) and sequencing into the homology region.   We generated 8 non-identical plasmids 
named pOlig2_(1-8) spanning the Olig2 locus, showing the robustness of the method . 
Second, the open reading frame of Olig2 +1 to +973 was surrounded by AscI 
restriction sites using red recombination (Figure 4.3B). The homology containing plasmids, 
including pOlig2_1 and pOlig2_8, were co-electroporated with the PCR amplified 
chloramphenicol cassette flanked by AscI sites and 50bp of homology immediately outside 
of the Olig2 open reading frame into recombinogenic DH5α cells. Recombinants were 
identified by chloramphenicol resistance. Retransformation was used to isolate 
concatemers or to remove unrecombined plasmids that appeared during screening. 
Restriction sites were added to 7/8 homology plasmids as shown by digest and partial 
sequencing. These plasmids were named pOlig2_(1-8)Asc. 
The third step was to bring the puromycin resistance cassette into AscI sites by 
cloning (Figure 4.3C).  The resistance cassette was prepared by a combination of PCR and 
cloning. The resistance cassette consists of the following elements from 5’ to 3’: AscI site, 
Kozak sequence (Kozak 1986; Thomas and Capecchi 1987), puromycin cassette with bgh 
polyA signal (Stratagene, PKO-Select Puro), LoxP, phosphoglycerate kinase I promoter 
driving the neomycin phosphotransferase gene (PGK-neo) with bgh polyA signal, Lox P 
(NCI Biological Resources Branch pL452), and AscI site.  This resistance cassette was 
cloned into an ES cell expression vector (Appendix D.3) to confirm functional puromycin 
and neomyocin genes. It was then cloned from the expression vector into AscI sites in the 
targeting vectors pOlig2_1Asc and pOlig2_8Asc. These two vectors were chosen because 
one had a longer region of homology upstream of the Olig2 gene and the other one had a 
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longer region of homology downstream of the Olig2 gene. Clones were screened by 
chloramphenicol sensitivity and orientation of the insert was verified by PCR of both 
junctions (Appendix D.2). Resulting plasmids were named pOlig2_1PN and pOlig2_8PN. 
The final step adds a herpes simplex virus thymidine kinase gene for negative 
selection and moves the targeting constructs into a high copy number origin (Figure 4.3D). 
The targeting vectors pOlig2_1PN and pOlig2_8PN were incubated with a multisite 
gateway plasmid (pWS-TK3) containing attR1 and attR2 site and TK gene. The P-Olig2 
fragment which contained attL1 and attR1 sites recombined with the gateway plasmid in 
the presence of clonase enzyme and exchanged by LR recombination. These final 
constructs were selected using ampicillin and verified by restriction digest (Appendix D.2). 
The final targeting vectors were named pOlig2_1PN-TK3 and pOlig2_8PN-TK3  
4.3.2 Generating P-Olig2 ES Cell Lines from RW4 
Normal Culture of ES Cells 
All ES cell experiments were done on the RW4 mouse embryonic stem cell line 
derived from Sv129 mouse. ES cells were maintained on gelatin-coated tissue culture 
plastic in the presence of leukemia inhibitory factor (LIF) according to standard methods 
(Bain, Kitchens et al. 1995; Rieger, Poppino et al. 2007; Zhang, Horrell et al. 2008).   
Electroporation 
Targeting in ES cells was performed with both pOlig2_1PN-TK3 and 
pOlig2_8PN-TK3 constructs. To generate the P-Olig2 knock-in lines, pOlig2-1 and 
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pOlig2-2, 1x107 RW4 ES cells were dissociated using 0.25% Trypsin-EDTA (Sigma, St. 
Louis, MO) and resuspended in electroporation buffer (20mM HEPEPS, pH 7.5, 137mM 
NaCl, 5mM KCl, 0.7mM Na2HPO4, 6mM dextrose),  with 10-15µg of ScaI-linearized 
targeting vector. Electroporation was conducted at 0.23kV and 960µF in a 0.4cm cuvette 
(Bio-Rad, Hercules, CA). Electroporated cells were plated on gelatin and dosed with G418 
(200µg/mL, Invitrogen) and 1-(2-Deoxy-2-fluoro-ß-D-arabinofuranosyl)-5-iodouracil 
(FIAU 100nM, Movarek Biochemicals, Brea, CA) 24 hours after electroporation. Resistant 
clones were picked 8 days following electroporation, trypsinized, and half of each clone 
was expanded on STO monolayers in 96 well plates. The other half was frozen in a 96 well 
PCR plate at -70 ºC and retrieved following identification of targeted clones.  
Targeting Detection by PCR 
For each ES clone, genomic DNA (2uL) was assayed by PCR for a novel junction 
generated by targeting of the short arm for each construct. Genomic DNA was prepared 
from confluent 96 well plates (Sambrook and Russel 2001). PCR was conducted using 
KTLA polymerase [1X KLA buffer 50mM Tris Base, 16mM Ammonium Sulfate, 0.1% 
Tween-20, 3.5mM MgCl2], 100 µM Betaine, 200 µM each dNTP, 200 nM each primer, 
4µg/mL BSA, and 0.01U KTLA per 20µL reaction. Thermocyling parameters were: 94 ºC 
degrees for 10 minutes, followed by 35 cycles of 94 ºC for 30 seconds, 58 ºC for 30 
seconds, and 72 ºC for 4 minutes. Primers for PCR detection are given in Appendix D.1.  
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Southern Hybridization 
Genomic DNA was prepared from 12x106 ES cells (RW4, B9, D9) using the ArchivePure 
DNA Cell/Tissue and Tissue Kit (5 Prime, Gaithersburg, MD) according to the 
manufacturer’s instructions. Proteinase K (300µg) was added to 3mL of Cell Lysis Solution 
to digest proteins bound to DNA and remove nucleases. For targeting confirmation 
genomic DNA (1-10µg) was digested with either HindIII (200U) or SpeI (50U) overnight 
at 37 ºC. Additional enzyme was added and digestion was continued for one hour. DNA 
was ethanol precipitated and electrophoresed on a 0.8% agarose gel in 0.5X Tris-borate-
EDTA (45 mM Tris-borate and 1 mM EDTA) buffer at 1V/cm for 19hrs. DNA was 
transferred to Hybond-XL (GE Healthcare Biosciences, Piscataway, NJ) membrane under 
neutral conditions for 20hrs. DNA was crosslinked to the membrane using UV Stratalinker 
2400 on auto-crosslink setting. Probes were prepared using [32P] dCTP (Easy Tide, Perkin-
Elmer, Waltham, Massachusetts) and Rediprime kit (GE Healthcare Biosciences), and 
purified with illustra ProbeQuantG-50 columns (GE Healthcare Biosciences). Blots were 
hybridized in Rapid hybe for two hours at 65 ºC (GE Healthcare Biosciences), washed, and 
autoradiographed by standard methods.  
Cre Excision and Subcloning 
To excise the floxed PGK-neo cassette contained in the targeted lines, 2x106 ES 
cells from each line were trypsinized and electroporated using an Amaxa nucleofector II 
(Amaxa Biosystems) with 5µg of Cre recombinase expressing plasmid (p1411, gift of Tim 
Ley, Washington University). Transfected cells were diluted and plated on STO feeder 
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monolayers. Single clones were picked and genomic DNA was assayed by PCR (Primers in 
Table 6) to demonstrate the removal of the PGK-neo cassette.  Cre-d lines (B9-1, D9-1) 
were used for the duration of the study. Following expansion of cre-excised ES cell lines, 
lines were further subcloned by dilution on STO monolayers. Subclones were expanded 
and re-validated by PCR and neomyocin sensitivity to ensure complete removal of PGK-
neo cassette. 
Neural Differentiation of ES Cell Lines  
Ventral neural differentiation of ES cells was performed by an established method 
using retinoic acid (RA) and sonic hedgehog (Shh) (Wichterle, Lieberam et al. 2002; Xian, 
Werth et al. 2005; Zhang, Horrell et al. 2008). The Shh agonist HhAg1.4 from Curis, Inc. 
(Cambridge, MA) was used throughout. Undifferentiated ES cells were scraped from flasks 
and cultured for 2 days as embryoid bodies (EBs) in DFK5 medium without inducing 
factors. EBs were then transferred to adhesive gelatin wells in DFK5, and RA (2µM) and 
Shh agonist (30 nM) were added to induce ventral neural phenotype. Culture was 
continued as indicated in the text.  
mRNA Analysis 
RNA was isolated from 5x106 ES cells, one 6 well of EBs, or one 6 well of neural 
cultures in 1mL of TRI Reagent (Life Technologies, Carlsbad, CA) according to 
manufacuter’s instructions. RNA was resuspended in 10mM Tris pH 8.0. and  
electrophesed on a 1.5% formaldehyde denaturing agarose gel alongside RiboRuler High 
Range RNA ladder (Fermentas, Glen Burnie, MD) for quantification. Total RNA was 
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quantified assuming 18S and 28S ribosomal RNA bands comprised 80% of total RNA. 
Reverse transcription reactions were conducted with 500ng of total RNA using the 
Retroscript kit according to manufacturer’s instructions (Life Technologies) using random 
decamers as primers. Two step reverse transcription was conducted by first heating RNA 
and primers to 80 ºC for 3 minutes then adding the remainder of components. The 
reaction was incubated at 44 ºC for 1 hour, and enzyme was heat inactivated at 92 ºC for 
10 minutes. Parallel reactions were prepared omitting reverse transcriptase enzyme. PCR 
reactions were performed with 1/20 of total cDNA. PCR was performed for the native 
and transgene Olig2 amplicon using KTLA polymerase for 35 cycles with an annealing 
temperature of 59 ºC and extension time of 45 seconds. Primers are given in Appendix 
D.1. 
Puromycin Treatment of Cell Cultures 
Puromycin dihydrochloride (Sigma Aldrich, St. Louis, MO) was dissolved in dH20 
at a concentration of 10mg/mL. Cells were dosed with 4µg/ml puromycin delivered in the 
appropriate culture media at stages described in the text.  
Immunocytochemistry 
Nuclear staining was performed by incubating cultures with 4 ,6-diamidino-2-
phenylindole dihydrochloride (Molecular Probes Inc., Eugene, OR) for 1 hour at 37°C 
before fixation. Then the wells were rinsed with cytoskeletal buffer (CB) (1.95 mg/ml 2-N-
morpholino ethanesulfonic acid, 8.76 mg/ml NaCl, 5 mM EGTA, 5 mM MgCl2, and 0.9 
mg/ml glucose; pH 6.1) twice, fixed in 3% paraformaldehyde in CB for 15 min, treated 
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with 0.2% Triton X-100 (Sigma Aldrich) for 12 minutes, and then incubated for 1 hour in 
3% bovine serum album in Tris-buffered saline (TBS) at pH 7.4. Primary antibodies to 
Olig2 (Millipore 1:500, Abcam 1:200) were applied overnight (4 °C). After washing in TBS 
for 15 minutes three times, Texas red-conjugated (Life Technologies) goat anti-rabbit IgG 
secondary antibody was applied (diluted 1:200). Experiments were performed in triplicate. 
Specificity of staining was confirmed by similar staining by two different Olig2 antibodies 
and by lack of staining on ES cell cultures, and with nonimmune serum controls performed 
with each experiment.  
Live Dead Assay 
Living cells were visualized by staining with calcein and dead cells were visualized 
by staining with EthD-1 (Life Technologies). Wells were washed by removing serum 
containing medium with detached cells to a tube and adding with Dulbecco’s PBS (D-
PBS). 3X Live/Dead solution was added to resuspend detached cells and returned to stain 
the attached cultures. Cultures were incubated in 1X Live/Dead reagent (1.3µM calcein, 2.7 
µM EthD-1) at room temperature for 30 minutes and visualized. 
Microscopy 
Cells were viewed with a Nikon TE2000S fluorescence microscope (Nikon 
Instruments Inc., Melville, NY). Images were acquired on the MetaVue image analysis 
software (Molecular Devices, Sunnyvale, CA) and analyzed using Adobe Photoshop. A 
smart sharpening filter with a radius of 10.4 pixels was applied to remove lens blur from 
fluorescence images. 
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4.4 Results 
 
The goal of this project was to generate an ES cell line that would enable us to 
purify Olig2 expressing cells from ES derived neural cultures. Gene targeting was used to 
engineer two ES cell lines with a drug resistance cassette expressed only in Olig2 
expressing neural cells. The ES cell lines, P-Olig2-1 and POlig2-2, were generated by 
replacing the protein coding region of Olig2 with a gene encoding puromycin 
acetyltransferase (PAC). P-Olig2 ES cells are differentiated into neural cells where 
approximately 33% (Xian, Werth et al. 2005; Zhang, Horrell et al. 2008) will express Olig2. 
Olig2 expressing cells are then easily purified from heterogeneous P-Olig2 neural cultures 
by selection with puromycin. 
First, targeting vectors were constructed to contain 10-20kb of the Olig2 locus, 
where the coding region was replaced by a gene conferring resistance to puromycin, PAC 
(Gomez Lahoz, Lopez de Haro et al. 1991).  Next, ES cells were electroporated with a 
targeting vector to generate targeted events by recombination.  Targeted ES cell clones 
were identified by PCR and confirmed by Southern analysis for two independent vectors.  
In targeted P-Olig2 ES cells, puromycin resistance is encoded in one Olig2 allele and 
therefore is expected to be expressed in cells that are expressing Olig2. Functional studies 
of two independently generated P-Olig2 ES cell lines show that puromycin resistance is 
conferred to a subset of neural cells that express Olig2. We conclude that the P-Olig2 
knock-in lines work as designed and will facilitate selection of Olig2 expressing cells from 
heterogeneous neural cultures with puromycin.  
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4.4.1 Pharmacology of Puromycin Selection on Neural Cells 
Before building the targeting vectors, puromycin was first investigated as a selector 
drug in neural cultures. Puromycin N-acetyltransferase (PAC) confers effective resistance 
to puromycin in ES cells and is often used as a selector for genetic engineering ES cells 
(Watanabe, Kai et al. 1995). However, the use of puromycin selection on neural cells has 
not been characterized. It is conceivable that neural cells cannot be protected from 
puromycin by PAC. For example, neural cells have extensive cellular processes and these 
might not receive PAC even if enzyme is made in the cell body. Unable to receive enzyme 
at its processes, a neural cell with the resistance gene could be killed by puromycin. To see 
if PAC protects neural cells we transformed RW4 ES cells with a linearized ubiquitously 
expressed PAC cassette. Random integrant ES clones were selected by puromycin and 
pooled together to generate a stable ES polyclonal culture where a PAC cassette was 
randomly integrated at multiple sites in the ES cell genome. This was then differentiated in 
parallel with nontransgenic RW4 ES cells and selected with puromycin drug for 24 hours.  
RW4 ES derived neural cells were sensitive to puromycin, exhibiting extensive cell death 
whereas some ES derived neural cells containing the PAC cassette remained alive. This 
experiment showed that the puromycin selection works in neural cells and so it was 
worthwhile to create the P-Olig2 knock-in.  
4.4.2 Design and Construction of Targeting Vectors 
 
As a first step in construction of targeting vectors, a 227kb Sv129 BAC clone 
containing the Olig2 region was obtained (Xian, McNichols et al. 2003). A Sv129 BAC was 
chosen because the RW4 ES cells used to generate the line are also derived from the Sv129 
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mouse strain. There is evidence that exact sequence homology, as would be derived from 
an isogenic strain, improves targeting efficiency (te Riele, Maandag et al. 1992). The 
frequency of targeting in ES cells is also proportional to the length of homology to the 
target sequence (Thomas and Capecchi 1987).  Although BACs have been used for 
targeting (Valenzuela, Murphy et al. 2003), BAC DNA was not used directly because 
handling BAC DNA and detecting a BAC targeting event in ES cells are challenging.  
Instead, an approach described by Wu et al (Wu, Ying et al. 2008) was followed, which uses 
recombineering to subclone BAC DNA. A linear vector is tailed with 50bp of homology to 
the ends of the region of interest in the BAC by PCR, and recombination is catalyzed by 
lambda red recombinase (Figure 4.3A). This method for constructing targeting vectors 
allows for generation of long regions of homology, minimizes mutations from PCR 
amplification of homology arms, and reduces time and expense of vector construction 
compared to traditional cloning. In addition, keeping one homology arm short, between 
1kb and 2kb, makes PCR detection of targeting events feasible. By using different primers 
for amplification of the rescue plasmid, eight independent plasmids between 10kb and 
20kb containing the Olig2 region were generated [pOlig2_1-8]; two with short 5’ arms and 
six with short 3’ arms. The structures of these plasmids were verified by restriction digest 
(8/8) and sequencing (7/8) from the vector backbone into the homology region.  
Next, recombineering was used to introduce restriction sites with base-pair 
precision at the boundaries of the open reading frame (Figure 4.3B). The restriction sites 
were brought into the targeting plasmids by recombination of a chloramphenicol cassette 
tailed with AscI sites and 50bp of homology just outside the Olig2 open reading frame, 
with the homology containing plasmid. Recombinants were selected by chloramphenicol 
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resistance and verified by restriction digest (7/8) and sequencing (5/5).  Seven out of eight 
plasmids [pOlig2-1-3Asc, pOlig2_5-8Asc] were successfully modified with restriction sites. 
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Figure 4.3: Engineering P-Olig2 Targeting Vectors by Recombineering and Cloning 
(based on (Wu, Ying et al. 2008)). (A) Two independent Olig2 regions of (12-15kb) were 
subcloned into plasmid vectors by recombination using 50bp of homology from a 227kb 
BAC (Xian, McNichols et al. 2003) containing the Olig2 region.  (B) AscI restriction sites 
were introduced at the boundaries of the Olig2 open reading frame by recombination of a 
linear chloramphenicol cassette flanked with AscI and 50bp of Olig2 homology. (C) The 
AscI flanked resistance cassette, containing the promoterless puromycin cassette and 
floxed PGK promoter neomyocin cassette, was then transferred the targeting vector by 
conventional cloning. (D) Gateway clonase enzyme was used to catalyze site specific 
recombination between attB and attR sites and introduce a high-copy replication origin and 
thymidine-kinase negative selection cassette to generate final targeting vectors. 
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The next step was cloning the expression cassette into the targeting vectors. Two 
vectors were chosen, pOlig2-1Asc, with a short 3’ homology region, and pOlig2-8Asc, with 
a short 5’ homology region (Figure 4.3). Constructing more than one targeting vector was 
desired because it is unknown how specific sequences contribute to targeting efficiency in 
ES cells. Having two targeting vectors with unique ends should increase the likelihood of 
obtaining a targeting event. The second reason these two vectors, with short ends on 
opposite sides of the expression cassette, were chosen was to enable pilot testing of the 
targeting detection PCR described in the following section. The expression cassette was 
then cloned into both pOlig2-1Asc and pOlig2-8Asc by conventional cloning (Figure 
4.3C). The expression cassette consists of a promoterless puromycin cassette which will be 
expressed under the control of the Olig2 promoter and ubiquitously active 
phosphoglycerate kinase (PGK) promoter driving a neomycin resistance cassette to select 
for insertion in ES cells. The cassette is flanked with AscI sites and consists of the 
necessary components for effective expression of puromycin resistance under the control 
of Olig2 promoter including: Kozak translational initiation sequence (Kozak 1986), start 
codon, and promoterless puromycin acetyltransferase and a bGH polyA+ signal. The 
neomycin resistance cassette is flanked by loxP sites and contains: the PGK promoter to 
control expression of the neomycin cassette with a bGH polyA+ signal. The PGK 
promoter is facing in the same direction as the Olig2 promoter. The flanking loxP sites 
(Sauer and Henderson 1988) allow for removal of the neomycin cassette by cre-
recombinase once the targeted line has been obtained.  
The expression cassette was generated by a combination of PCR and cloning. Due 
to the possibility of mutagenesis during PCR of the puromycin, the amplified puromycin 
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cassette with left most AscI site was cloned into a custom built expression vector 
(Appendix D.3) before being inserted in the targeting vectors. In the expression vector an 
EF-1alpha promoter (Chung, Andersson et al. 2002), a strong promoter in ES cells, was 
used to drive expression of the amplified puromycin acetyltransferase gene. Puromycin 
resistant ES cells were generated with the expression vector confirming the functionality of 
the amplified puromycin cassette. The expression vector also contained the PGK-neo 
cassette and right-most AscI site, so that the entire expression cassette was flanked by AscI 
sites. The expression cassette was cloned conventionally into the targeting vectors using 
AscI sites.  A PCR assay for both junctions was used to detect correct insertion of the 
expression cassette in the targeting vectors. The two plasmids were named pOlig2_1PN 
and pOlig2_8PN.   
All of the steps described above had been performed on low copy number vectors 
to reduce possibility of plasmid instability (Wu, Ying et al. 2008). As a last step, the 
targeting vectors were transferred to a high-copy number plasmid for production of DNA 
for targeting ES cells and to add a negative selection cassette containing herpes simplex 
virus thymidine kinase (TK) gene for enrichment of targeting events by selection with 1-(2-
Deoxy-2-fluoro-ß-D-arabinofuranosyl)-5-iodouracil (FIAU, Movarek Biochemical, Brea, 
California (Capecchi 1989; Wu, Ying et al. 2008). Random insertion events in the ES cell 
genome will contain the TK gene and exhibit sensitivity to FIAU, whereas homologous 
recombination events will exclude the cassette from the ES cell genome. This backbone 
transfer was performed by a site specific recombination reaction between L1/R1 and 
L2/R2 catalyzed by clonase enzyme (Invitrogen, Carlsbad CA) (Figure 3D).  Final vectors 
pOlig2_1PN-TK3 and pOlig2_8PN-TK3 were validated by restriction digest with three 
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different enzymes. The final vectors pOlig2_1PN-TK3 and pOlig2_8PN-TK3 have been 
though rigorous structural analysis throughout the construction process and have been 
validated by multiple methods including: restriction enzyme digests, junction PCR assays, 
appropriate antibiotic sensitivity or resistance, and sequencing.  
4.4.3 Generation of the P-Olig2 Knock-In ES Cell Lines 
 
Targeting in ES cells is typically detected by either short arm junction PCR or 
Southern analysis. Short arm junction PCR has the advantage of being an amplifying 
method and being easily scaled to analyzing many clones. Detection of a targeting event 
relies on amplification across a novel junction between the expression cassette and the 
neighboring genome. The novel junction needs to be detected in a genomic DNA, so the 
PCR assay needs to be very robust.  Since the junction is novel in ES cells, typically there is 
no positive control for the PCR assay. By having two complementary targeting vectors 
with opposite short arms, the structure of the targeting event in ES cells is present the in 
long arm of the complementary targeting vector, providing a positive control template for 
optimization of the PCR assay. 
To generate the targeted P-Olig2 ES cell lines, RW4 ES cells were transfected by 
electroporation of two independently generated targeting vectors, pOlig2_1PN-TK3 and 
pOlig2_8PN-TK3, in separate experiments. Successful recombination (Figures 4.4.1A, 
4.4.2B) resulted in replacement of the Olig2 open reading frame (+1 to +973) with a 
promoterless puromycin cassette followed by a PGK-neo cassette for both vectors. Four 
independent electroporations were performed for each construct. Following positive 
selection with neomycin and negative selection with FIAU, clones were screened by 
junction PCR across the short arm (Figure 4.4.1A, 4.4.2A) from inside the targeting 
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construct into neighboring genomic DNA. Targeting efficiency was 5.2% (15/288) for 
pOlig2 _1PN-TK3 and 3.7% (14/376) for pOlig2 _8PN-TK3. 
4.4.4 Structural and Functional Validation 
 
Southern analysis was used to independently verify correct integration of the 
puromycin cassette in one clone derived from each targeting event. By using a probe for 
the Southern analysis external to the targeting vector in the Olig2 genomic region the 
unaltered allele could be compared to the engineered allele by examining shifts in 
restriction fragment size due to correct integration of the cassette at the Olig2 locus. 
Southern analysis on a P-Olig2 targeted clone from each construct and RW4 unengineered 
line (Figure 4.4.1C, 4.4.2C) produced the predicted structures. Targeting of pOlig2_1PN-
TK3 to the Olig2 locus introduces two new SpeI sites reducing the detected band size 
from 7.8kb to 3.5kb for the targeted allele in clone D9 (Figure 4.4.1C). Clone B9 was 
produced by targeting pOlig2_8PN-TK3 to the Olig2 locus lengthening the HindIII 
fragment from 4.8kb to 6.7kb in the targeted allele (Figure 4.4.2C). In summary, southern 
analysis confirms correct chromosomal integration of the puromycin cassette into one 
allele of Olig2 in the targeted lines.  
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Figure 4.4.1: Successful Targeting of Puromycin Cassette to Olig2 Locus by Two 
Independent Targeting Events. (4.4.1) Targeting of pOlig2_1PN-TK3 to the Olig2 Locus 
in ES Cells. (A) The blue line represents the homology arms and black boxes are the two 
exons of Olig2.  The targeting vector contained a promoterless puromycin cassette 
followed by a floxed neo cassette which was used for positive selection. A TK cassette was 
used for negative selection in ES cells. (B) Targeting events were identified by junction 
PCR. Junction PCR identified clone D9, a targeted clone by appearance of 1.7kb band. (C) 
Genomic DNA from D9 was digested with SpeI and Southern blot confirmed targeting of 
the cassette to the Olig2 locus by a new 3.5kb band detected by the 3’ probe. (D) Cre-
excision of the PGK-neo cassette was confirmed by the presence of a 350bp band and 
sensitivity to neomycin (not shown). 
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Figure 4.4.2: Successful Targeting of Puromycin Cassette to Olig2 Locus by Two 
Independent Targeting Events. (4.4.2) Targeting of pOlig2_8PN-TK3 to the Olig2 locus in 
ES Cells. (A) The blue line represents the homology arms and black boxes are the two 
exons of Olig2.  The targeting vector contained a promoterless puromycin cassette 
followed by a floxed neo cassette which was used for positive selection. A TK cassette was 
used for negative selection in ES cells. (B) Targeting events were identified by junction 
PCR. Junction PCR identified clone B9, a targeted clone by appearance of 2.1kb band. (C) 
Genomic DNA from B9 was digested with HindIII and Southern blot confirmed targeting 
of the cassette to the Olig2 locus by a new 6.7kb band detected by the 5’ probe. (D) Cre-
excision of the PGK-neo cassette was confirmed by PCR by the presence of a 350bp band 
and sensitivity to neomycin (not shown). 
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Cre-excision of the PGK-Neomyocin Cassette is Required for Correct mRNA 
Regulation 
Once the structure of the targeted P-Olig2neo lines, B9 and D9, had been 
validated, we next investigated the expression profile of the puromycin resistance transgene 
in the targeted lines. Since the lines were puromycin acetyltransferase knock-ins into Olig2, 
we expected expression of the P-Olig2 PAC transgene to follow the same temporal and 
cellular specificity of the native Olig2 gene. To test this we isolated RNA from ES, EB and 
2-/4+ ventral neural cells from targeted lines and RW4 as an unengineered control.  Olig2 
and the P-Olig2 PAC mRNAs were measured by RT-PCR. Based on knock-in design 
principles, we expected to find that the P-Olig2 PAC mRNA would be expressed only in 
neural cells with the same regulation as the native Olig2 allele. As expected, Olig2 mRNA 
was detected in only 2-/4+ ventral neural cells in the targeted lines B9 & D9, and RW4. 
Unexpectedly, we found that the P-Olig2 PAC mRNA was expressed at all stages (the ES, 
EB and 2-/4+stages) and is not restricted to neural cells like the native mRNA (Figure 4.5).  
To explore this unexpected finding further, we treated P-Olig2-neo ES cells with 
4µg/ml puromycin and found that they were sensitive to the drug. This result directly 
contradicts the presence of the PAC mRNA in ES cells. It suggests that the PAC mRNA 
we measured was not being translated into a functional PAC enzyme at the ES cell stage. 
Furthermore, puromycin treatment of P-Olig2-neo ventral neural cells resulted in a subset 
of cells that was resistant to the drug. This contradictory result suggests that in neural cells 
PAC mRNA is translated into functional PAC enzyme.  Together, these results led us to 
suspect that the misregulation of the transgene was only occurring at the mRNA level.  
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Figure 4.5: Excision of the PGK Promoter Is Required for Correct Regulation of   
P-Olig2 PAC mRNA.  (A) Diagram of engineered allele before and after cre-excision. (B) 
Targeting the Olig2 locus with a PGK-neo cassette disrupts mRNA regulation of the 
transgenic allele.  P-Olig2 PAC mRNA is expressed in all cell types unlike Olig2 which is 
restricted to neural cells. Despite unregulated mRNA expression, ES, EB and a subset of 
neural (2-/4+) cells show sensitivity to puromycin.  
 
Since the mRNA expression of the P-Olig2 PAC mRNA appeared to follow the 
ubiquitous expression pattern of the PGK promoter, instead of Olig2 we reasoned that the 
very strong PGK promoter immediately adjacent to the puromycin cassette was interfering 
with proper regulation of the P-Olig2 message, despite the fact that the PGK promoter is 
arranged to direct transcription of the neomycin cassette downstream. There have been 
published accounts of nonspecific transcriptional activity and incorrect regulation of 
cassettes due to the presence of the PGK promoter (Pham, MacIvor et al. 1996; Scacheri, 
Crabtree et al. 2001). To attempt to eliminate the inappropriate expression of the knock-in, 
we used Cre recombinase to excise the floxed PGK-neo cassette. Resulting clones where 
PGK-neo had been excised were identified by junction PCR (Figure 4.4.1D, Figure 4.4.2D) 
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and neomyocin sensitivity. Excision of the PGK promoter restored proper mRNA 
regulation in both lines, restricting P-Olig2 PAC mRNA expression to induced ventral 
neural cells (2-/4+). From this we conclude that the PGK-neo cassette was responsible for 
the unexpected P-Olig2 PAC mRNA expression. This carries a general lesson for gene 
targeting that introducing sequences, especially strong promoters such as PGK, can have 
unintended effects. All subsequent data is from Cre-excised lines. 
P-Olig2 Undifferentiated ES cells are Sensitive to Puromycin  
 
Because Olig2 is not expressed in ES cells, it is expected that PAC will not be 
expressed in ES cells and P-Olig2 ES cells will be sensitive to puromycin. To learn about 
the functional regulation of the PAC, RW4 and P-Olig2 undifferentiated ES cells were 
plated and treated with puromycin over three days. A Live/Dead assay was performed to 
observe the action of the drug after 24, 48, and 72 hours. Cells are treated with two 
compounds, calcein and EthD-1, for Live/Dead staining. Living cells are visualized by 
calcein, a membrane permeant esterase substrate dye that is cleaved by intracellular 
esterases in living cells causing the cytoplasm of living cells to fluoresce bright green. Dead 
cells fluoresce red because EthD-1 is excluded by the membrane of living cells and can 
permeate the membrane of dead cells and bind to nucleic acids.  As shown in Figure 4.6, 
untreated ES cells show bright green calcein stained living cells and very few EthD-1 
stained dead cells. Within 24 hours of selection, 50-75% of RW4 and P-Olig2 ES cells are 
dead as shown by increased EthD-1 staining and a small percentage of detached rounded 
cells stained with calcein. Viability is less than ~4% for all three cell types after 48 hours. 
There are no calcein-stained surviving cells after 72 hours of puromycin for all three cell 
types. P-Olig2 ES cell lines are as sensitive to puromycin treatment as non-transgenic RW4 
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control ES cells. The knock-in is regulated as expected; the P-Olig2 transgene is not 
conferring functional resistance to puromycin in ES cells.  
Figure 4.6: P-Olig2 ES Cells are Sensitive to Puromycin. Native RW4 ES cells as well as 
targeted P-Olig2 ES cells (POlig2-1, P-Olig2-2) are sensitive to puromycin. ES were seeded 
in 24 well plates and dosed as with 4µg/mL puromycin for the number of days shown. 
Live/Dead staining of untreated cells shows abundant living cells (green) and few dead 
cells (red).  RW4 and transgenic ES cells are susceptible to puromycin as 24 hours and near 
complete cell death ~<4% green within 48 hours and no remaining viable cells after 72hrs. 
Scale bars are 50µm. 
 
A Subset of P-Olig2 Ventral Neural Cells Survive Puromycin Treatment 
 
If the PAC transgene is regulated similarly to the native Olig2 gene, at 2-/5+ and 2-
/6+ 30% of P-Olig2 expressing ventral neural cells (Xian, Werth et al. 2005; Zhang, 
Horrell et al. 2008) should be protected from puromycin by expression of PAC. After 
treatment with puromycin for two days (2-/4+ to 2-/6+), RW4 and P-Olig2 neural cells 
(2-/6+) were observed by phase contrast microscopy and living cells were visualized 
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calcein staining as shown in Figure 4.7.  Under phase contrast, RW4 and P-Olig2 neural 
cultures both display clear signs of cell death resulting from puromycin treatment. Many of 
the RW4 EBs detached from the surface of the dish during the course of treatment, but 
some remain attached. In contrast, calcein staining reveals living cells in the selected P-
Olig2 neural cultures that are not seen in RW4 controls. The simplest interpretation is that 
expression of the transgene is protecting P-Olig2 neural cells from puromycin.  
 
 
 
Figure 4.7: Expression of the Puromycin Acetyltransferase Gene (PAC) Protects  
 P-Olig2 Neural Cells from Puromycin. Native RW4 and P-Olig2 ES cells were 
differentiated into neural cells for six days (2-/4+) and treated with 4µg/mL puromycin for 
2 days (2-/4+ to 2-/6+). (A) Phase contrast image of treated puromycin treated RW4 
neural cells shows dead cells and many EBs that have detached from the dish. (B) Calcein 
staining confirms that puromycin has killed all RW4 cells. (C) Phase contrast shows an 
attached P-Olig2 EB that looks very similar to RW4. (D) Calcein staining of P-Olig2 neural 
cell reveals abundant living cells beneath the debris providing evidence for a subset of 
neural cells protected from puromycin. Scale bars are 50µm. 
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The cellular phenotypes resulting from selection were visualized by calcein staining 
in treated and untreated cultures of P-Olig2 cells. After two days of puromycin treatment 
P-Olig2 cultures contain surviving cells, arranged in rosettes found both within and on the 
outskirts of most EBs (white arrows). Neural extensions are also visible (white arrows).  
Flattened neural cells that surround EBs in untreated cultures have been selected against 
(Figure 4.8). 
 
 
 
 
Figure 4.8: Treatment with Puromycin Selects a Subset of P-Olig2 Neural Cells.  (Left) 
Calcein staining of Olig2-puro neural cells (2-/6+) shows rosettes and neurites (white 
arrows) but also other flattened neural cell types that surround embryoid bodies and 
decorate the surface of the dish (yellow arrows). (Right) Calcein staining of Olig2-puro 
neural cells (2-/6+) treated for two days with puromycin (from 2-/4+ to 2-/6+). Cells 
surviving treatment are arranged in rosettes both outside and inside of EBs and show some 
weak neural extensions (white arrows).  Flattened neural cells that surround EBs present in 
untreated cultures have been selected against. Scale bars are 50µm. 
 
  In a separate experiment, selection was extended for one additional day. Rosettes 
and neural extensions become even more pronounced after three days of selection, and 
neural cells that surround EBs on the surface of the dish have not returned. In addition, 
there are surviving cells radiating from a few rosettes that have a radial glial morphology 
(Figure 4.9). 
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Figure 4.9: After Three Days of Selection, Resistant P-Olig2 Cells Thrive. Calcein 
staining of P-Olig2 neural cells (2-/7+) and P-Olig2 neural cells (2-/7+) selected for three 
days by puromycin (from 2-/4+ to 2-/7+).  (A) Untreated P-Olig2 (2-/7+) have flattened 
neural cell types that surround embryoid bodies and decorate the surface of the dish which 
are absent in selected cultures. (B) After three days of selection P-Olig2 neural cells have 
cells surviving treatment arranged in rosettes similar to what is seen after two days of 
selection. (C) Selected P-Olig2 cells show a more pronounced radial glial morphology after 
three days. (D) Extensive neural processes are visible in P-Olig2 neural cultures after 3 days 
of puromycin selection.  
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Drug based selection allows for continuous selection of Olig2 expressing cells 
Unlike selection using GFP and a FACS machine, drug based selection allows for 
continuous selection in culture. Selection of Olig2 expressing cells can be performed 
beyond the two days necessary for the action of the drug. Induction with retinoic acid and 
sonic hedgehog was extended to thirteen days, and drug selection was applied for nine days 
beginning at day (2-/4+).  To insure that active puromycin was present, cells were redosed 
with puromycin at 2-/9+ and 2-/11+. Diverse cellular phenotypes were seen in selected P-
Olig2 neural cultures stained with calcein including: rosettes, neural extensions, radial glial-
like cells, large flat cells, and small rounded cell bodies with and without extensions (Figure 
10). Continuous selection of Olig2 expressing cells is possible using drug selection.  
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Figure 4.10: Continuous Selection Reveals Diversity of Olig2-Expressing Cells (A-F). 
Calcein staining of P-Olig2 neural cells (2-/13+) selected with 4µg/mL puromycin for 9 
days (2-/4+ - 2-/13+). Cells were given a half feeding and redosed at 2-/9+ and 2-/11+. 
(A) Radial glial-like cells (seen in Figure 4.9) have continued to extend long processes 
through the course of selection. (B) Cells with flattened cell bodies and spindly processes 
appear. (C) Large rosettes are still visible which radiate processes. (D) Very large flat cells 
absent at 3 days of selection have emerged. (E) Smaller rosettes appear to be losing their 
shape as cells bodies radiate outward (F) Numerous small round cell bodies are visible 
through abundant processes. 
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Surviving Cells Express Olig2 
 
Specificity of resistance to puromycin selection was investigated by staining selected 
cultures with Olig2 antibody. P-Olig2 neural cells were differentiated for 7 days (2-/5+) 
with selection applied to one set of cultures for 24 hours and stained with Olig2 antibody 
(Figure 4.11).  
 
 
 
Figure 4.11: Surviving Cells Express Olig2. (A) P-Olig2 (2-/5+) neural cells contain 
many cell types including: rosettes, neurites, and flattened supporting cells that are visible 
using phase contrast. (B) Only rosettes stain with Olig2 antibody. (C) Selection of   P-Olig2 
neural cells for 24 hours with 4µg/mL puromycin (from 2-/4+ to 2-/5+) kills supporting 
cells and neurites, while rosettes survive. (D) The surviving rosettes express Olig2. Scale 
bar for all images is 50µm.  
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Under phase contrast unselected P-Olig2 cultures have diverse phenotypes. These 
include cells arranged in rosettes, neural extensions, and flatted supporting cells that 
surround embryoid bodies. However, only cells localized in rosettes stain with Olig2 
antibody.  After 24 hours of selection P-Olig2 neural cultures, only cells localized to 
rosettes are present. Neural extensions and supporting cells that were visible in unselected 
cultures are missing. Antibody staining of selected P-Olig2 cells shows that the selected 
cells stain with Olig2 antibody.  The loss of several cell types from the selected cultures and 
strong Olig2 antibody staining of remaining selected cells demonstrates that selection of P-
Olig2 cells with puromycin has indeed enriched for Olig2 expressing neural cells; the ES 
cell lines are working as designed. 
4.5 Discussion 
 
The ability to generate large numbers of well-defined ES cell derived neural cells is 
essential for stem cells to fulfill their potential in biomedical research and applications in 
regenerative medicine. A strategy employing a drug and cells genetically engineered with 
corresponding resistance gene has the ability to improve access, yield, and purity of 
selected cell populations (Klug, Soonpaa et al. 1996; Li, Pevny et al. 1998; Billon, Jolicoeur 
et al. 2002; Ying, Stavridis et al. 2003; Zandstra, Bauwens et al. 2003; Meissner, Wernig et 
al. 2007).  Therefore, we investigated drug selection to isolate a subset of ES derived neural 
cells. Our goal was to generate an ES cell line where puromycin could be used to select for 
Olig2 expressing cells in ES derived neural cultures. 
We successfully generated two knock-in ES cell lines termed P-Olig2-1 and P-
Olig2-2.  Both are generated by inserting a promoterless puromycin acetyltransferase gene 
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(PAC) into one allele of Olig2. In both knock-in lines PAC expression recapitulates the 
expression of the native Olig2 gene. Therefore, when P-Olig2 ES cells are differentiated 
into ventral neural cells, Olig2 expressing cells express PAC and are resistant to puromycin. 
The P-Olig2 ES lines are a new tool for research. By simply adding puromycin, Olig2 
expressing cells can be selected from heterogeneous ES derived neural cells in a 
convenient, effective, and inexpensive manner.  
The puromycin resistance profile of both P-Olig2 ES cell lines is highly similar to 
Olig2 expression. As expected, P-Olig2 undifferentiated ES cells were sensitive to 
puromycin. After two days of selection, approximately 95% of P-Olig2 ES cells were killed.  
After three days there were no surviving cells. On the other hand, a subset of differentiated 
P-Olig2 ES derived neural cells survived two and even three days of puromycin selection. 
Calcein staining allowed us to observe the surviving cells, which were arranged in rosettes 
found most often within embryoid bodies. Survival of rosettes gives strong evidence that 
the cell lines are indeed selecting for Olig2 expressing neural cells. Previous work with the 
G-Olig2 cell line has shown that rosettes in ES derived neural cultures contain Olig2 
expressing cells (Xian and Gottlieb 2004). Olig2 antibody staining of P-Olig2 ES derived 
neural cultures gives further evidence for Olig2 expression in rosettes and has been shown 
previously (Zhang, Horrell et al. 2008). We also saw that P-Olig2 ES derived neural 
cultures become enriched in Olig2 containing rosettes following selection. Based on this 
evidence, we believe that puromycin selection in this system is purifying Olig2 expressing 
cells. 
Drug selection allows for application of continuous selection and permits 
observation of highly organized and interconnected cellular networks of selected cells. 
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Following three days of puromycin selection of P-Olig2 ES derived neural cells, we 
observed surviving Olig2 expressing cells by calcein staining. We observed extensive 
processes radiating from cell bodies located in rosettes both within and outside of 
embryoid bodies. In some cases, cell bodies appeared to migrate away from the center of 
rosettes in a radial glial morphology.  This agrees with observations of Olig2 expression in 
radial glial cells in the E11 spinal cord (Masahira, Takebayashi et al. 2006).  Continued 
culture with retinoic acid and sonic hedgehog and selection over 9 days reveals multiple 
Olig2-expressing cellular phenotypes.  These cells could belong to oligodendrocyte 
precursor lineage, which emerges from Olig2 expressing cells (Masahira, Takebayashi et al. 
2006; Mukouyama, Deneen et al. 2006; Wu, Wu et al. 2006). Alternatively, these cells may 
represent phenotypes that do not exist in nature. In the embryo Olig2 expressing cells are 
subject to signals from neighboring Olig2 negative cells. These signals may restrict lineage 
progression of Olig2 expressing cells to a small number of allowable cell fates. Continued 
selection in vitro removes these signals, alleviating the restrictions. It is conceivable that 
Olig2 expressing cells can then differentiate into cells that do not occur in vivo. As a next 
step, gene expression profiles and antibody staining can be used to further characterize 
selected cells.  
Genetically engineering ES cells introduces new sequences into the genome. These 
sequences, especially strong promoters such as PGK (Pham, MacIvor et al. 1996; Scacheri, 
Crabtree et al. 2001), can have unintended effects. In the initial targeted lines, the Olig2 
puromycin acetyltransferase transgene was located directly upstream of a PGK promoter, 
an active promoter in ES cells.  In these lines the Olig2-PAC mRNA was expressed in ES 
cells unlike the native Olig2 gene. Yet, despite the presence of Olig2-PAC mRNA, both ES 
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cell lines were sensitive to puromycin. We hypothesize that the proximity of active PGK 
promoter to the PAC transgene may have resulted in chromatin modifications in the region 
that permitted transcription. However, this transcript was not translated into functional 
enzyme as it did not confer resistance to puromycin.  Removing the PGK-neo cassette, 
restored proper regulation to the PAC mRNA. Notably, excision of a PGK-neo cassette 
was also necessary for detectable GFP expression in the human ES R-Olig2 line (Xue, Wu 
et al. 2009). Techniques that facilitate removal of a positive selection cassette should be 
considered in design of future targeting vectors.   
Several aspects of this work will be able to be used to develop selection methods of 
other subsets of neural cells. First, we have shown that puromycin selection can work in 
neural cells. Puromycin has very favorable kinetics for selection, allowing for selection in 
two days (Watanabe, Kai et al. 1995). We have also shown puromycin selection can be 
continuously applied for up to nine days in neural cells. It is very likely that puromycin 
selection will work with other neural promoters, and has been recently shown to function 
with endothelial specific promoters (Kim and von Recum 2009). Second, advances in 
recombineering technology have improved vector construction methods, increased 
targeting efficiency (Wu, Ying et al. 2008), and are also applicable to human ES (Xue, Wu 
et al. 2009). Using these methods we were able to construct two vectors and detected 
targeting in ES by PCR with an efficiency ranging from 3.7-5.2%. These approaches should 
be applicable to other neural genes. 
Differentiation and puromycin selection of the P-Olig2 ES cell lines provide an 
easily accessible source of large numbers of Olig2 expressing cells. These selected cells will 
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become a key research tool in three areas: basic science investigations, transplantation 
research, and as a platform for drug toxicity and discovery.   
For basic science studies of gene expression and epigenetic regulation, having a 
reliable source of selected cells will facilitate biochemical analysis, leading to new 
knowledge. Gene expression profiles of sorted Olig2 GFP cells have been obtained (Xian, 
Werth et al. 2005; Shin, Xue et al. 2007; Xue, Wu et al. 2009) at one or two points during 
the course of differentiation and interestingly show different coordinately expressed genes 
depending on the extent of differentiation. By making selection convenient and efficient, 
gene expression profiles of Olig2 expressing cells can be systematically investigated. 
Heterogeneity of ES derived neural cultures has also confounded investigations into 
epigenetic mechanisms that participate in regulation of Olig2 expression. An easily 
accessible population of Olig2 expressing cells will help decipher whether chromatin marks 
and non-coding RNAs (Lorberbaum D.S., Rieger, C.R, and Gottlieb, D.I., in preparation) 
observed in heterogeneous ventral neural cultures occur in cells that are expressing Olig2 
or are from cells with silenced Olig2 expression. Several models have been proposed for 
fate determination of Olig2 expressing cells (Takebayashi, Yoshida et al. 2000; Rowitch, Lu 
et al. 2002; Wu, Wu et al. 2006). These cell lines provide a new tool to investigate these 
models. Selection can be applied at any time, in a pulsed or continuous manner, and the 
resulting cell phenotypes observed. 
Several groups are currently investigating ES derived ventral neural cells as 
therapeutics for neurodegenerative disease and spinal cord injury (McDonald, Liu et al. 
1999; Deshpande, Kim et al. 2006; Nayak, Kim et al. 2006; Coutts and Keirstead 2008; 
Willerth and Sakiyama-Elbert 2008; Johnson 2009). One great challenge for transplantation 
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researchers is to determine which subset of neural cells is most effective for restoring lost 
structures and function. For safety purposes, it is also critical for the therapeutic cells to be 
well-defined and not cause secondary tumors. Obtaining selected cells with a GFP line and 
FACS sorting is suitable for a proof of principle transplantation study. However, GFP 
selection becomes prohibitive for the necessary series of transplantation experiments. 
Several practical concerns limit the application of GFP selected cells for 
transplantation research, namely scheduling, cost, and convenience. Transplantation studies 
require coordination of an animal surgery with the availability of replacement cells. Many 
laboratories that study transplantation have only limited access to a FACS. This is further 
compounded by the need to coordinate an animal surgery with cell selection at the FACS, 
with the additional problem that cell culture and surgical facilities are unlikely to be located 
in proximity to the FACS. Unforeseen delays in either surgery or cell sorting could easily 
introduce new variables, including contamination of sorted cells, which have the potential 
for derailing an expensive transplantation study. Using GFP selection with neural cells 
raises unique concerns because neural cells are delicate and must be dissociated from highly 
interconnected structures before selection. A drug selection based approach avoids many 
of the concerns described and will create opportunities for transplant experiments that 
otherwise would not be performed.   
One drawback of the P-Olig2 lines for transplantation research is that the 
transplanted P-Olig2 cells will not be easily identified in an animal model. Transplantation 
researchers favor GFP lines because they allow for easy tracking of transplanted cells in the 
animal host.  To this end, we are currently adding a ubiquitously expressed GFP to P-Olig2 
line to aid in identification of transplanted cells.  
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Even before selected cells are transplanted into an animal model, drug selected cells 
can be used to test tissue engineering approaches.  With a ready supply of cells, biomaterial 
scaffolds and combinations of growth factors (Reviewed by (Willerth and Sakiyama-Elbert 
2008), (Levenberg, Burdick et al. 2005; Mahoney and Anseth 2007; Johnson, Parker et al. 
2009)) can be optimized in vitro to obtain a desired differentiated cell population for 
transplantation.  
An area of increased interest in research and industry is using subsets of 
differentiated ES cells as a testing platform to discover new growth factors, evaluate new 
drugs, and test compounds for toxicity (Reviewed by (Rubin 2008)). Screening assays 
require large numbers of biologically relevant cells. Once the desired population of cells is 
identified, methods to obtain sufficient yield and purity must be optimized. Recently, using 
a differentiation paradigm similar to that described here, optimum conditions to 
differentiate human ES to spinal motor neurons and oligodendocyte precursors were 
identified. Both of these important cell populations are derived from an Olig2 expressing 
intermediate (Hu, Du et al. 2009; Hu and Zhang 2009). Adding a drug selection strategy 
similar to P-Olig2 to these differentiation schemes could lead to increased yield and purity. 
Drug selection has the potential to facilitate production of a selected population of cells at 
a scale pivotal for investigations by the pharmaceutical industry.   
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Chapter 5 
  
Conclusion 
5.1 Summary of Findings 
The overall goal of the thesis was to develop tools to advance investigations of 
stem cells in tissue engineering based therapeutics for neurodegenerative disease and spinal 
cord injury. Stem cells offer a renewable source of cells that can be differentiated into 
neural cells and have the potential to replace lost cells. Due to the complexity and 
heterogeneity of the nervous system, the optimal cell types for therapeutic use must be 
determined experimentally. The ability to both characterize and purify subpopulations of 
stem cells and neural cells is essential to advance these experiments. To accomplish the 
goal of this thesis, two tools to measure cell fate and a tool to purify a subset of cells were 
developed and evaluated.   
In chapter 2, a digital method to measure mRNA as a tool for defining cell fate was 
developed and evaluated. Because stem cells occur as small populations and are 
heterogeneous, an mRNA profiling method that is sensitive, quantitative and allows for 
analysis of many genes simultaneously is desirable. We adapted polony technology (Mitra 
and Church 1999), a digital PCR based method, to measure mRNA expression from 
several key stem cell genes in small numbers of ES cells. Polonies measured mRNA from 
samples as small as 10 ES cells and one-fifth of a blastocyst, which contains approximately 
35 ES cells (Chisholm, Johnson et al. 1985; Johnson and McConnell 2004). Polony counts 
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for three pluripotency genes were obtained from a single blastocyst. Furthermore, polony 
counts were comparable to the number of cDNAs measured by competitive PCR, a 
standard highly quantitative method (Zentilin and Giacca 2007).  In summary, the results 
of chapter two show that the polony method is sensitive, can be applied to most genes, and 
allows for a degree of multiplexing.  
In chapter 3, DNA methylation assays were developed and evaluated as a tool to 
characterize differentiation from ES to neural cells. We tested the hypothesis that 
methylation is associated with silencing of genes involved in neural cell fate specification. If 
true, methylation has the potential to be useful as a marker of cell fate. First, we developed 
and validated direct bisulfite sequencing to measure methylation. Then, methylation was 
measured for five genes in ES cells, ES derived neural cells, and non-neural tissues. In 
accordance with previous studies (Gidekel and Bergman 2002; Hattori, Nishino et al. 2004; 
Li, Pu et al. 2007; Fouse, Shen et al. 2008) pluripotency gene Oct3 was unmethylated in ES 
cells where it is expressed, and methylated in differentiated cells and tissues where Oct3 is 
silenced. Phosphoglycerokinase-1 (Pgk-1) a constitutively expressed housekeeping gene 
was unmethylated in all cells and tissues. Methylation status of three neural fate 
determining genes Sox1, Olig1, and Olig2 was not indicative of expression. These neural 
genes were largely unmethylated in non-neural cells and tissues where they are silenced. In 
summary, for some genes, such as Oct3, methylation status can serve as a diagnostic 
marker of cell fate. In contrast, methylation status of neural fate determining genes does 
not provide any information about cell fate.  
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In chapter 4, genetically engineered drug selection was developed and evaluated as 
a tool to purify subsets of neural cells. Genetically engineered drug selection offers a 
convenient, effective, and inexpensive method to obtain large numbers of purified cells, 
thereby facilitating transplantation research with the purified cells. We hypothesized that 
engineering ES cells with puromycin acetyltransferase gene (PAC) under the control of the 
Olig2 promoter would allow for selection of Olig2 expressing neural cells with puromycin. 
Before proceeding to the genetic engineering, we showed that PAC was able to confer 
resistance to puromycin in neural cells. Then, targeting vectors were designed and built 
with PAC inserted into the Olig2 gene. Correct targeting resulted in two ES cell lines, P-
Olig2-1 and P-Olig2-2; one from each targeting vector was detected using PCR. Southern 
analysis confirmed the expected genomic structure for both ES cell lines. In both P-Olig2 
lines PAC expression recapitulated the expression of the native Olig2 gene. As expected, P-
Olig2 undifferentiated ES cells were sensitive to puromycin. As intended, a subset of P-
Olig2 ventral neural cells was resistant to puromycin. Selected P-Olig2 neural cells were 
arranged in rosettes, typical of Olig2 expressing cells (Xian and Gottlieb 2004; Zhang, 
Horrell et al. 2008). Olig2 antibody staining confirmed that surviving cells express Olig2.  
A subset of P-Olig2 neural cells survived continuous selection for up to nine days. In 
summary, puromycin selection of P-Olig2 ES derived neural cells enables purification of 
Olig2 expressing cells. 
Overall, this thesis achieves its goal by contributing tools to measure cell fate and 
purify subsets of neural cells. The tools help define and limit cellular heterogeneity, which 
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will be useful in the development of cellular and tissue engineering therapeutics for 
neurodegenerative disease and spinal cord injury.  
5.2 Future Directions 
5.2.1 Characterizing Cell Fate 
The landscape of nucleic acid-based technologies for cell characterization has vastly 
improved since this thesis was initiated over 4 years ago.  At that time digital PCR 
(Vogelstein and Kinzler 1999), polonies (Mitra and Church 1999; Mikkilineni, Mitra et al. 
2004), and molecular colonies (Chetverina, Samatov et al. 2002) were at the forefront of 
the field. Advancements in high-throughput DNA sequencing technology have also 
advanced mRNA analysis.  Newly developed mRNA profiling methods including: Illumina 
mRNAseq, ABI SOLiD SAGE, and Roche454 GS FLX Titanium Series Transcriptome 
Sequencing, are now standard tools in research and industry.  
To use these technologies to measure mRNA, mRNA must be reverse transcribed 
into cDNA. However, reverse transcription introduces several biases and artifacts into the 
measurement of mRNA. First, conversion of mRNA to cDNA is inefficient. Similar to 
results found by others (Dufva, Svenningsson et al. 1995), in chapter 2 we measured a 
conversion efficiency of 5% using a model mRNA transcript. Second, reverse transcription 
is not equally efficient for all genes; so, the quantitative relationships measured between 
particular cDNAs may not reflect the abundance of their mRNAs. Reverse transcription 
efficiency is influenced by the structural properties of the particular mRNA, choice of 
primer to initiate reverse transcription, processivity of the particular enzyme, and location 
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of DNA sequence readout relative to priming site. Finally, cDNAs measured may not 
reflect natural mRNAs. Reverse transcriptases have demonstrated template switching 
artifacts (Cocquet, Chong et al. 2006), synthesis of spurious second-strand cDNA (Gubler 
1987), and primer-independent reverse transcription. In summary, the ability to measure 
mRNA directly would alleviate biases and artifacts due to reverse transcription. 
 One approach that is poised to revolutionize mRNA profiling is the development 
of direct RNA sequencing technology (Ozsolak 2009). Measuring mRNA directly has the 
potential to increase sensitivity and make mRNA analysis more quantitative. In direct 
sequencing technology, polyadenylated mRNAs are captured on a surface coated with 
oligodT50 nucleotides. Using the oligo dT50 as a primer, a modified polymerase is used to 
synthesize a complementary strand of each tethered mRNA. Incorporated nucleotides are 
labeled by a fluorescent terminator. After each nucleotide is incorporated, the surface is 
imaged to capture sequence information. Then, the fluorescent terminator is cleaved to 
prepare for addition of the next nucleotide. The sequences obtained correspond to the 
particular mRNAs, and the numbers of molecules with a particular sequence reflect 
abundance. Thus, mRNA analysis can be performed without using reverse transcriptase.  
Direct RNA sequencing technology is sensitive, quantitative, and highly multiplex. It has all 
of the desirable attributes to be an improvement over current methods for stem cell 
mRNA profiling. 
5.2.2 Cell Separation 
Genetically engineered drug selectable ES cell lines that can be used to obtain 
relatively homogeneous populations of neural cells are not widely available ((Billon, 
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Jolicoeur et al. 2002; Ying, Stavridis et al. 2003), chapter 4). Most researchers still rely on 
FACS sorting of GFP knock-in and promoter reporter lines to obtain the purified cells that 
they need. Our ability to translate an established successful GFP reporter line (G-Olig2) 
into new successful drug selectable lines (P-Olig2) has strong implications for the 
development of new drug selectable lines for neural genes where valuable GFP reporter 
lines already exist.  
An example of a neural gene where reporter lines have provided great insight is 
Homeobox gene Hb9. Hb9 is a transcription factor expressed specifically in spinal motor 
neurons (Arber, Han et al. 1999; Thaler, Harrison et al. 1999). Hb9 plays an essential role 
in specifying motoneuron identity during development and its expression persists in adult 
motoneurons.  In 2002, Wicheterle et al (Wichterle, Lieberam et al. 2002) generated an ES 
cell line where GFP is expressed under the control of the Hb9 promoter. GFP expression 
recapitulates native Hb9 gene expression in vivo and is an effective tool for both visualizing 
and isolating motoneurons from ventral neural cultures. Development of a drug selectable 
line based on the expression of Hb9 could be very powerful. With new optimized growth 
factors regimens  to differentiate hES cells to motoneurons (Hu and Zhang 2009) and the 
ability to purify these motoneurons using drug selection, we would be one stem closer to 
clinically relevant numbers of well-defined motoneurons for transplantation research and 
therapy. 
 
 
 124 
 
 
Appendix A 
A Gene Targeting Cis-Trans Test Using 
Polonies  
 
A.1 Abstract 
 
Repeated cycles of gene targeting to the same allele are desired in chromosomal 
engineering. After the first targeting event, it is necessary to determine if the secondary 
targeting event has occurred on the same allele (in cis) or has altered the unmodified allele 
(in trans).   Typical cis-trans tests including Southerns and PCR lose the ability to detect 
linkage when the distance between targeting events is greater than 10kb.  Here we describe 
a polony cis-trans test which easily detects linkage over 14kb and can be extended for 
targets spanning megabase distances. 
A.2 Introduction 
 
Chromosomal engineering is an emerging discipline for studying gene function and 
regulation. Genomic DNA is targeted to generate insertions, deletions (knock-outs), and 
replacements (knock-ins) through homologous recombination. To map regulatory elements 
of a particular locus, repeated cycles of gene targeting to the same allele are desired. For 
example, a primary targeting event introduces a reporter gene such as GFP into the open 
reading frame of a gene of interest. Gene regulation by neighboring cis-DNA elements 
could then be studied by secondary targeting events to predicted promoter, enhancer, or 
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repressor regions.  Once a subsequent new targeting event is obtained it is necessary to 
determine whether the new targeting event occurred in cis or trans to an existing targeting 
event (Figure A.1).   
Figure A.1:   Two Outcomes of Sequential Targeting Events  
 
Two outcomes result from sequential targeting events. Events can occur on the same allele 
(cis) or on different alleles (trans) of the same chromosome. A cis-trans test is required to 
identify desired cis-events which will facilitate the study of gene regulation.  
 
 Traditional gene targeting cis-trans tests are performed using Southern Analysis 
(Leung, Malkova et al. 1997), PCR(Langston and Symington 2004), and Cre-Lox 
excision(Zheng, Sage et al. 2000). As the genomic distance between the two targeting 
events increases, the limitations of all three of these methods become apparent. Southern 
detection of cis-targeting events requires generation of a restriction fragment that spans the 
two targeting events. As fragment sizes approach 15kb, few restriction sites are available 
and bands become weak. Similarly, the practicality of using liquid phase PCR for cis-trans 
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detection decreases as the distance between the two targeting events increases beyond 
10kb. Another common, but limited approach for determining cis-targeting events relies 
on LoxP site insertion flanking each targeting event.  The addition of cre-recombinase is 
used to selectively loop out the region between the LoxP sites in the cis-linked events, 
producing changes in expression of a selectable marker or a new junction that can be 
assayed by PCR.  
 In principle, the polony method is better suited for performing cis-trans analysis on 
longer range targeting events than existing techniques. In a polony reaction amplification 
products from two independent targets in nearby genomic loci occupy the same micro-
region in the gel matrix. Cis elements are clearly identified by overlapping polonies, while 
targets in trans conformation are distinguished by unique polony signatures.  The polony 
cis-trans test can be performed in a relatively short period of time.  More importantly, the 
polony method is not constrained by the distance between the targeting events. Cis-linkage 
has been observed with polonies in the form of genotyping and haplotyping on targets 
45kb apart (Mitra, Butty et al. 2003), and with targets separated by 50-100Mb with 
modifications to the DNA preparation method (Zhang, Zhu et al. 2006). Here we 
demonstrate the feasibility of a polony gene targeting cis-trans test.  
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A.3 Materials and Methods 
 
DNA was extracted from ES cells (maintained by DD) by 5 Prime prep (5 Prime 
Gaithersburg, MD, done by XZ or SH) and diluted to an appropriate concentration for 
polonies in 10mM Tris-EDTA, pH 8.0 (B5 1:50, TG25 1:20). Polony slides were prepared 
according to previous work (Mitra and Church 1999). DNA was added to a liquid phase 
acrylamide gel mix containing PCR components and both the Neo gene and genomic 
target were amplified within the gel as described in Chapter 2. 
 Each amplicon was detected by its internal Cy-5 linked hybridization probe as 
previously described.  Images for each probe pair were overlayed using the screen function 
in Adobe Photoshop. Polonies were counted manually using ImageJ software and cell 
counter applet.  Olig2+14kb hybridization staining was pseudo colored red and Neo 
cassette hybridization staining was pseudo colored green.  
A.4 Results 
 
To establish the polony method as an alternative cis-trans test, we used polonies to 
determine cis linkage in DNA from two ES cell lines containing a Neomycin cassette (Neo) 
and two copies of the genomic target, an arbitrary region 14kb upstream of the Olig2 gene 
(UCSC browser build mm9; Chr. 16: 91,100,054 – 91,100,400). The cis-linked cell line 
(TG25) contains Neo in the open reading frame of one allele of the Olig2 gene (Chr. 16: 
91,114,409- 91,117,534; (Xian, McNichols et al. 2003)). The unlinked cell line (B5) contains 
Neo on an entirely different chromosome (UCSC browser build mm9; Chr. 12: 32,013,051) 
than the genomic target and thereby serves as a model for a trans relationship.  
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 Polonies were prepared from a cis-linked (TG25) cell line and an unlinked cell line 
(B5).  Slides were prepared with DNA from a single cell line and included primers for both 
the genomic target and a region of the Neomycin gene. Primer sequences are given in 
Table A.1.   
 
Table A.1: Primers for Cis-Trans Polony Assay 
 
Primer Name Sequence (5’-3') 
NeoF4 ctttcgacctgcagccaatatggga 
NeoR1_Ac Ac-gcaggagcaaggtgagatgacagga 
Hybridization 1 Cy5-tgaatgaactgcaggacgag 
Olig2_+14kbF3 taggagggagggaaacctgggatgtaataa 
Olig2_+14kbR3_Ac Ac-agtgtggagcagggtagctacacaaatggt 
Olig2_+14kbhybe3 Cy5- tcaatcaatcaatcaatcagca 
Reverse primers have an Acrydite functional group on the 5’ end to crosslink one 
strand of the polony amplicon into the gel matrix. After amplification, the free 
complementary strand is denatured, facilitating identification of each amplicon with 
an internal gene specific Cy5 labeled hybridization probe. For the second gene 
assayed, the first probe was removed before the second hybridization sequence was 
annealed. Amplicons for both genes were ~350bp.  
 
Polonies for each gene were sequentially identified by unique hybridization probes, 
images were pseudo colored for each gene and images of the same slide overlaid. Sample 
regions from polony slides for the B5 and TG25 cell lines are shown in Figure B.2.  
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Figure A.2: Polony Cis-Trans Test on DNA from Two Transgenic ES Cell Lines 
 
Genomic target polonies 14kb upstream of the Olig2 gene are red while Neo polonies are 
green. Overlapping polonies, which are yellow and have been circled in white, indicate 
presence of both genomic target and Neo amplicons in close proximity and predict a cis 
relationship. a) Region of a polony slide containing DNA from unlinked (B5) cell line. b) 
Region of a polony slide from DNA from cis-linked (TG25) cell line.   
 
In Figure A.2 genomic target polonies 14kb upstream of the Olig2 gene are red 
while Neo polonies are depicted in green. Yellow polonies, a result of overlapping red and 
green polonies, depict the presence of both genomic target and Neo amplicon in close 
proximity and predict a cis relationship.  By visual inspection of the slides, many yellow 
polonies were observed on slides prepared with TG25 DNA while only a few yellow 
polonies were seen on slides prepared with B5 DNA, demonstrating cis-linkage of Neo 
with the genomic target in the TG25 cell line.  
 To confirm observations and obtain quantitative estimates of the efficiency of the 
assay, polonies were counted on 8 slides, four prepared with B5 DNA and four with TG25 
DNA. Polony counts are given in Table A.2.  
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Table A.2:  Polony Counts from Cis-Trans Test on Two Transgenic ES Cell Lines 
 
Cell Line 
Total Genomic 
Target polonies 
(Red) 
Total Neo 
Polonies 
(Green) 
Cis-events 
(Yellow) 
B5  (B) 299 115 3 
B5 (B) 167 112 4 
B5 (D) 377 96 1 
B5 (D) 343 103 2 
TG25 (B) 286 119 24 
TG25 (B) 724 244 47 
TG25 (D) 222 87 16 
TG25 (D) 356 87 15 
 
Cis-elements can be distinguished from un-linked elements by polony counts. Four 
slides were prepared with DNA from the cis-linked cell line (TG25) and four slides 
were prepared with DNA from the un-linked cell line (B5). (B) stands for 1M Betaine 
incorporated into the reaction. (D) stands for 2% DMSO incorporated into the 
polony reaction. Betaine and DMSO were added to the polony mix to attempt to 
minimize differences in amplification efficiency due to amplicon GC content. 
 
For a yellow polony to be counted, more than 75% of the area of both polonies needed to 
be overlapping based on visual observation.  Based on the numbers of overlapping 
polonies, a cell line with two elements in cis orientation is clearly distinguished from a cell 
line with unlinked targets. The number of overlapping polonies for cis-linked TG25 DNA 
ranged from 15-47, while a background of 1-4 of overlapping polonies were present on 
polony slides prepared with unlinked B5 DNA. The tenfold increase in polony overlap 
apparent in TG25 over B5 is enough to set linked apart from unlinked.  
 Efficiency estimates can also serve as a metric independent of the actual number of 
overlapping polonies on a particular slide to distinguish cis-targeting events.  This is 
particularly relevant when sample DNA concentrations differ. The percentage of cis-linked 
polonies of the total number of polonies, also termed the co-amplification efficiency 
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(Mitra, Butty et al. 2003), for a particular target can be calculated to aid in determining a cis 
targeting event from an unlinked or trans targeting event and also estimate efficiency of the 
polony reaction.  For this experiment the percentage of cis-linked polonies of the total 
number of Neo polonies averaged 18.8% ± 1.3% for TG25 and 2.3% ± 1.1% for B5 and 
for cis-linked polonies of the total number of genomic target polonies averaged 6.6% ± 
1.7% for TG25 and 1.1% ± .9% for B5. 
A.5 Discussion 
 
The field of chromosomal engineering and study of gene regulation will benefit 
from improved methods for detecting cis-targeted elements. We demonstrate that the 
polony cis-trans test successfully detects cis-linked elements 14kb apart from unlinked 
elements in DNA from two transgenic ES cell lines.  
 The polony cis-trans test uses two sets of primers, one for each event, to generate 
polonies.  Polonies visualized for a particular amplicon are specific to that amplicon and 
corresponding internal hybridization probe.  Polony experiments on a non-transgenic ES 
cell line (RW4) confirmed that genomic targets were present, and the cell line did not 
contain a Neo cassette (data not shown). There also were no polonies on slides prepared 
without DNA. Polonies that are amplified from independent molecules remain spatially 
distinct, although a small number of overlapping polonies do appear, likely as a result of 
co-localization of independent templates in the gel.  When the two regions of interest 
reside on the same molecule, amplification of each target generates a polony molecule that 
occupies the same small region of the gel matrix, indicating cis-linkage of the two 
amplicons.  
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   In this particular assay, if polonies were generated from all cis-linked targets with 
100% efficiency, we would expect that 100% of Neo (green) polonies would overlap with 
genomic target Olig2+14kb (red) polonies and 50% of genomic target Olig2+14kb (red) 
polonies would overlap with Neo (green) polonies.  The observed co-amplification 
efficiency in the linked cell line for this study for Neo was 18.8% and 6.6% for the genomic 
target.  Previously reported co-amplification efficiencies from polony haplotyping studies 
varied from 4-34% and were influenced by the DNA quality (Mitra 2003). DNA 
degradation or fragmentation may be responsible for lower than anticipated co-
amplification efficiency by disrupting linked elements. As long as co-amplification 
efficiency is greater than the background noise, increasing the number of polonies present 
on a slide will ease cis-trans discrimination.  
 Several factors will enhance the polony cis-trans test beyond what is demonstrated 
here.  For the model system described, we expect the total number of genomic target 
polonies to the number of Neo polonies in both the cis-linked and unlinked cell lines to be 
in a ratio of 2:1, unlike a two targeting event recognition or haplotyping, where the two 
transgene targets would be expected in a 1:1 ratio.  Thus, cis-events should be even easier 
to spot in a true two transgene targeting study due to decreased background.  Further 
modification of the polony protocol by decreasing amplicon size from 350bp used here to 
100bp and the use of an argon chamber to decrease the amount of unpolymerized 
acrylamide in the gel would likely improve coamplification efficiency (Mitra and Church 
1999); (Mitra, Butty et al. 2003). The use of a bead-emulsion digital PCR amplification and 
flow cell detection (Kim, Porreca et al. 2007) instead of a gel based system would further 
increase the sensitivity and processivity of the cis-trans polony assay.  With stringent 
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genomic DNA extraction techniques (Zhang, Zhu et al. 2006), one could imagine 
extending the polony cis-trans test for targets spanning megabase distances. 
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Appendix B 
Supplemental information for  
Chapter 2: Polony profiling stem cells and 
blastocysts 
 
Table B.1: Polony primers for ES and blastocyst expression analysis 
 
Gene Accession # Primers Sequence 5'-3' 
Forward CGCCAATCAGCTTGGGCTAGAGAAG 
Reverse Ac-TGCCTCAGTTTGAATGCATGGGAG
Oct 3/4  NM_013633 
Hybridization Cy5-GGGGCTGTATCCTTTCCTCT 
Forward  GTGCTTGAACACCCTTACCCACGCC 
Reverse Ac-GGACTCCAAGGACAAGCAAGCACC
Nanog NM_028016 
Hybridization Cy5-CACCCACCCATGCTAGTCTT 
Forward  GCA AAGGCAGGGAAGAAATGCTGA 
Reverse Ac-TCTGCCGTATGCAAAAGTCCCCAT 
Rex 1  NM_009556 
Hybridization Cy5-GATTGTCCTCAGGCTGGGTA 
Forward ATC AGCCTCTTTTGCCCCAGCTCTT 
Reverse Ac-CCACCCCTTCCTGATTTGTGGAGA 
Cdx 2  NM_007673 
Hybridization Cy5’-AACTACAGGAGCCAGAGGCA 
Forward GCCCTGTCCAGACACTTGCCTTCT T 
Reverse Ac-CCAGTGCTTCCAACTGGTCTCAGG 
GLUT-1  NM_011400 
Hybridization Cy5-CCTATGGCCAAGGACACACT 
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Table B.2: Primers for BNI5polyA RNA RT efficiency studies 
 
Primer  Sequence 5'- 3' 
Construction primers  
YeastF TCGACTCTAGAGGATCCCCGGGTAATGCAT 
Forward Linker tggtctcaaatttggtgacagattttggcaTTTAGTTCCAATCCAAAAT
TGGCCATTTTC 
Reverse Linker AAATGGCCAATTTTGGATTGGAACTAAAtgccaaaatctgt
caccaaatttgagacca 
pTRI-Xef ccgggcgagctcgaattcgcgaaattccg 
Polony Primers   
Forward 1 AATTGTCCCAATCGCTCTGGAGGAA  
Reverse1_AC AC GCCCAGCTCAGACGCTGATGTGATA 
Hybridization 1 Cy5-GCCCTACAAATCCGTTCAGA 
Forward 4 CGGTGAGCAGCAATTCCAATTCAAG 
Reverse 4_AC AC ACTCCGACCTCATATTTCTCCTTCG 
Forward 5 CATCAGCGTCTGAGCTGGGCAGTAT  
Reverse 5_AC AC CGCCACGATCAATTTGCTTTCTCAG 
Hybridization 3 Cy5-GGGCAGTATTGCCAAGCTGGA 
 
All sequences from BNI5 plasmid are in CAPS.  All sequences from pTRI-Xef 
(Megascript kit, Ambion) which contained a 70bp polyA+ region that was 
appended to the BNI5 gene are in lower case.   BamHI and SacI restriction sites 
are in bold.  Dilution experiment was performed using Forward 5, Reverse 5_AC, 
and Hybridization 3 
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Table B.3: Primers for competitive PCR analysis 
Gene, Accession #, 
& Primer Sequence 5’-3’ 
Amplicon 
length (bp) 
Oct3/4 (296bp)  NM_013633  
Forward primer CGCCAATCAGCTTGGGCTAGAGAAG 
Reverse primer  GTGCCTCAGTTTGAATGCATGGGAG 
296 
Competitor with 
50bp deletion 
gtgcctcagtttgaatgcatgggagagccctgagtagagtgtggtgaagtggg
ggcttcc 
246 
Nanog (315bp) NM_028016 
Forward primer GTGCTTGAACACCCTTACCCACGCC 
Reverse primer  GGACTCCAAGGACAAGCAAGCACC 
315 
Competitor with  
50 bp deletion 
gtgcttgaacacccttacccacgcccaccctcattttgaggggtgaggtttaaa
agtata 
265 
Rex1 (276bp) NM_009556 
Forward primer GCAAAGGCAGGGAAGAAATGCTGA 
Reverse primer TTCTGCCGTATGCAAAAGTCCCCAT 
276 
Competitor with 
50bp deletion 
ttctgccgtatgcaaaagtccccatcccctggaactatgccatggaataccaa
aagaggc 
226 
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Appendix C 
 Supplemental Information for  
Chapter 3: From ES to Neural Cells:  
DNA Methylation as a Marker of  Neural 
Cell Fate 
This appendix contains tables with the primers used for methylation mapping experiments 
and source code for computational methods used for experimental design and data 
analysis. 
 
C.1 Primers 
 
Table C.1. Primers for construction and testing of mock methylated template 
Primer Sequence 5’-3’ 
SK F3 CACAATTCCACACAACATACGAGCCGGAAG 
SK R4 TACGCGCAGCGTGACCGCTACACTTGCCAG 
PSK_F1 gtaaaacgacggccagtgAAAAGGCCAGCAAAAGGCCAGGAAC 
PSK_R1/2 GgaaacagctatgaccatgTGCACACAGCCCAGCTTGGAGC 
PSK_BF1 GtaaaacgacggccagtgAAAAGGTTAGTAAAAGGTTAGGAAT 
PSK_BR1/2 GgaaacagctatgaccatgTACACACAACCCAACTTAAAC 
PSK_F2 GtaaaacgacggccagtgATGTGAGCAAAAGGCCAGCAAAAGGCCAG 
PSK_BF2 GtaaaacgacggccagtgATGTGAGTAAAAAGGTTAGTAAAAGGTTAG
PSK_F3 GtaaaacgacggccagtgGCAGAAGTGGTCCTGCAACTTTATC 
PSK_R3 ggaaacagctatgaccatgGAATTATGCAGTGCTGCCATAACCATGAGT 
PSK_BF3 gtaaaacgacggccagtgGTAGAAGTGGTTTTGTAATTTTATT 
PSK_BR3 ggaaacagctatgaccatgAAATTATACAATACTACCATAACCATAAAT 
PSK_F4 gtaaaacgacggccagtgGTTTGGTATGGCTTCATTCAGCTC 
PSK_R4 ggaaacagctatgaccatgCAATGATGAGCACTTTTAAAGTTCTGCTAT 
PSK_BF4 gtaaaacgacggccagtgGTTTGGTATGGTTTTATTTAGTTT 
PSK_BR4 ggaaacagctatgaccatgCAATAATAAACACTTTTAAAATTCTACTAT 
PSK_F5 gtaaaacgacggccagtgCCAAGTCATTCTGAGAATAGTGTATG 
PSK_R5 gtaaaacgacggccagtgAGAGTATGAGTATTCAACATTTCC 
PSK_BF5 gtaaaacgacggccagtgTTAAGTTATTTTGAGAATAGTGTATG 
PSK_BR5 ggaaacagctatgaccatgAAAATATAAATATTCAACATTTCC 
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Table C. 2. Gene primers for methylation analysis by bisulfite sequencing 
 
a. Primers for promoter analysis. All primers were located within 500bp surrounding 
transcription start site (UCSC genome browser July 2007 build), GC content for overall 
region analyzed (see Figure 3.2) and CpG Observed/ Expected are also given. Sequencing 
primers are located at the 5’ end of each primer and the last two rows of the table. 
Primer Sequence 5’-3’ 
GC
% 
Obs/ 
Exp 
Pgk1_F6 gtaaaacgacggccagtgTCCCAAGGCAGTCTGGAGCATG 
Pgk1_R6 ggaaacagctatgaccatgTTCCCAGCCTCTGAGCCCAG 
62% 0.71 
Oct4_F6 gtaaaacgacggccagtgGCTGTCTTGTCCTGGCCTTGGACAT 
Oct4_R6 ggaaacagctatgaccatgGGTCCTCTCACCCCTGCCTTGGGT 
Oct4_F7 gtaaaacgacggccagtgTGCAGTGCCAACAGGCTTTGTGGTG 
Oct4_R7 ggaaacagctatgaccatgACCCTCTAGCCTTGACCTCTGGCC 
Oct4_F8 gtaaaacgacggccagtgGTGACCCAAGGCAGGGGTGAGAG 
Oct4_R8 ggaaacagctatgaccatgTGAAGCCAGGTGTCCAGCCATGGGG 
59% 0.34 
Olig2_F6 gtaaaacgacggccagtgAAACTCCAGGTGTGGCAAGCAACCT 
Olig2_R6 ggaaacagctatgaccatgCCTCTCAGCACACAGCCAATGGGC 
Olig2_F7 gtaaaacgacggccagtgCATTGGCTGTGTGCTGAGAGGAG 
Olig2_R7 ggaaacagctatgaccatgAATTAGATTTGAGGTGCTC 
Olig2_F8 gtaaaacgacggccagtgCCATTGGCTGTGTGCTGAGAGGA 
Olig2_R8 ggaaacagctatgaccatgCTGTAATAAGCATCCACACCTTTC 
61% 0.76 
m13 -20F  Gtaaaacgacggccagtg 
m13 -27R Ggaaacagctatgaccatg 
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b. Primers for Olig2 mapping. Sequence for each primer, location of each primer relative 
to the transcription start site (TSS) of each gene (UCSC genome browser July 2007 build), 
GC content, and CpG Observed/Expected are given for each amplicon. Sequencing 
primers are located at the 5’ end of each primer and the last two rows of the table. 
 
Primer_name Sequence 5’-3’ 
Locat
ion 
rel to 
TSS 
GC
% 
Obs/
Exp 
Olig2_6_BF1 TGTGTTGGAGAGTAATGGATTAATAGA -5516
Olig2_6_BR1 AAATTCTAACCACCTAAACCAC -5254 61% 0.82 
Olig2_6_BF2 TTTGGGAATTAGGTTAATTAGATGG -4851
Olig2_6_BR2 CACAAACTCCTCCTATCCCTTTATA -4551 58% 0.41 
Olig2_6_BF3 TTGTATAATTGTTTGAGAAGGTTT -3376
Olig2_6_BR3 TCCTTCCTTCCTACTAACATTCAAA -3025 60% 0.63 
Olig2_6_BF4 AGGATTAAATAGGGAATTAGGGAAT -2982
Olig2_6_BR4 TCCTAAACTATTAACCTCCTCCTTCA -2768 63% 0.68 
Olig2_6_BF5 TAGGGAAGGTATATTGGTTTAGTTG -2697
Olig2_6_BR5 ATCTCCTTCTCCTCTCAACTACCTT -2399 58% 0.57 
Olig2_6_BF7 ATTGTTTGTTTGTTTGTTTGTTAAA -1528
Olig2_6_BR7 AACCCATACAAATAACCCTACCTAC -1221 47% 0.67 
Olig2_6_BF8 TAAGATGTTGGAAGTTTAGTGGTTG -881
Olig2_6_BR8 CTCCCTTAACTCCTTTCTACTTAATAACA -598 51% 0.59 
Olig2_g_BF1 TGATTGTTTGGGTGTTTATATTTAT 234
Olig2_g_BR1 ACATACAAATTATCCTAATCTCTCTCCTC 609 52% 0.79 
Olig2_g_BF2 TTTATTGAGGGTTATTTAGAAGTTT 526
Olig2_g_BR2 AACAAATACACAAACACAAACACAC 779 56% 0.56 
Olig2_g_BF3 TTTATAGGAGGGATTGTGTTT 950
Olig2_g_BR3 AACTCAATCATCTACTTCTTATCTTTCTTA 1161 65% 0.90 
Olig2_g_BF4 GAAAGATAAGAAGTAGATGATTGAG 1135
Olig2_g_BR4 TCCTCCAACRAATTAATAAAC 1354 62% 1.11 
Olig2_g_BF7 GTTTTGGAGAGTTAAGGGTTG 1841
Olig2_g_BR7 CCCTTAAAATATTCAACCAAAA 2054 60% 0.69 
Olig2_g_BF9 ATAATATTAAAAAGTTGTTGTGAATATAGT  2679
Olig2_g_BR9 CATAAAAAAATTTACCCCTC  2914 45% 
 
1.0 
m13 -20F  gtaaaacgacggccagtg    
m13 -27R ggaaacagctatgaccatg   
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c. Primers for Olig1 and Sox1 analysis. Sequence for each primer, location of each primer 
relative to the transcription start site (TSS) of each gene (UCSC genome browser July 2007 
build), GC content, and CpG Observed/Expected are given for each amplicon. 
Sequencing primers are located at the 5’ end of each primer and the last two rows of the 
table. 
 
Primer_name Sequence 5’-3’ 
Locatio
n rel to 
TSS GC% 
Obs/
Exp 
Olig1_5_BF1 TGAAGTTAGTAAGTGTGTTTATAGTAAA -2235
Olig1_5_BR1 ACTAACCAATAAATAACATCAAACC -1952 46% 0.43
Olig1_5_BF2 GGGAGGTAGAGATAAGGAGGATTT -1324
Olig1_5_BR2 CAAATATATCCAATTAACAAACAACCA -1009 45% 0.64
Olig1_5_BF3 AGTGAGAATTAAGATAAGTAGAGGG -647
Olig1_5_BR3 AATATAATCAACCAATAATCCCATC -339 43% 0.46
Olig1_g_BF1 TTGTATGAGTTGGTGGGTTATAGGTA 202
Olig1_g_BR1 CATAACCAAATTCAAATCCTACATAC 450 65% 0.83
Olig1_g_BF2 TTTAAGTGAGGGTTGGTTGG 883
Olig1_g_BR2 AAACTTCTAACTCTAAACAAATAAA 1140 60% 0.62
Olig1_g_BF3 TTATTATAATTTATTTATTGGTAGGG 1149
Olig1_g_BR3 TAAACTTTCTAAACCTCCTAAATCC 1454 63% 0.55
Olig1_g_BF4 GGATTTATTAAAATAGGTAGTAAGGTA 1756
Olig1_g_BR4 AATCAAATAAAATACCAATTAAATTC 2106 50% 1.2
Sox1_5k_BF2 GGGTTTATATTGATAGGTTTAGGG -3725
Sox1_5k_BR2 ACAAACTCTAATATACCCTCACAAA -3412 55% 0.45
Sox1_5k_BF3 GAATGGTTTGAAATGAAAGTTTAAT -1609
Sox1_5k_BR3 AACAAACCTAATCAAATACCTACAAAC -1312 45% 0.60
Sox1_g_BF1 GGTATTTGGGATTAGTATATGTTTAG 316
Sox1_g_BR1 AAACCACAACAACAACAACAAC 685 60% 0.72
Sox1_g_BF4 TTGTTGGAGGAGAAATTATTTGTAG 2866
Sox1_g_BR4 TTAACCTTATCCCACCACTAAACAC 3183 44% 0.38
m13 -20F  Gtaaaacgacggccagtg    
m13 -27R Ggaaacagctatgaccatg   
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C.2 Source code for primer design, sequencing 
data analysis, and amplicon analysis 
 
C.2.1 cg_search.pl -  Mapping CpG sites in a region of interest 
 
#!/usr/bin/perl 
use strict; 
############################################################# 
#Cara Rieger 
#March 27, 2008 
#cg_search.pl - use for defining a region of interest in a 
#sequence and mapping CpG sites 
#Also can be used for printing subsequence for primer design 
############################################################# 
#declare variables 
my $infile; 
my $sequence=""; 
my @sites; 
my $region_of_interest=700; 
 
#Check inputs 
if (@ARGV!=1){ 
die "\n Usage perl cg_search.pl <sequencefile>\n\n";} 
 
#Get filename and open file handle 
$infile=shift; 
open IN, $infile or die "Couldn't open $infile\n"; 
 
####Read in contents of file line by line 
while(my $line =<IN>){ 
    if ($line=~/^\w/){ #if line begins with a word char.keep it and 
append seq 
 chomp($line); 
    $sequence.=uc($line); 
    } 
} 
#print $sequence; 
close IN; 
 
######Split the sequence into array on each character  
##Dual checking## 
my $substring= substr ($sequence,0,$region_of_interest); 
print "$substring\n\n"; #use for printing sequence and designing 
primers 
my $cg_count= $substring =~ s/CG/CG/g; 
print "Number of CGs $cg_count \n\n"; 
my $cpg=0; 
@sites=split(//,$substring); #split sequence on each character 
my $location=-500; #starting location relative to TS startsite 
my $i=0; 
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for($i=0; $i<@sites; $i++){     
    if($sites[$i] eq "C" && $sites[$i+1] eq "G"){ 
 print "$location\n"; 
 $cpg++;} 
    $location++;} 
 
print "\nCpGs in breakdown $cpg\n"; 
print "number in sequence $i\n"; 
#!/usr/bin/perl 
C.2.2 primer.pl -  append universal tails to primers; 
identify  
unbisulfite treated cognate primers 
 
use strict; 
######################################################### 
#Cara Rieger 
#March 27, 2008 
# 
#Before running this program 
#Obtain sequences of interest and use MethPrimer to generate primers 
#for methylation specific PCR 
#Store primer results as text file with > header for each entry 
#Generate fasta file of sequences of interest  
###primer1.pl 
#Input:Output from MethPrimer and sequence files 
#Can also be used to add tails  
#Output: Tailed Bisulfite primers | Tailed Regular Primers  
############# 
# To run: perl primer1.pl primerfile.txt sequences.fa 
########################################################## 
 
#Take in sequences for analysis 
## 
#Check the contents of the file 
if (scalar (@ARGV) !=2){ 
    die "Usage perl primer1.pl fastafile.fa primerfile.txt\n"; 
} 
 
#Open the fasta file containing the sequences and store then 
my $fasta_file=shift(@ARGV); #takes first argument for cmd line 
open IN, $fasta_file; #IN is file handler to read file 
 
#Read through the file one line at a time 
#and store the sequences and headers as elements in an array 
my @sequence; 
my $sequence_counter=0; 
my $sequence_counter=0; 
my @header; 
 
while (my $line=<IN>){ 
#seaching for the >= will break each record 
    if ($line=~/^>/){ 
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 chomp($line); 
 $header[$sequence_counter]=substr($line,1); 
 $sequence_counter++; 
    }elsif($line=~/^\w/){ 
 chomp($line); 
 $sequence[$sequence_counter-1]=$sequence[$sequence_counter-
1].$line; 
    } 
} 
close IN; 
 
######################################### 
#Open the primer file which has each gene annotated with a  
#>Name 
#Followed by copied output from MethPrimer 
###################################### 
 
#Variables: 
my $line_counter=0; 
my $lp_tail="gtaaaacgacggccagtg"; #M13 Forward -20 
my $rp_tail="ggaaacagctatgaccatg"; #M13 Reverse -27 
my $primer_num; #starting number for all primers 
my $primer_name; 
my $primer_counter=0; #total number of primers; 
my @outputB;#Bisulfite output 
my @outputR;#Regular output 
 
#Open the primer file 
my $primer_file= shift @ARGV; #takes first argument from cmd line 
(file name) 
open INPUT, $primer_file; # INPUT is file handler to read $primer_file     
 
#Read through the file one line at a time 
#Parse data keeping important stuff 
 
while (my $line = <INPUT>){ #line is equal to next line of file 
#Seaching for the >= will break each record 
    if ($line=~/^>/){  
 
#Capture primer name 
 chomp($line); #get rid of new lines 
  $primer_name = substr($line,1,7); #gets the sequence query name 
 $primer_num=6; #starting number for all primers 
 $line_counter=0; 
    } 
    elsif($line=~/^(\s)*$/){ 
 $line_counter++; 
    } 
################################################# 
#Divide the line into a data array with slots 
#[num, left,primer, LP, LP_length, TM, GC%, C's, LSequence] 
##[right, primer, RP, RP_length, TM, CG%, C's, RSequence] 
##[Product, size:, PS, ProductTM, CpGs in Product, prodCpGs] 
############################################ 
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    elsif($line_counter>=1 && $line!~/^(\s)*$/){ 
 chomp($line); 
  
 if ($line=~/Left/){ 
 #put primer name and primer F/R and number on array 
   my $primer_nameL=$primer_name.'_'.'BF'.$primer_num; #generates 
a unique name for each primer 
   my @dataL = split (/\s{2,}/ , $line) ; #splits the string of 
data into an array as defined by 2 or more spaces 
 for(my $i=0; $i<3; $i++){ 
     shift(@dataL); #get rid of number, left, primer 
 } 
 my $lp_start= shift(@dataL); 
 my $lp_length=shift(@dataL); 
 my $lp_seq=$lp_tail.pop(@dataL);  
   my $lp_start_len=join(",",$lp_start,$lp_length); 
 push(@outputB, $primer_nameL,$lp_seq,$lp_start_len); 
   $primer_counter++; 
     
      }elsif($line=~/Right/){ 
 my @dataR = split (/\s{2,}/ , $line) ; #splits at 2 or more 
spaces  
 my $primer_nameR=$primer_name.'_'.'BR'.$primer_num; 
    for(my $i=0; $i<2; $i++){ 
 shift(@dataR);#dump the text 
    } 
        my $rp_start= shift(@dataR); 
        my $rp_length=shift(@dataR); 
 my $rp_start_len=join(",",$rp_start,$rp_length); 
        my $rp_seq=$rp_tail.pop(@dataR); 
 push(@outputB, $primer_nameR, $rp_seq, $rp_start_len); 
 $primer_num++; #advance the primer_numbers for both primers 
 $primer_counter++; #increment the counter for overall primers 
    }        
    } 
} 
 
my @final_outputB=@outputB; 
 
close $primer_file; 
 
################### 
#Generating regular primers from methprimer bisulfite primers 
#Shift off primer name and exchange for regular primer name 
#Match the gene name from primer name to header name in sequence file 
#Get corresponding sequences using start and length of sequence 
#Make reverse complement for reverse sequence 
############## 
 
for(my $i=0;$i<$primer_counter;$i++){ 
    my $primer_name= shift(@outputB); 
    my @name= split(/_B/,$primer_name); 
    $primer_name=join("_",shift(@name),pop(@name)); 
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    push(@outputR, $primer_name); 
#j corresponds for the number of sequences from fasta file 
    for(my $j=0; $j<scalar(@header);$j++){ 
 if($primer_name=~/^$header[$j]/){ 
 shift(@outputB);#get rid of bisulfite sequence in outputB 
     if($primer_name=~/_F/){ 
  my $lp_s_l=shift(@outputB); 
  my @lp_start_length=split(/,/,$lp_s_l); 
  my $lp_seq=substr($sequence[$j],($lp_start_length[0]-
1),$lp_start_length[1]); 
  $lp_seq=$lp_tail.$lp_seq; 
  push(@outputR,$lp_seq,$lp_s_l); 
     } 
 if($primer_name=~/_R/){ 
     my $rp_s_l=shift(@outputB); 
     my @rp_start_length=split(/,/,$rp_s_l); 
     my $rp_seq=substr($sequence[$j],($rp_start_length[0]-
$rp_start_length[1]),$rp_start_length[1]); 
     $rp_seq=reverse($rp_seq); 
#need to complement reverse sequence; 
     my @rc_seq; 
     my @seq= split(//,$rp_seq); 
     for (my $i=0; $i<scalar(@seq); $i++){ 
  if ($seq[$i] eq "A"){ 
      $rc_seq[$i]="T"; 
  }elsif($seq[$i] eq "T"){ 
      $rc_seq[$i]="A"; 
  }elsif($seq[$i] eq "C"){ 
      $rc_seq[$i]="G"; 
  }else{ 
      $rc_seq[$i]="C";} 
     } 
     $rp_seq=join(//,@rc_seq); 
     $rp_seq=$rp_tail.$rp_seq; 
     push(@outputR, $rp_seq,$rp_s_l); 
 } 
    } 
    } 
} 
 
########################################## 
###Print out the bisulfite and regular primers in Tab delimited format 
############################ 
print "Primer_name\tSeq\tStart,Length\n"; #header line 
for (my $i=0; $i<$primer_counter/2; $i++){ 
    my $primer_nameL=shift(@final_outputB); 
    my $lp_seq=shift(@final_outputB); 
    my $lp_start_len=shift(@final_outputB); 
    my $primer_nameR=shift(@final_outputB); 
    my $rp_seq=shift(@final_outputB); 
    my $rp_start_len=shift(@final_outputB); 
print "$primer_nameL\t$lp_seq\t$lp_start_len\n"; 
print "$primer_nameR\t$rp_seq\t$rp_start_len\n"; 
} 
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print "\nPrimer_name\tSeq\tStart,Length\n"; #header line 
for (my $i=0; $i<$primer_counter/2; $i++){ 
    my $primer_nameL=shift(@outputR); 
    my $lp_seq=shift(@outputR); 
    my $lp_start_len=shift(@outputR); 
    my $primer_nameR=shift(@outputR); 
    my $rp_seq=shift(@outputR); 
    my $rp_start_len=shift(@outputR); 
    print "$primer_nameL\t$lp_seq\t$lp_start_len\n"; 
    print "$primer_nameR\t$rp_seq\t$rp_start_len\n";} 
 
C.2.3 seqsort.pl -  take in sequencing data and parse out 
important data for alignment and calculation  
 
#!/usr/bin/perl 
use strict; 
 
####################################################### 
#Cara Rieger 
#April 1, 2008 
#seq_sort.pl - use for taking a file of all sequencing reads and 
parsing out important data for alignment and calculation 
#derived from running  
#%>strings *.seq.bin>sequences.seq in directory with all sequence data 
################################################################ 
#declare variables 
my $infile; #file containing sequences of interest 
my @header; 
my @sequence; 
my $record=0; 
 
#Check inputs 
if (@ARGV!=1){ 
die "\n Usage perl seq_sort.pl <sequences.seq>\n\n";} 
 
#Get filename and open file handle 
$infile=shift; 
open IN, $infile or die "Couldn't open $infile\n"; 
 
####Read in contents of file line by line 
while(my $line =<IN>){ 
    if ($line=~/seq/){ 
 chomp($line); 
 $record++; 
 my @name=split('_', $line);# get rid of well numbers 
 $header[$record-1]=shift(@name); 
 $header[$record-1]=substr($header[$record-1],2); #get rid of 
initials 
    }elsif($line!~/mBIN/ && $line!~/seq/){  
#if line is not the .seqline or a mBIN line keep it and append seq 
 chomp($line); 
    $sequence[$record-1].=uc($line); #store each sequence as element 
in array 
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    } 
} 
close IN; 
 
 
#Want to reverse complement the reverse sequences 
for (my $i=0; $i<scalar(@sequence);$i++){ 
    if ($header[$i]=~/R$/){ 
 $header[$i]=$header[$i]."_RC"; 
    my $r_seq=reverse($sequence[$i]); 
#need to complement reverse sequence; 
 my @rc_seq; 
 my @seq= split(//,$r_seq); 
 for (my $i=0; $i<scalar(@seq); $i++){ 
 if ($seq[$i] eq "A"){ 
     $rc_seq[$i]="T"; 
 }elsif($seq[$i] eq "T"){ 
     $rc_seq[$i]="A"; 
 }elsif($seq[$i] eq "C"){ 
     $rc_seq[$i]="G"; 
 }else{ 
     $rc_seq[$i]="C";} 
    } 
    $sequence[$i]=join(//,@rc_seq); 
    } 
} 
 
#print "$header[0]\t$header[1]\n"; 
my $name=substr($header[0],0,3); 
my $file="$name.fa"; 
open OUT, ">$file"; 
 
 
##Print the matching gene sequences to a new fasta file for algnment 
purposes 
for (my $i=0;$i<$record; $i++){ 
    print OUT  ">$header[$i]\n"; 
    print OUT "$sequence[$i]\n"; 
 if (substr($header[$i],0,3) ne substr($header[$i+1],0,3) && 
$i!=$record-1){    
     close OUT; 
     $name=substr($header[$i+1],0,3); 
     $file="$name.fa"; 
     open OUT, ">$file"; 
 } 
}close OUT; 
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C.2.4 count8.pl -  take in sequencing data and generate a 
bisulfite conversion matrix and overall statistics 
 
#!/usr/bin/perl -w 
use strict; 
 
#Cara Rieger 
#April 23, 2008 
#count8.pl 
 
################################# 
#Need a reference sequence name_ref in fasta sequence file  
#Can be used with Fasta output of aligned ClusalW from bisulfite 
sequencing 
#To generate matrix of C->C and C->T conversions  
#################################### 
 
 
# Check to make sure that one file was given on the command line, if 
not 
# print a correct usage statement. 
# 
if (@ARGV != 1) { 
    die "\nUsage: perl count8.pl <fasta file>\n\n"; 
} 
 
# Get the file name and open an instream to it. 
# 
my $file = shift; 
open IN, $file or die "Couldn't open file: $file\n"; 
 
#Initialize two arrays for fasta headers and sequence information# 
my $contig_no=-1; # keep track of number of contigs 
my @all_sequences; 
my @all_headers; 
 
# Read in the contents of the file one line at a time and store it in 
$line 
# 
while (my $line = <IN>) { 
         
    # if it's a line that begins with a '>' or non-word char if 
($line=~ /^\W/) 
    # store the line in @all_headers - giving you the fasta info 
    # chomp off the newline (chomp($line))  
    # if it is sequence it will be stored in @all_sequences 
    # uppercase it for easier counting (uc($line) 
    # and append it to the end of $all_sequences, the string that is 
the growing  
    # within the array ($all_sequences[$contig_no]  .= uc($line)) .   
    # 
    # 
    if ($line =~ /^>/) { 
 chomp($line); 
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 $contig_no=$contig_no +1; 
 $all_headers[$contig_no]=$line; 
 #print "header: $all_headers[$contig_no]  \n"; 
       } 
    else{ 
       chomp($line); 
 $all_sequences[$contig_no].= uc($line); 
      #print "$all_sequences[$contig_no] \n"; 
    } 
} 
 
#We're done with the file, so close it 
# 
close IN; 
 
my @bases; #2D array of bases for all sequences 
my @reference_seq;# array containing reference sequence separated by 
bases 
my $ref_length;#length of reference sequence 
my $ref; #index of reference sequence 
 
######################## 
#Find the reference sequence 
#################################### 
 
for (my $i=0; $i<$contig_no+1; $i++){ 
    if($all_headers[$i]=~/ref/){ 
 $ref=$i; 
    } 
} 
 
my $k=0; #counter for ref sequence location 
my $j_start=0; #start of ref sequence relative to alignment 
my $j_end; #end of ref sequence relative to alignment 
my @C_sites; #array containing the location of all C sites in 
reference 
my @CpG_sites; #array containing the location of all CpG sites in 
reference 
 
######################### 
#Get the start and stop of reference sequence and indices of C's and 
CpGs 
######################### 
my @temp=split(//, $all_sequences[$ref]); 
for (my $j=0; $j<scalar(@temp);$j++){ 
    if($temp[$j]=~/\w/ || $temp[$j+1]=~/\w/){ #takes care of one bp 
gap in ref 
 $reference_seq[$k]=$temp[$j]; 
 if($reference_seq[$k]=~/C/){ 
     push(@C_sites,$k); 
 }if($reference_seq[$k]=~/C/ && $temp[$j+1]=~/G/){ 
     push(@CpG_sites,$k); 
 } 
 $j_end=$j; 
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 $k++; 
  
    }elsif($k==0){ 
    $j_start++; 
} 
} 
 
#################################################### 
#Make 2D array of bases, cropping to same size as reference, by 
getting rid of leading and trailing sequence 
################################################### 
for (my $i=0; $i<$contig_no+1; $i++){     
    @temp=split(//, $all_sequences[$i]); 
    $k=0; 
    for (my $j=$j_start; $j<$j_end; $j++){ 
 $bases[$i][$k]=$temp[$j]; 
 $k++; 
    } 
}   
 
my @C_conversion_matrix; #contains 0 for C->T and 1 for C->C for each 
location 
my @C_counts;# maintains a count of total number of C's in sequence 
my @CG_conversion_matrix; #contains 0 for C->T and 1 for C->for each 
location 
my @CG_counts; # maintains a count of total number of CG's in sequence 
my @C_interest; #maintains a list of locations where C->C 
my @CpG_interest;# maintains a list of locations where CG->CG 
my @T_counts; # count of C->T converters 
my @TpG_counts; #count of CG->TG converters  
############################################## 
#Have 2D array of bases, and indices of C's and CpGs 
#Now put a 1 for every C match and 0 for every C->T, -1 for C-
>something else 
#Keep array of sites of interest (those that remain C's) 
################################### 
 
for(my $i=0; $i<$contig_no+1; $i++){ 
    $C_counts[$i]=0; 
    $T_counts[$i]=0; 
    $C_interest[$i]=""; 
    for(my $j=0; $j<scalar(@C_sites); $j++){ 
 my $position=$C_sites[$j]; 
 if($bases[$i][$position]=~/C/){ 
     $C_conversion_matrix[$i][$j]=1; 
     $C_counts[$i]++; 
     $C_interest[$i].="$position,"; 
 }elsif($bases[$i][$position]=~/T/){ 
     $C_conversion_matrix[$i][$j]=0; 
     $T_counts[$i]++; 
 }else{ 
     $C_conversion_matrix[$i][$j]=-1; 
 } 
    } 
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} 
 
#######Now for the CpG sites 
 
for(my $i=0; $i<$contig_no+1; $i++){ 
    $CG_counts[$i]=0; 
    $TpG_counts[$i]=0; 
    $CpG_interest[$i]=""; 
    for(my $j=0; $j<scalar(@CpG_sites); $j++){ 
        my $position=$CpG_sites[$j]; 
        if($bases[$i][$position]=~/C/){ 
            $CG_conversion_matrix[$i][$j]=1; 
     $CG_counts[$i]++; 
     $CpG_interest[$i].="$position,"; 
        }elsif($bases[$i][$position]=~/T/){ 
            $CG_conversion_matrix[$i][$j]=0; 
     $TpG_counts[$i]++; 
        }else{ 
            $CG_conversion_matrix[$i][$j]=-1; 
        } 
    } 
} 
############################################################### 
###Print out statistics about bisulfite conversion 
###################################### 
my $totalC= scalar(@C_sites); 
my $totalCG= scalar(@CpG_sites); 
 
###Print Names and C and CG counts 
print "Name\tC->C\tCG->CG\tC->T\tCG->TG\n"; 
for (my $i=0; $i<$contig_no+1; $i++){ 
    print "$all_headers[$i]\t"; 
    print "$C_counts[$i]/$totalC\t"; 
    print "$CG_counts[$i]/$totalCG\t"; 
    print "$T_counts[$i]/$totalC\t"; 
    print "$TpG_counts[$i]/$totalCG\n"; 
} 
 
for (my $i=0; $i<$contig_no+1; $i++){ 
    print "\n$all_headers[$i]\n"; 
    print "C's of interest: $C_interest[$i]\n"; 
    print "CG's of interest: $CpG_interest[$i]\n"; 
} 
 
############################# 
###Print C_conversion matrix and CpG_Conversion_matrix 
################################################### 
#print "\n-----------------------------------------\n"; 
#print "Csites\t@C_sites\n"; 
#for (my $i=0;$i<$contig_no+1;$i++){ 
#    print "$all_headers[$i]\t"; 
#    for (my $j=0; $j<scalar(@C_sites);$j++){ 
#        print "$C_conversion_matrix[$i][$j] "; 
#    }print "\n"; 
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# } 
 
#print "CGsites\t@CpG_sites\n"; 
#for (my $i=0;$i<$contig_no+1;$i++){ 
#    print "$all_headers[$i]\t"; 
#    for (my $j=0; $j<scalar(@CpG_sites);$j++){ 
#        print "$CG_conversion_matrix[$i][$j] "; 
#    }print "\n"; 
#} 
############################# 
C.2.5 cg_count.pl – used to calculate GC% and observed 
over expected CpGs for any sequence of fasta file of 
sequences 
 
#!/usr/bin/perl 
use strict; 
 
########################################### 
#Cara Rieger 
#cg_count.pl - use for calculating observed/expected CpG over a fasta 
file of sequences particular 
#Adapted from Assignment 1 solution from Bio5488 course 
#July 28, 2008 
############################################# 
 
#declare variables 
my $infile; 
my $sequence=""; 
 
#Check inputs 
if (@ARGV!=1){ 
die "\n Usage perl cg_search.pl <sequencefile>\n\n";} 
 
#Get filename and open file handle 
$infile=shift; 
open IN, $infile or die "Couldn't open $infile\n"; 
 
####Read in contents of file line by line 
print "Gene_amplicon\tGC%\tLength\tObsCpG\tExpCpG\tObs_Expect\n"; 
while(my $line =<IN>){ 
     
    if ($line=~/^\w/){ #if line begins with a word char.keep it and 
append seq 
 chomp($line); 
 $sequence.=uc($line); 
    } 
 
    elsif ($line=~/^\>/){ #if line begins with carat keep the text as 
title for line and increment counter 
 chomp($line); 
 if($sequence=~/\w+/){ # if sequence is not empty we need to 
count it 
     ##Do counts on the sequence## 
     my $c_count= $sequence =~s/C/C/g; 
 153 
     my $g_count= $sequence =~s/G/G/g; 
     my $t_count= $sequence =~s/T/T/g; 
     my $a_count =$sequence =~s/A/A/g;  
        
 my $total_bases= $c_count + $g_count + $t_count + $a_count; 
 my $expect = 
int((($c_count/$total_bases)*($g_count/$total_bases))*$total_bases-1); 
 my $gc_percent= sprintf "%.2f", ($c_count + 
$g_count)/$total_bases; 
 my $cpg= $sequence =~s/CG/CG/g; 
 my $o_e= sprintf "%.2f", $cpg/$expect; 
  
 print "$gc_percent\t"; 
 print "$total_bases\t";     
 print "$cpg\t"; 
 print "$expect\t"; 
 print "$o_e \n"; 
 
 }   
 print "$line\t"; # print the line if sequence is empty 
 $sequence=""; # reset the sequence 
    } 
 
} 
 
close IN; 
  
##Do counts on the last sequence## 
my $c_count= $sequence =~s/C/C/g; 
my $g_count= $sequence =~s/G/G/g; 
my $t_count= $sequence =~s/T/T/g; 
my $a_count =$sequence =~s/A/A/g; 
 
my $total_bases= $c_count + $g_count + $t_count + $a_count; 
my $expect = 
int((($c_count/$total_bases)*($g_count/$total_bases))*$total_bases-1); 
my $gc_percent= sprintf "%.2f", ($c_count + $g_count)/$total_bases; 
my $cpg= $sequence =~s/CG/CG/g; 
my $o_e= sprintf "%.2f", $cpg/$expect; 
print "$gc_percent\t"; 
print "$total_bases\t"; 
print "$cpg\t"; 
print "$expect\t"; print "$o_e \n"; 
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Appendix D 
Supplemental Information for  
Chapter 4: Engineering ES Cells for Drug 
Selection of  a Subset of  Neural Cells 
 
D.1 Primer Tables 
 
All locations are relative to Olig2 ATG Chr. 16 - 91,226,645   
(UCSC browser, mm9 July 2007 build) 
 
 
Table D.1: Olig2 BAC Mapping Primers  
Name Sequence 5'-3' 
Location 
 
Amplicon 
size 
Olig2_Bac_MapF1 CCACAGGGGTGGGTTAAAGAGATAGCC -14,794   
Olig2_Bac_MapR1 GAAATCACTGCAGGAGCAGGAGGAATC -14,514 306
Olig2_Bac_MapF2 AGTCATAGAGTTGGTGACAACGAGGAC -12,277   
Olig2_Bac_MapR2 CCTCTTTATTTCCAACGTAGGATCAGG -11,907 396
Olig2_Bac_MapF3 ACGTGGAAGGCTTATGTTCTTGTGTTA -7,626   
Olig2_Bac_MapR3 CGGTACATTCCATGAGTACACAGACAG -7,349 303
Olig2_Bac_MapF4 TACTCCTGAGAATGGGTCCGTGGAAAG -5,370   
Olig2_Bac_MapR4 CAGTGTGTGCGATGTGGAGGTTTAGGT -4,932 464
Olig2_Bac_MapF5 AGCTGGAAATGTCCGGATGTGAGAAAC -2,192   
Olig2_Bac_MapR5 CTCCGCTGTGGATGGGAGTTGATACTT -1,813 405
Olig2_Bac_MapF6 CGAAAGGTGTGGATGCTTATTACAGAC -838   
Olig2_Bac_MapR6 TGGACCGGAGATCTGAATAGAGAAGTA -410 454
Olig2_Bac_MapF7 GTGTTTGATGAGGATTCACCAGTCTCT 2,783   
Olig2_Bac_MapR7 AGTGATCACCCAACATGTCATCTGTTA 3,144 387
Olig2_Bac_MapF8 GGCAAAATCAGCTTAGAACTCTGAACA 4,967   
Olig2_Bac_MapR8 ATGAAGGAGTTACCTGGTTTGGTCAT 5,335 393
Olig2_Bac_MapF9 AGGCCACAAGCAATTTCCCTCTCTTTC 7,014   
Olig2_Bac_MapR9 GTTCTTCAGGATGATGCTGCACTGGTC 7,292 304
Olig2_Bac_MapF10 TCACACTCAAATTCTAGGAAGCCAGAG 12,290   
Olig2_Bac_MapR10 GGCGTTAGCTTTCTATGAACACTCAGA 12,613 349
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Table D.2:  BAC Subcloning Primers  
Name 
 
5’ Upstream & Antisense Homology + cgactgaattggttcctttaaagc 3’ 
Ol2_rec2b 
AGCTGGACCAGGATAACACAAGTGTGTCGCAGCA 
TTTTATTAGCCAAGGA 
OL2_rec4b 
AGCAGACAAACAGTAATTGGTCTTCTTGTAGCAAA 
GTCAGAACAGGCATG 
OL2_rec5b 
AGAGGCAACATTATTTGCAAAGAATTATCGGAGGCT 
CTCCGCTGTGGATG 
  
 
5’ Downstream & Sense Homology +  gccgcactcgagatatctagacccag 
3’ 
Ol2_rec6b 
ACTCTGAAGCGGTGCTACTGTCCCATGTTCAGGCCA 
GAGATCTATGTGAG 
Ol2_rec7b 
GAAATGATCAGTCAGGACCCAGGCATTTCCTAAAGC 
TAAAATGGACGATT 
Ol2_rec8b 
CATACAGCACCTACTCTGTTCATGGACAGACAGTGA 
CAGCAGTGACAAAG 
OL2_rec9b 
GTTAACACGAGGGGCAAACCCCTTCATGCGCGCTCC 
CTGGCGCGACCTGC 
OL2_rec10b 
TTCAGTTCCAGTCGCCCCTCTGTCACCAATTTCTGAA 
GTGTCAGCCTGAT 
 
Upper case letters indicate Olig2 sequence. Lower case is appended on the 3’ end 
of primer to amplify pStartK. 
 
 
Table D.3:  Olig2 Homology Plasmids  
Name 
 
Left end Right End
Total size of plasmid 
(bp) including 
pStartK region 
pOlig2_1 -8894 2,036 13,676
pOlig2_2 -8894 3,076 14,716
pOlig2_3 -2415 5,600 10,761
pOlig2_4 -2415 8,905 14,066
pOlig2_5 -2415 12,962 18,123
pOlig2_6 -1800 5,600 10,146
pOlig2_7 -1800 8,905 13,451
pOlig2_8 -1800 12,962 17,508
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Table D.4:  Primers for Insertion of AscI Sites and Chloramphenicol Resistance  
Name 
 
5’ Homology + GGCGCGCC + agcattacacgtcttgagcgattgt 3’ 
Relative 
to Olig2 
ATG 
Ol2_Asc_CatF 
AAGGTTGAAAAAAGAAGGATCATTCGAGAGCTTAGATC 
ATCCCTGGGGCC 
-1 
 5’ Homology + GGCGCGCC + cacttaacggctgacatgggaatta  
OL2_Asc_CatR 
CGCGCTGCTCCGCAGCCCTTGGCTCTCCAGGACGCAC 
CCCCGCTGGCCGG 
973 
 
Table D.5: Primers for Junction PCR to Detect Cassette Cloning 
Name Sequence 5’ to 3’ 
cr 1_29 casetteF AAGGATCATTCGAGAGCTTAGATCA 
Reverse Junction1 GCGCCAGGAGGCCTTCCATCTGTTGCT 
neo detect forward1 GCCTTCTATCGCCTTCTTGACGAGTTCTT
cr 1_29 casetteR AGTGTTCAGCCAAAGAGTCAACCAG 
 
Table D.6:  Primers for ES Targeting Detection  
Name Sequence 5’ to 3’ 
 Detection of Targeting of 1PN-TK3 
Neo detect F1 GCCTTCTATCGCCTTCTTGACGAGTTCTT 
ES detect 3_3 ACACAAACTGAAAACACCTGCCTTGCTTTA 
 
 
Detection of Targeting of 8PN-TK3 
ES detect 5_ 2 CCCAGATCCAGTTTCTCAGCTTTGTATGTG 
Puro_R4 GTGAGGAAGAGTTCTTGCAGCTCGGTGAC 
 
Table D.7:  Primers for Southern Probes 
Name Sequence 5’ to 3’ 
 Detection of Targeting of 1PN-TK3 
S-3’F ttaacagatgacatgttgggtgatcactgg 
S-3’R ttaaggacccacaaaagtcaatgtggtctg 
 
 
Detection of Targeting of 8PN-TK3 
S-5’F ccaagtgtacagaatgtcaggcagttctcc 
S-5’R catctcgtgccttctgaagcattgttttc 
 
Table D.8:  Primers for RT-PCR Detection 
Name Sequence 5’ to 3’ 
PCR_N_F1 GGATGCTTATTACAGACCGAGCCAACACC 
PCR_N_R2 ACGAGGACACAGTCCCTCCTGTGAAG 
PCR_puroT_R3 GCGTGAGGAAGAGTTCTTGCAGCTC 
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Table D.9: Sequencing Primers 
 Name Sequence 5’ to 3’ 
Gap Repair WS275 TAAACTGCCAGGCATCAAACTAAGC 
 WS276 AGTCAGCCCCATACGATATAAGTTG 
Chloramphenicol 
Insertion WS187 ATGCCGCTGGCGATTCAGGTTC 
 WS188 GCCGATCAACGTCTCATTTTCG 
 
 
D.2 Supporting Data for Targeting Vectors 
 
Figure D.1: Mapping Olig2BAC 227 by Short Amplicon PCR. Primers and expected 
amplicon sized are given in Table D.1.  
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Figure D.2: Restriction Digests of Olig2 Subcloned Plasmids, pOlig2_1 and pOlig2_8 
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Figure D.3: Restriction Digests of AscI Modified Plasmids, pOlig2_1Asc and 
pOlig2_8Asc. 
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Figure D.4: Junction PCR for Detection of PAC-neo Cassette Insertion. Primers are 
given in Table D.5. 
 
 
 
Figure D.5: Restriction Digests of PAC-neo Modified Plasmids, pOlig2_1PN and 
pOlig2_8PN 
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Figure D.6: Restriction Digests of Gateway Modified Plasmids, pOlig2_1PN-TK3 and 
pOlig2_8PN-TK3 
 
 
Figure D.7: Targeting Detection PCRs. Primers are given in Table D.6.  
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D.3 ES Cell Expression Vector 
 
This vector was designed in consultation with J. Kuhn and D. Lorberbaum. It was built 
and validated by J. Kuhn and D. Lorberbaum. 
 
 
Rationale 
 
In chapter 4, we engineered targeting vectors to insert a promoterless puromycin 
acetyltransferase gene (PAC) into the open reading frame of Olig2, the targeted gene. Once 
targeted to the Olig2 locus, PAC will be expressed by the Olig2 promoter.  In order to 
incorporate the promoterless PAC into the targeting vector, it must be amplified using 
PCR to isolate the sequence from its source and incorporate restriction sites that are 
necessary for cloning into the targeting construct. Loss of function mutations of the PAC 
due to PCR are a concern. Because Olig2 is not expressed in ES cells, we would not know 
if PAC was functional or had incorporated a loss of function mutation until the ES cells 
are differentiated into Olig2 expressing neural cells. Therefore, it is best to avoid this 
scenario. Typically cDNA cassettes, like PAC, are extensively sequenced once they are 
cloned into a targeting vector to ensure that no mutations have occurred. This is tedious 
given that most targeting vectors range from 10-20kb.  
It would be better to functionally test the PAC in ES cells before proceeding with 
the targeting experiment. To do this, we designed and build an ES cell expression vector, 
where expression of the amplified PAC is governed by a strong ES cell promoter (Chung 
2002). This allows the activity of the PAC cDNA to be seen before targeted clones are 
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detected, expanded, and differentiated. Additionally, PAC can be sequenced once in the ~ 
7kb expression vector for further validation. The functional PAC can then be transferred 
to the targeting vector by cut and paste cloning, eliminating mutagenesis of  PAC. 
 
 
Building the Vector 
 
The cDNA expression vector is comprised of three parts. The first component is 
the promoter that will be used to drive expression of the inserted cDNA in ES cells. We 
chose to use cellular polypeptide chain elongation factor 1 alpha (EF-1a) which has been 
shown to robustly drive gene expression in ES cells (Chung, Andersson et al. 2002). The 
second part of the expression vector is the cDNA we want to express. We chose to use the 
puromycin acetyltransferase gene (PAC, (Gomez Lahoz, Lopez de Haro et al. 1991); 
(Watanabe, Kai et al. 1995)) as our cDNA because we are interested in generating targeted 
ES cells where Olig2 expressing neural cells can be purified with puromycin. The third 
component of the expression vector is the positive selection cassette which consists of a 
floxed PGK-neo. PGK-neo is a standard positive selection cassette for gene targeting in 
ES cells. It is flanked by loxP sites, “floxed”, so that it can be excised from the ES cell 
genome once targeted clones have been obtained. 
A map of the complete puromyocin-ES expression vector (pBSKANPe) is shown 
in Figure D.8. All primers used for construction are listed in Table D.10. Four steps were 
performed to assemble the expression vector. First, pBluescriptSKII(+) (Stratagene) was 
modified to contain an AscI site by inverse PCR with primers tailed with AscI  sites. The 
linear PCR fragment was digested with AscI and ligated to form pBSAscI. Next, a floxed 
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PGK-neo cassette with bgh Poly(A+) was cloned from pL452 (NCI Recombineering 
Website) from EcoRI to NotI. Then, the puromyocin cDNA cassette containing bgh 
Poly(A) was amplified from pKO SelectPuro (Stratagene) by PCR and cloned into the 
expression vector from HindIII to EcoRI sites. The 5’ puromyocin primer contained a 
HindIII and an AscI site which will be used for later cloning into the targeting vector. The 
first 6 bases of the Kozak sequence were also added in the 5’ primer to facilitate translation 
upstream of the puromyocin ATG. The 3’ primer contained an EcoRI site for cloning into 
the expression vector. Finally, the EF-1α promoter element was cloned into pBSAscI by 5’ 
SalI and 3’ HindIII restriction sites added during PCR amplification of EF-1α from 
pTracer – EF/BsdA (Invitrogen) completing the expression vector.   
 
Table D.10: Primers for ES cDNA Expression Vector 
Name  Sequence 5’-3’ 
Inverse AscI fit F gatcGGCGGCCGGAGCTCCAGCTTTTGTTCCCTTTAGTGAGGGT 
Inverse AscI fit R gatcGGCGCGCCCCGCGGTGGCGGCCGCTCTAGAACTAGTGGAT 
EF-1α F ttatGTCGACGTGAGGCTCCGGTGCCCGTCAGTGG 
EF-1α R cggcAAGCTTCAAGCTAATTCCTCACGACACCTGAAATGG 
Puro F tgcaaAAGCTTGGCGCGCCGCCAATATGACCGAGTACAAGCCCACGGTGC
Puro R cgtaatGAATTCCCCAGCTGGTTCTTTCCGCCTCAGAAG 
Bold or underlined 
sequences 
SalI = GTCGAC; HindIII = AAGCTT; Kozak=GCCAAT;  
AscI = GGCGCGCC; EcoRI =GAATTC 
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Figure D.8: ES Cell Expression Vector Tests Amplified Puromycin Resistance Gene 
 
 
 
 
Testing the Vector 
  
As shown in Figure D.8, the completed PBSKANPe vector was linearized with 
KpnI electroporated into 107ES cells. The electroporated cells were divided evenly among 
two 100mm dishes. One dish was treated with 240µg/mL geneticin 24 hours after 
electroporation and the other was treated with 4µg/mL puromycin 48 hours following 
electroporation. Clones were counted seven days following selection. There were abundant 
puromycin resistant clones ~1200 indicating that the amplified puromycin resistance gene 
was indeed functional. In addition, approximately ~600 neomycin resistant were counted 
clones indicating that the PGK-neo cassette was also functional. The quantitative 
differences in the number of clones may be due uneven splitting of electroporated cells, or 
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it could reflect the relative activity of the EF-1a promoter compared to the PGK promoter 
in ES cells. 
Conclusion 
Using an ES cell expression vector, we show that a simple ES cell electroporation 
experiment is sufficient to ensure that the amplified promoterless puromycin 
acetyltransferase cDNA is functional. This functional PAC can be directly transferred to 
targeting vectors without the concern of mutagenesis. In addition, the vector contains a 
functional floxed positive selection PGK-neo cassette downstream of the promoterless 
cDNA which can be used for positive selection in ES cells during gene targeting.  Once 
targeting events have been detected, the PGK-neo cassette then is able to be removed by 
Cre recombinase. The expression vector it is well suited to our targeting vector 
construction strategy (Wu, Ying et al. 2008) and will aid in future targeting experiments. In 
conclusion, we have designed and built an ES cell expression vector that allows us to test 
functionality of any amplified cDNA in ES cells before targeting it to our gene of interest.  
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